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ABSTRACT
The growth suppressive functions of the retinoblastoma protein (pRB), the first identified tumor
suppressor, are considerably mediated through the repression of the E2F transcription factors.
Functional inactivation of pRB, and subsequent deregulation of E2F activity, is a critical event in
the formation of most human cancers. pRB is a member of the pocket protein family, which
includes p107 and p130. The pocket proteins have some functional redundancy; however, they
have differential binding properties to the E2Fs and make very different contributions to the
suppression of tumors. The E2F proteins that associate with the pocket proteins can be divided
into two groups based on structural and functional similarities. The activating E2Fs, E2F1, E2F2
and E2F3a, are exclusively regulated by pRB and are primarily involved in activating the
transcription of E2F-responsive genes that are required for cell cycle progression. The repressive
E2Fs, E2F3b, E2F4 and E2F5, are regulated by the entire pocket protein family and are
important for transcriptional repression. Mechanistically, the inappropriate proliferation
promoted by the absence of pRB is, in large part, attributed to the activating E2Fs. This study
investigates the contribution of a repressive E2F, E2F4, to the growth inhibitory properties of
pRB during normal development and tumorigenesis. The characterization of mutant mice
demonstrated that E2F4 loss significantly suppresses tumor formation in the Rb+' animals.
Molecular analyses suggest a novel mechanism in which p107 and p130 compensate for the loss
of pRB by re-establishing the proper regulation of the activating E2Fs. The function of E2F4 in
the developmental phenotypes arising from homozygous mutation of Rb was also assessed. In
contrast to the tumor setting, E2F4 loss aggravated the placental defect in the Rb-'- mice, resulting
in earlier lethality. Furthermore, there was no cooperation between E2F4 and pRB within the
developing embryo. These results indicate that E2F4 acts in a manner differing from the
activating E2Fs in mediating the effects of pRB deficiency in development. Thus, this study has
established that E2F4 is a key downstream effector of pRB and has reshaped our understanding
of the roles of the activating and repressive E2Fs with respect to the pocket proteins.
Thesis Supervisor: Jacqueline A. Lees
Title: Professor of Biology
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Chapter One
Introduction
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Part I: The Retinoblastoma Tumor Suppressor Protein
Genetic factors have long been linked to the development of cancer. This was
substantiated by the discovery of oncogenes and tumor suppressor genes, which were primarily
identified by their mutated states in human cancers. The retinoblastoma gene (RB-I) was the
first tumor suppressor to be isolated and has been the prototypical model for the study of this
class of genes (Friend et al. 1986; Fung et al. 1987; Lee et al. 1987a). Individuals with one
mutated RB-I allele develop tumors associated with the loss of the remaining wild-type allele
(reviewed in Lohmann and Gallie 2004). The importance of the retinoblastoma protein, pRB, in
cell cycle control is underscored by the fact that RB-I is mutated in one-third of all human
cancers and the gene product is functionally inactivated in most (Weinberg 1992; Sherr 1996).
Molecular and cellular studies, as well as analyses of mutant mouse models, have revealed that
pRB has critical functions in cell cycle regulation, terminal differentiation and cell survival.
Furthermore, studies have demonstrated that pRB shares many functional and structural
properties with two related proteins, p107 and p130. Since p107 and p130 have not been
identified as tumor suppressor proteins, it will be essential to determine the underlying
mechanism responsible for this difference.
A. Discovery and characterization of the retinoblastoma protein
Retinoblastoma is a pediatric tumor of the eye that occurs in familial and sporadic forms
(reviewed in Lohmann and Gallie 2004). The sporadic form is usually characterized by a
unilateral, unifocal tumor in the retina. Familial retinoblastoma often manifests as bilateral,
multifocal retinal tumors and is frequently accompanied by other tumor types, including
osteosarcomas. Based on statistical analysis of the inheritance patterns and occurrences of these
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two forms of retinoblastoma, A. G. Knudson proposed the two-hit hypothesis, which postulates
that two mutations are required for tumor formation (Knudson 1971). Thus, non-hereditary
retinoblastoma would result from acquisition of two somatic mutations whereas individuals with
one inherited germline mutation would require only one somatic mutation for tumorigenesis.
Retinoblastoma was indeed found to arise from homozygous loss of one genetic locus.
Retinoblastoma susceptibility was mapped to chromosome 13q14 based on cytogenetic studies
of non-tumorigenic cells, such as lymphocytes and fibroblasts, from retinoblastoma patients
(Sparkes et al. 1980; Benedict et al. 1983; Dryja et al. 1986). RB-I was subsequently cloned by
chromosomal walking techniques and genetic lesions at this locus were verified to occur in
retinoblastomas, as well as osteosarcomas (Friend et al. 1986; Fung et al. 1987; Lee et al. 1987a).
Mutations in RB-1 have also been characterized in small cell lung carcinoma (Harbour et al.
1988; Yokota et al. 1988), breast cancer (Lee et al. 1988; T'Ang et al. 1988), and prostate cancer
(Bookstein et al. 1990a). Loss of pRB was first demonstrated to be essential for tumorigenesis
when the oncogenic transformation properties of RB-i-deficient cancer cell lines, including
retinoblastoma, osteosarcoma and prostate, were suppressed upon reintroduction of functional
pRB (Huang et al. 1988; Bookstein et al. 1990a).
The RB-I locus spans 183 kb and encodes a 928 amino acid nuclear protein (reviewed in
Lohmann and Gallie 2004). Structurally, the 110 kD protein has three distinct protein binding
domains (Figure 1). The A and B domains compose the pocket structure, which is a frequent site
for naturally occurring mutations (Hu et al. 1990; Kaelin et al. 1990). In addition, many pRB-
interacting proteins bind to the A/B pocket (reviewed in Morris and Dyson 2001). The pocket
domain is not sufficient to suppress cellular growth alone (Huang et al. 1992; Qin et al. 1992;
Hiebert 1993). A portion of the C-terminal domain is also required for growth suppression,
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Figure 1. The pocket protein family.
The homologous domains of the pocket proteins, pRB, p107 and p130, are indicated in
the schematic diagram. The A and B domains comprise the pocket domain, which is
conserved in all three proteins. In contrast, the C domain in pRB is not conserved in the
other pocket proteins. p107 and p130 are more closely related to each other than to pRB
and they have a larger spacer region which contains a cyclin binding domain.
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which together with the A/B pocket are referred to as the large pocket. The C domain is
important for binding to a subset of pRB binding partners, such as c-Abl (Welch and Wang
1993), MDM2 (Xiao et al. 1995) and PPla (Durfee et al. 1993; Ludlow et al. 1993). The A/B
pocket and C domains are functionally independent in that they can interact with separate
proteins simultaneously (Welch and Wang 1993).
Viral oncoproteins, such as adenovirus early region 1A protein (E1A), simian virus 40
(SV40) large T antigen and human papillomavirus (HPV) type 16 E7 protein, interact with pRB
to mediate cellular transformation (DeCaprio et al. 1988; Whyte et al. 1988; Dyson et al. 1989;
Dyson et al. 1990). The conserved LxCxE motif in the viral oncoproteins binds to pRB and is
required for transformation (DeCaprio et al. 1988; Dyson et al. 1989; Ewen et al. 1989; Dyson et
al. 1992). Moreover, the viral oncoproteins bind to the A/B pocket domain of pRB (Hu et al.
1990; Huang et al. 1990; Kaelin et al. 1990). The crystal structure reveals that the LxCxE motif
of an HPV E7 peptide directly associates with a conserved groove on the B domain of pocket
while the A domain is needed for stable folding of the B domain (Lee et al. 1998). Thus, the
viral oncoproteins efficiently inactivate pRB by interfering with interactions between the pocket
domain of pRB and numerous cellular proteins.
pRB expression is relatively constant throughout the cell cycle and its activity is
regulated by phosphorylation (Lee et al. 1987b). The hypophosphorylated, or active, form of
pRB exclusively binds to the SV40 large T oncoprotein (Ludlow et al. 1989; Shew et al. 1989).
Once phosphorylated, pRB is inactivated (Cobrinik et al. 1992). The phosphorylation status of
pRB varies during the cell cycle (Buchkovich et al. 1989; Chen et al. 1989; DeCaprio et al. 1989;
Mihara et al. 1989). In GO/G1-arrested cells, as well as in differentiated cells, pRB is
underphosphorylated. In late G1 and S phases, pRB is increasingly phosphorylated by cyclin
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D/CDK4 and cyclin D/CDK6 followed by cyclin E/CDK2 (Hinds et al. 1992; Ewen et al. 1993;
Kato et al. 1993; Hatakeyama et al. 1994; Lundberg and Weinberg 1998). pRB is then
dephosphorylated late in mitosis by protein phosphatase 1 (Ludlow et al. 1993). Thus, the
hypophosphorylated form of pRB acts to promote growth suppression.
B. The pocket protein family
The pocket domain of pRB is the hallmark for pRB-related proteins, also referred to as
the pocket proteins. The pocket protein family consists of three members, pRB, p107 and p130.
p107 and p130 were initially identified as targets bound by small DNA tumor viruses (Harlow et
al. 1986; Whyte et al. 1989). Subsequent isolation of their cDNAs revealed significant
homology to pRB in the A/B pocket domain (Figure 1) (Ewen et al. 1991; Hannon et al. 1993; Li
et al. 1993). Consistent with properties observed for pRB, these proteins are phosphorylated in a
cell cycle dependent manner, bind to the E2F transcription factors (discussed in Part II) and can
induce G1 growth inhibition when ectopically expressed in a variety of cell lines (reviewed in
Classon and Dyson 2001).
Despite the similarities, there are clear differences between the pocket proteins.
Structurally, p107 and p130 are most alike with approximately 50% amino acid identity to each
other versus 30-35% to pRB (Figure 1) (Ewen et al. 1991; Hannon et al. 1993; Li et al. 1993).
p107 and p130 have a larger spacer region between the A and B domains compared to that found
in pRB. This region is important for cyclin E/CDK2 and cyclin A/CDK2 binding to p107 and
p130 (Ewen et al. 1992; Faha et al. 1992; Hannon et al. 1993; Li et al. 1993). Although the
biological significance of cyclin dependent kinase (CDK) binding is unclear, the spacer region
has been demonstrated to be necessary for growth suppression by p107. Moreover, p107 and
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p130 are not homologous to pRB at the carboxyl terminal regions. Finally, the pocket proteins
have distinct expression patterns during the cell cycle. While p130 is induced in quiescent cells,
p107 is highly expressed in proliferating cells and pRB is moderately expressed throughout the
cell cycle (Chen et al. 1989; Baldi et al. 1995; Beijersbergen et al. 1995; Mayol et al. 1995; Xiao
et al. 1996). These properties may reflect functional differences among the pocket proteins.
The most striking physiological difference between the pocket proteins is that only pRB
is classified as a tumor suppressor, since homozygous inactivation of RB-I has been detected in
numerous human cancers. There is emerging evidence for p130 involvement in cancer;
however, it is unclear whether loss of this locus acts in a manner analogous to RB-I. In addition
to decreased p130 expression correlating with increased tumor malignancy (Baldi et al. 1997;
Susini et al. 1998; Tanaka et al. 1999), mutations in the p130 gene have been identified in
nasopharyngeal (Claudio et al. 2000a), and small cell lung and non-small cell lung carcinomas
(Baldi et al. 1997; Helin et al. 1997; Claudio et al. 2000b). Accompanying loss of the RB-1
locus, however, was detected in some cases (Helin et al. 1997), suggesting that loss of pRB
function may be the basis for tumorigenesis. Systematic analyses of RB-I status will be
necessary to determine whether loss of p130 is sufficient for tumor growth in these cases.
Mouse models have been used at length to investigate the growth properties associated with the
pocket proteins and, consistent with in vitro experiments with human cells, the pocket proteins
have significant functional redundancy as well as distinct roles. (This will be discussed in detail
below.) At any rate, pRB is the most extensively studied pocket protein due to the clinical
implications of RB-I loss.
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C. Mechanisms of transcriptional repression
The growth inhibitory functions of pRB are largely dependent upon its ability to bind to
the cellular transcription factor E2F (also identified as DRTF1), the most well characterized
downstream effector of the pocket proteins (reviewed in Trimarchi and Lees 2002). The
identification of E2F-responsive genes established that E2F activity was essential for control of
the G1 to S transition of the cell cycle. This generated a straightforward model for pRB
regulation of the cell cycle. In the G1 phase, hypophosphorylated pRB inhibits E2F
transcriptional activity. When pRB is inactivated, either by phosphorylation or viral oncoprotein
binding, disruption of the pRB-E2F complex and concomitant release of E2F results in the
transcriptional activation of E2F target genes that are necessary for S phase entry. Therefore,
pRB is a pivotal regulator of E2F activity. Studies into the mechanism of pRB-mediated
repression have shown that the repressive action of pRB can be achieved in more than one way.
(E2F will be discussed in Part II.)
One mechanism by which pRB inhibits E2F activity is by physically obstructing
transcriptional activation. E2F does not have an LxCxE motif, which the viral oncoproteins use
to bind to pRB. Instead, E2F interacts with pRB through an 18 amino acid sequence found
within the transactivation domain (Helin et al. 1992). Thus, upon stable complex formation,
pRB conceals the E2F transactivation domain and prevents transcription of target genes (Hiebert
et al. 1992; Flemington et al. 1993; Helin et al. 1993a). This is illustrated by the crystal structure
of the pRB pocket domain bound to the pRB binding domain of an E2F transcription factor (Lee
et al. 2002). Several highly conserved residues in the transactivation domain of E2F are
inaccessible upon interaction with pRB. Therefore, there is a structural basis for this type of
'passive' repression.
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Pocket protein-E2F complexes have been found in association with chromatin
remodeling enzymes, suggesting a mechanism for the 'active' repression of E2F transcriptional
activity. Histone deacetylases (HDACs), whose activities are widely associated with
transcriptional repression, interact with pRB to repress E2F target gene expression (Brehm et al.
1998; Luo et al. 1998; Magnaghi-Jaulin et al. 1998). Transcriptional co-repressors that cooperate
with HDACs, such as RBP1, also bind to pRB, suggesting that pRB may participate in larger co-
repressor complexes to mediate transcriptional repression (Lai et al. 1999). In addition, p107
and p130 interact with HDAC1 at E2F-responsive promoters in GO and early G1 phases of the
cell cycle (Ferreira et al. 1998; Rayman et al. 2002).
pRB may also affect transcription through nucleosome remodeling. pRB can associate
with BRG1 and hBRM, human homologs to components of the yeast SWI/SNF complex
(Dunaief et al. 1994; Strober et al. 1996; Trouche et al. 1997). Though initial studies
demonstrated the requirement for BRG1 and pRB to effectively arrest cells, there is growing
evidence that pRB can affect transcription in a BRG1-independent manner. For example, pRB-
mediated growth arrest can occur in the presence of BRG1 lacking the ability to bind to pRB
(Kang et al. 2004). These differences may be a consequence of over-expression or due to cell
type specificity. Further analyses will be necessary to determine the exact nature of the
interaction between pRB and members of the human SWI/SNF complex.
Another mode of pRB-mediated 'active' repression may be facilitated by histone
methyltransferases. pRB can bind to the histone methyltransferase SUV39H1 at the cyclin E
promoter, an E2F target gene (Nielsen et al. 2001). SUV39H1 methylates lysine9 on histone H3,
a modification corresponding to transcriptionally silent chromatin, and leads to the recruitment
of a heterochromatin protein, HP-1 (Bannister et al. 2001; Lachner et al. 2001). pRB association
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with HP-1 at E2F-responsive promoters has also been detected in senescent cells (Narita et al.
2003). Furthermore, interaction between p107 (or p130) and SUV39H1 has been reported at the
dihydrofolate reductase (DHFR) promoter (Nicolas et al. 2003). The physiological significance
of this last observation remains to be determined. In general, much of the data on pocket protein
recruitment of chromatin remodeling enzymes is based on over-expression studies. Thus, it is
not clear whether the pocket proteins have differential binding properties to the chromatin
modifying factors as well as to specific promoters in vivo.
The pocket proteins can also mediate transcriptional repression through direct interaction
with components of the basal transcriptional machinery. The entire pocket protein family can
negatively regulate RNA polymerase III (PolIII) in transfection and in vitro transcription assays
(White et al. 1995; Sutcliffe et al. 1999). In fact, primary fibroblasts lacking either pRB or p107
and p130 have elevated levels of PolIII transcription. PolIII repression may be achieved through
direct interaction with TFIIIB, a multi-subunit complex that recruits PolIII to promoters (Chu et
al. 1997; Larminie et al. 1997; Sutcliffe et al. 1999).
D. Regulation of cellular proliferation
To date, there are over 100 proteins reported to interact with pRB (reviewed in Morris
and Dyson 2001). In addition to factors that regulate the cell cycle, pRB interacts with cellular
proteins involved in additional processes, including differentiation and apoptosis (discussed in
the next section). In order to understand how pRB may relate cell cycle control with other
biological processes, it is important to determine the mechanisms through which pRB, as well as
the pocket proteins, function in each process.
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The pocket proteins are key regulators of the G1 phase of the cell cycle. Studies
employing microinjection, infection and transfection techniques showed that over-expression of
a pocket protein can lead to growth arrest in a variety of cell types (Huang et al. 1988; Bookstein
et al. 1990b; Vairo et al. 1995; Zhu et al. 1995). The physiological significance of the pRB
family members has been extensively studied through the analysis of the mouse embryonic
fibroblasts (MEFs) resulting from mutant mouse models. The role of pRB in the G1 to S
transition is exemplified by the fact that Rb-'- MEFs have a defect in G1 control. Cell cycle
profiling has demonstrated that Rb-' cells have a shortened G1 phase and a proportionally
lengthened S phase (Herrera et al. 1996). Although the proliferation rate in these cells is
unchanged relative to wild-type cells, there is a multitude of evidence to suggest that this is
largely due to functional compensation by the other pocket proteins. First, Rb-' and p130'- cells
have elevated p107 mRNA and protein levels (Herrera et al. 1996; Mulligan et al. 1998). In
quiescent p130' T lymphocytes, the increased p107 expression correlates with increased
p107/E2F binding (Mulligan et al., 1998). Second, the simultaneous absence of two pocket
proteins, p107 and p130 or p107 and pRB, exhibit a further decrease in the proportion of cells in
G1 phase relative to Rb- - MEFs (Hurford et al. 1997; Classon et al. 2000; Dannenberg et al.
2000). Rb -';p107 - - cells also have a slightly increased proliferative capacity compared to Rb-'
cells (Dannenberg et al. 2000). Third, cells deficient for all three pocket proteins are
unresponsive to a variety of growth arrest signals, including contact inhibition, serum
deprivation, DNA damage, and senescence inducers (Dannenberg et al. 2000; Sage et al. 2000).
Finally, acute loss of Rb in quiescent primary fibroblasts stimulates cell cycle re-entry due to the
inability to induce p107 in a timely manner (Sage et al. 2003). Thus, the pocket proteins have
overlapping functions in blocking progression through the cell cycle.
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Since only pRB is a bona fide tumor suppressor, there must be functional differences
between the pocket proteins. The growth arrest achieved by the pocket proteins is due, in part, to
the regulation of different subsets of genes. While loss of either p107 or p130 does not result in
E2F target gene deregulation or alterations in cell cycle kinetics, the absence of both induces the
expression of a number of E2F target genes (i.e., cyclin A2, E2fJ, B-myb, thymidylate synthase,
ribonucleotide reductase subunit M2 and cdc2) (Hurford et al. 1997). On the other hand, p107
and cyclin E are induced in Rb- - MEFs (Herrera et al. 1996). Thus, the derepressed E2F-
responsive genes in plO7'-,p130 -'- fibroblasts differ from those seen in Rb-'- MEFs. This may be
due to the differential binding properties of the pocket proteins to the E2F transcription factors
(see Part II).
There is growing evidence that pRB has roles in the cell cycle outside of the G1 to S
transition. pRB mediates repression of cyclin A, which subsequently affects cyclin B
degradation, suggesting a role in G2/M control (Lukas et al. 1999). More recent work has shown
that the gene encoding Mad2, a mitosis spindle checkpoint component, is repressed by pRb-E2F
complexes in mouse and human cells (Hernando et al. 2004). In fact, RB-I ablation in cells
induces MAD2 expression and results in aneuploidy, implicating pRB in spindle checkpoint
regulation. pRB also has a role in S phase checkpoint control in response to DNA damaging
agents (Knudsen et al. 1998). Moreover, there is evidence that pRB has a functions in
maintaining GO arrest and senescence. Acute inactivation of pRB in murine senescent cells
induces cells to re-enter the cell cycle (Sage et al., 2003). In addition, pRB has been detected at
E2F-responsive promoters during senescence (Narita et al., 2003) and growth arrest in response
to p16INK4a (Dahiya et al. 2001; Young and Longmore 2004). Furthermore, cyclin C/cdk3
phosphorylation of pRB facilitates transition from GO to G1 (Ren and Rollins 2004). Thus, these
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studies suggest that pRB has functions throughout the cell cycle. Further studies are required to
determine the mechanisms through which pRB is functioning in these processes, as well as how
it coordinates multiple tasks.
E. Roles of the pocket proteins in development and differentiation
The analyses of genetically modified mice for members of the pocket protein family have
underscored the roles of these proteins in normal development and differentiation. It has become
apparent that while pRB, p107 and p130 share functional properties, they also possess distinct
and separate functions in vivo.
i. The retinoblastoma protein
The analyses of mutant mouse models have shown that pRB regulates cellular
proliferation, apoptosis and terminal differentiation. Rb-' mice die in utero by embryonic day (E)
15.5 with defects in the nervous system, ocular lens, erythropoeisis and extra-embryonic tissues
(Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992; Wu et al. 2003). The cause of death in
these animals is a primary placental defect that results in reduced nutrient and gas delivery to the
embryos (Wu et al. 2003). In order to circumvent the early lethality of Rb-'- mice and to analyze
the effects of pRB loss on later stages of development and in specific tissues, numerous groups
have employed transgenic, chimeric and conditional gene targeting strategies (Robanus-Maandag
et al. 1994; Williams et al. 1994b; Zacksenhaus et al. 1996; Lipinski et al. 2001; Ferguson et al.
2002; de Bruin et al. 2003b; MacPherson et al. 2003; Wu et al. 2003; Zhang et al. 2004). These
studies have implicated pRB in additional processes, such as muscle differentiation.
Furthermore, they have revealed that some of the initially characterized developmental defects in
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the Rb-'- embryos are cell non-autonomous. Other studies have assessed the involvement of pRB
downstream effectors in the developmental functions of pRB through the generation of
compound mutant animals (discussed in Part II).
Rb'- animals exhibit inappropriate cellular proliferation and widespread apoptosis in a
number of tissues, including the lens of the eye, the central nervous system (CNS), and the
peripheral nervous system (PNS) (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992; Lee et al.
1994; Morgenbesser et al. 1994). The status of p53, a critical regulator of apoptosis and growth
arrest, was assessed in various tissues of the Rb'- animals (Morgenbesser et al. 1994; Macleod et
al. 1996). In the developing lens and the CNS, apoptosis was dependent upon p53. As such,
combined loss of p53 and pRB suppressed the apoptosis in these structures. In contrast, p19ARF,
an upstream regulator of p53, was dispensable for the programmed cell death in the Rb-' animals
since there was no amelioration of the apoptotic defects in Rb;pl9,RF double mutants (Tsai et al.
2002). With respect to the inappropriate proliferation arising from pRB loss, the absence of p53
or p19 increased the level of ectopic DNA synthesis, corresponding with the role of the p53
pathway in growth arrest (Macleod et al. 1996; Tsai et al. 2002). Upon investigation of the
apoptosis in the PNS, it was found to be p53-independent (Macleod et al., 1996) and caspase 3-
dependent (Simpson et al. 2001). Thus, pRB is critical for cell cycle control and cell survival in
vivo.
The first indication that the apoptosis originally characterized in the nervous system was
a cell non-autonomous effect came from the analysis of chimeric mice (Robanus-Maandag et al.
1994; Williams et al. 1994b; Lipinski et al. 2001). Apoptosis in the CNS is also suppressed in
mice with specific homozygous deletion of Rb in either the CNS (MacPherson et al. 2003) or the
telencephalon (Ferguson et al. 2002). Conditional and tetraploid experiments that resulted in Rb-
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/' embryos provided with normal functioning placentas further support that apoptosis in the
nervous system is not due to the loss of pRB (de Bruin et al. 2003b; Wu et al. 2003). Instead, the
programmed cell death was a consequence of defects in the extra-embryonic tissues, which led to
hypoxic conditions for the developing embryo. In most of these studies, apoptosis in the ocular
lens persisted as well as the increased levels of inappropriate proliferation in the various tissues,
indicating cell autonomous functions of pRB. Although the involvement of pRB in cellular
survival is not as widespread as initially thought, it does have an important role in the lens.
Analyses of chimeric animals also suggested that the erythroid defect in Rb-' mice was
cell non-autonomous (Robanus-Maandag et al. 1994; Williams et al. 1994b). Rb-' embryos die
in mid-gestation from E13.5 to E15.5, a time period when the fetal liver is the major site of
definitive erythropoiesis (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992). Rb-' mice are
pale in appearance, have reduced cellularity in the fetal livers and have an increased level of
immature nucleated erythrocytes. Chimeric mice, on the other hand, have apparently normal
levels of mature enucleated red blood cells. Moreover, Rb mutant mice provided with normal
functioning placentas also have a significant amelioration in erythropoiesis, similar to the
apoptosis in the CNS (de Bruin et al. 2003b). Rb-' fetal liver cells are also able to reconstitute
lethally irradiated wild-type recipient mice in adoptive transfer experiments (Hu et al. 1997;
Spike et al. 2004). More recently, it was suggested that the insufficient microenvironment
provided by the macrophages in the Rb-'- fetal livers was responsible for the defects in
erythropoiesis (Iavarone et al. 2004). All these lines of evidence point to a cell non-autonomous
effect of pRB loss in developing erythrocytes.
While there is no doubt that the placental defect significantly contributes to the
erythropoietic defect in Rb-' mice, there are some indications that pRB does have a cell intrinsic
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role in red blood cell maturation. First, a significant fraction of nucleated erythrocytes persists in
chimeric and conditional Rb mutant mice (Hu et al. 1997; de Bruin et al. 2003b). Second, Rb-'-
erythroid progenitors fail to differentiate in co-culture experiments with wild-type progenitor
cells (Clark et al. 2004). Third, acute deletion of Rb in cultured erythroblasts leads to the same
defects observed in Rb-'- cells (Spike et al. 2004). Fourth, adoptive transfer experiments with Rb-
'-;Rb+"' chimeric bone marrow cells have demonstrated that, despite the presence of wild-type
cells, the mutant cells failed to exit the cell cycle and did not properly regulate markers required
for terminal differentiation (Spike et al. 2004). Finally, it was suggested that the cell intrinsic
role of pRB is in stress erythropoiesis since the erythroid defect, which was found to be absent in
young Rb-';Rb +'+ chimeras, was evident in aging chimeras developing tumors and in mice with
hemolytic anemia (Spike et al., 2004). Thus, there is growing evidence that pRB does, in fact,
have a role in erythroblast differentiation although this currently remains controversial.
In rescue experiments where Rb'- mice survive beyond E15.5, the animals exhibit
additional differentiation defects, most notably in the skeletal muscle (Zacksenhaus et al. 1996;
de Bruin et al. 2003b). pRB loss results in inappropriate DNA synthesis within myotubes,
myoblast apoptosis, abnormal myotubes, and reduced muscle fibers. Marker expression analysis
in transgenic Rb mutants and in vitro differentiation assays of MEFs, C2C12 and Saos-2 cells
shows that pRB loss does not disrupt early marker expression (myogenin and MEF2), but does
inhibit the expression of late markers (MCK and MRF4) (Novitch et al. 1996; Zacksenhaus et al.
1996; Li et al. 2000). This suggests that while pRB is not involved in cell fate determination,
pRB does participate in end-stage differentiation. There seems to be some level of functional
compensation by the other pocket proteins during myogenesis since teratocarcinomas from
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embryonic stem cells lacking all three pocket proteins have a dramatic lack of muscle cells
compared to teratocarcinomas from wild-type cells (Dannenberg et al. 2000).
The molecular mechanism underlying pRB function during muscle differentiation has
been extensively investigated in vitro. The role of pRB in muscle differentiation depends on
pRB association with tissue-specific transcriptional regulators that promote differentiation. It
has been proposed that pRB enhances MyoD transcriptional activity to promote MEF2
transcription (Gu et al. 1993). To date, this interaction has not been detected in vivo, suggesting
that pRB may function by an alternate mechanism to regulate MyoD (Halevy et al. 1995; Zhang
et al. 1999b; Li et al. 2000). Recently, loss of N-Ras, a proto-oncogene, in the Rb-deficient
background resulted in an amelioration of the skeletal muscle defects attributed to pRB loss
(Takahashi et al. 2003). In addition to restored muscle fiber density and myotube length, MCK
expression (a late marker) was normal and transcriptional activity of MyoD and MEF2 were
enhanced in vitro. Thus, pRB influences MyoD activity, but the precise mechanism of action
remains to be determined. Other pRB interacting proteins, such as HBP1, MRF4 and myogenin,
have been suggested to have a role in this process, but further studies are necessary to determine
the nature of the interactions (Gu et al. 1993; Shih et al. 1998).
In addition to myogenesis, pRB has been significantly studied in the development and
differentiation of other tissues. In neurogenesis and adipogenesis, early marker expression is not
affected by pRB loss, though the expression of late differentiation markers is disrupted (Lee et
al. 1994; Chen et al. 1996). This is highly reminiscent of pRB function in muscle differentiation,
suggesting that pRB may function in an analogous manner to promote differentiation in different
cell types. Most evidence for pRB involvement in differentiation, including osteogenesis and
adipogenesis, comes from human tumor cell lines and primary murine cells since the available
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mouse models do not exhibit defects in these tissues. With the increasing number of tissue-
specific Cre mouse strains, conditional knockout technology will be important to investigate
pRB function in a variety of tissues.
ii. p107 and p130
The analyses of germline and conditional mutant mice have contributed immensely to our
understanding of the functional similarities and differences among the pocket proteins. In
contrast to Rb-' mice, p107' / and p130'- mice (on a C57B1/6 background) are viable and have no
overt abnormalities (Cobrinik et al. 1996; Lee et al. 1996). On a Balb/c background, however,
p130-'/ animals die in utero from El 11 to E13 with neural and muscle defects (LeCouter et al.
1998). In addition, p107 ' animals on a Balb/c background are viable, but are growth retarded
and display myeloid hyperproliferation (LeCouter et al. 1998). Recent evidence has shown that
the disrupted p130 allele in the C57B1/6 background is a hypomorphic allele (Rayman et al.
2002). Thus, the residual p130 activity may be modulating the phenotypes associated with p130
loss, resulting in the observed differences in the different genetic backgrounds. Yet, strain-
specific effects can clearly influence the developmental consequences associated with p107 loss
and may also be affecting the phenotypes caused by p130 loss.
Compound mutant mouse models have confirmed the redundant nature of the pocket
proteins. In general, any combination of homozygous mutations results in decreased survival
and accelerated, or novel, defects. p07;p130-' - mice (on a 129/Sv x C57B1/6 genetic
background) die perinatally and exhibit endochondral bone defects and defects in chondrocyte
cell cycle exit (Cobrinik et al. 1996). Furthermore, the loss of either p107 or p130 in the Rb-'-
background causes earlier lethality and leads to increased cell death in the central nervous system
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(Lee et al. 1996). In light of the Rb-related placental defect, the earlier lethality may be due to an
exacerbation of this phenotype. Further studies will be necessary to determine whether p107 and
p130 have a role in the extra-embryonic tissues. Finally, the complete ablation of all the pocket
proteins results in greatly reduced survival, as evidenced by the inability to generate primary
mouse fibroblasts from germline mutant mice (Dannenberg et al. 2000; Sage et al. 2000). Thus,
the pocket proteins have substantial overlap in their functions during normal development.
F. The tumor suppressive properties of the retinoblastoma protein
Of the pocket proteins, only pRB is classified as a tumor suppressor. Humans and mice
with one mutant Rb allele are predisposed to develop tumors. Targeted disruption of the Rb gene
in mice, however, does not lead to retinoblastoma, as observed in humans. Rb+'- mice have a
reduced lifespan of approximately 1 year and are predisposed to develop pituitary
adenocarcinomas (90-100% penetrance) and medullary thyroid tumors (approximately 70%
penetrance) (Jacks et al. 1992; Hu et al. 1994; Williams et al. 1994a). Similarly, retinoblastoma
does not form in chimeric animals generated from injection of Rb-'- embryonic stem cells into
wild-type blastocysts (Robanus-Maandag et al. 1994; Williams et al. 1994b). Instead, they
develop the same tumors observed in Rb+'- mice at an accelerated rate. It will be important to
determine the cause for the tissue specificity of tumor formation between species, as well as
within a given organism.
Initially, it was thought that the balance between apoptosis and proliferation was essential
for retinal tumor growth in mice. In Rb-'- chimeric retinas, there are considerable levels of
ectopic proliferation and cell death (Robanus-Maandag et al. 1994). Transgenic animals
expressing SV40 large T antigen or HPV E7 and E6 oncoproteins in the retina develop
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retinoblastoma (Windle et al. 1990; Howes et al. 1994; Saenz Robles et al. 1994). These models
result in the inactivation of all the pocket proteins as well as p53. On the other hand, mere
expression of HPV E7, which inhibits the pocket proteins, in the retina does not lead to tumor
formation (Howes et al. 1994). Thus, murine retinoblastoma formation was thought to rely upon
loss of p53 to evade programmed cell death.
The first line of evidence that functional redundancy may account for the lack of
retinoblastoma formation in Rb mutant mice came from compound mutant mouse studies. Rb+'-
;p107'- mice develop pituitary and thyroid tumors, but also display retinal dysplasia (Lee et al.
1996). In chimeric and conditional mice with specific loss of pRB and p107 or pRB and p130 in
the retina, retinoblastomas develop at high frequencies (Robanus-Maandag et al. 1998; Chen et
al. 2004; Dannenberg et al. 2004; MacPherson et al. 2004). Identification of the cell type of
origin, amacrine cells, indicated that there is no requirement to override the apoptotic program
for retinal tumor development, since the aberrantly proliferating cells originated from a region
devoid of apoptosis. Thus, in contrast to humans, the levels of the pocket proteins seem to differ
in the murine retinas in which pRB deficiency is insufficient to promote tumor formation.
Functional compensation by p107 and p130 in the absence of pRB has also been
observed in other tissues since Rb'-;plO7'- and Rb'-;pl30 -' - germline mutant mice and Rb-'
;p107' and Rb-'-;p30-'- chimeric animals develop an array of novel tumor types not observed in
single mutant chimeras (Robanus-Maandag et al. 1998; Dannenberg et al. 2004). Further studies
will be helpful to determine the molecular mechanisms underlying the tissue-specific nature of
tumor development in the absence of pRB. It may simply be a matter of the expression levels of
the various pocket proteins. Yet, elucidating the regulatory pathways in which the pocket
proteins function will be critical since these proteins could merely be acting in the same pathway
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or have non-overlapping functions with additive effects. Addressing these issues will provide
further insight into the functions of the pocket proteins during oncogenic transformation and
normal development, which will inevitably broaden our understanding of how functional
inactivation of pRB promotes human cancers.
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Part II: The E2F Family of Transcription Factors
A. Discovery and characterization of the E2F transcription factor
The E2F transcription factor was first identified as a cellular component that cooperates
with E1A to activate the transcription of the early adenoviral E2 gene (Kovesdi et al. 1986).
Transcriptional activation, and consequently cellular proliferation, by E1A were dependent on
E2F DNA recognition sites, 5'-TTTCGCGC-3', in the E2 promoter and the disruption of cellular
E2F-pRB complexes (Kovesdi et al. 1987; Yee et al. 1987). The properties of E2F paralleled
those of another cellular activity, DRTF1 (differentiation regulated transcription factor 1), which
decreased during F9 embryonal carcinoma stem cell differentiation (La Thangue and Rigby
1987). DRTF1 bound to the same DNA binding motif required for E2F activity and DRTF1
interacted with pRB (La Thangue and Rigby 1987; Bandara and La Thangue 1991). Subsequent
cloning of the cDNAs demonstrated that these were in fact the same factor.
The E2F transcription factor plays a pivotal role in the regulation of the G1 to S transition
of the cell cycle. E2F recognition sites have been identified in genes involved in cell cycle
regulation (e.g., B-myb, cdc2, Cyclin E, E2fl, Rb), nucleotide metabolism (e.g., DHFR,
ribonucleotide reductase, thymidine kinase) and DNA replication (e.g., PCNA, MCMs, cdc6)
(reviewed in Trimarchi and Lees 2002). At least one intact E2F DNA binding site is important
for the temporal expression of most of these genes, supporting a principal role for E2F
transcriptional activity in regulating cell division (Blake and Azizkhan 1989; Means et al. 1992).
B. Members of the E2F transcription factor family
E2F transcriptional activity is carried out by a heterodimer of one E2F protein and one
DP protein (Bandara et al. 1993; Helin et al. 1993b; Krek et al. 1993). To date, there are eight
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mammalian E2F genes (E2fl through E2f8) and two DP genes (DPi and DP2). The DP proteins
can bind to E2F1 through E2F6 interchangeably with no differences between DP1- or DP2-
containing E2F complexes. The DP moiety enhances DNA binding activity and the E2F subunit
confers functional specificity. Structural and functional differences have led to the division of
the E2Fs into three subgroups: the activating E2Fs (E2F1, E2F2, E2F3a), the repressive E2Fs
(E2F3b, E2F4, E2F5), and the E2Fs that act as transcriptional repressors independently of pocket
protein regulation (E2F6, E2F7, E2F8).
i. E2F1
The founding member of the E2F family of transcription factors is now termed E2F1.
E2F1 was cloned as a result of its ability to interact with pRB (Helin et al. 1992; Kaelin et al.
1992; Shan et al. 1992). Structural analysis identified distinct domains for DNA binding, DP
dimerization and transactivation (Figure 2). The DP dimerization domain consists of a
hydrophobic heptad repeat (a putative leucine zipper) and a marked box motif. Both regions are
important for DP dimerization and the marked box is also involved in DNA bending (Cress and
Nevins 1996). Furthermore, the pRB binding domain lies within the acidic transactivation
domain (Helin et al. 1992; Kaelin et al. 1992). Notably, the pRB binding region does not contain
the conserved LxCxE motif that is found in other pRB-interacting proteins, such as the viral
oncoproteins E1A, SV40 large T antigen and HPV E7. Functional studies revealed that E2F1 is
a strong transcriptional activator and is solely regulated by one pocket protein, pRB. In addition,
E2F1 expression is cell cycle regulated with induced expression during G1/S.
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Figure 2. The E2F family of transcription factors.
'
The conserved domains of the E2F and DP proteins are indicated in the schematic
diagram. The DNA binding domain (DBD) is conserved in all of the E2F and DP
proteins. Proteins that function as heterodimers composed of an E2F protein (confers
functional specificity) and a DP protein (enhances DNA binding) contain a dimerization
domain (DD). DDs of E2F1 through E2F6 consist of a putative leucine zipper (LZ) and a
marked box (MB) region. The transactivation domain (TA) and sequences for pocket
protein binding (PP) are conserved in E2F1 through E2F5. The cyclin A/cdk binding
domain (CA) is only present in E2F1, E2F2, E2F3a and E2F3b. Based on the
homologous domains in the E2F proteins, they can be divided into three distinct groups:
the activating E2Fs (E2FI, E2F2, E2F3a), the repressive E2Fs (E2F3b, E2F4, E2F5), and
the E2Fs that are not regulated by the pocket proteins (E2F6, E2F7, E2F8).
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ii. E2F2 and E2F3
Electrophoretic mobility shift assays suggested that E2F DNA binding activity in cellular
extracts could not be entirely attributed to E2F1. Low stringency library screening with an E2F1
probe yielded two additional E2F species, E2F2 and E2F3 (Ivey-Hoyle et al. 1993; Lees et al.
1993). These proteins are very similar to E2F1 in structure (Figure 2), function and regulation.
First, the DNA binding, dimerization, transactivation and pRB binding domains are highly
conserved in E2F2 and E2F3 (45%-100% similarity to E2F1) (Lees et al. 1993). Second, E2F2
and E2F3 exclusively bind to pRB and not p107 or p130. Third, E2F2 and E2F3 are expressed
in an equivalent cell cycle regulated pattern as E2F1. Fourth, E2F2 and E2F3 are strong
transcriptional activators and act analogously to E2F1 in over-expression, reporter and DNA
binding assays (Ivey-Hoyle et al. 1993; Lees et al. 1993; Lukas et al. 1996; DeGregori et al.
1997).
Recent findings have shown that the originally identified E2f3 locus encodes two distinct
gene products, E2F3a and E2F3b (Leone et al. 2000). E2F3a is the initially characterized E2F3
protein. E2F3b is transcribed from an intronic promoter that results in an alternative exon 1,
termed exon lb. At the protein level, the first 122 residues at the amino terminus of E2F3a are
absent in E2F3b and replaced with six distinct amino acids. Yet, the remainder of the sequences,
which include domains for cyclin A binding, DNA binding, dimerization, transactivation and
pRB binding, are identical in the two proteins. Thus, like E2F3a, E2F3b is solely regulated by
pRB. In contrast to E2F3a, E2F3b is expressed throughout the cell cycle. Moreover, there is
evidence that instead of transcriptional activation E2F3b participates in transcriptional repression
(Aslanian et al. 2004).
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iii. E2F4 and E2F5
E2F1, E2F2 and E2F3, which only bind to pRB, did not account for all of the E2F DNA
binding activity associated with the three pocket proteins (Shirodkar et al. 1992; Cobrinik et al.
1993). In the pursuit of isolating binding partners to p107 and p130 and/or additional E2F
members, E2F4 and E2F5 emerged (Beijersbergen et al. 1994; Ginsberg et al. 1994; Hijmans et
al. 1995; Sardet et al. 1995). In general, E2F4 and E2F5 had greater homology to each other
(approximately 80% similarity) than to the other identified E2Fs (30-60%) (Figure 2). In
comparison to E2F1, there was significant homology in the DNA binding and pRB binding
domains. Crystallographic analysis of an E2F4-DP2-DNA complex reveals that the DNA
binding domains for both E2F and DP proteins have a winged helix fold and use residues that are
strictly conserved among all family members to contact DNA (Zheng et al. 1999). In contrast to
E2F1, E2F4 and E2F5 are constitutively expressed throughout the cell cycle and are regulated by
various pocket proteins. E2F4 binds to all of the pocket proteins and E2F5 primarily interacts
with p130 in vivo (Beijersbergen et al. 1994; Ginsberg et al. 1994; Hijmans et al. 1995; Moberg
et al. 1996). Although initial studies demonstrated that E2F4 is capable of activating
transcription in vitro, ectopic expression of E2F4 or E2F5 did not effectively induce cell cycle
progression in quiescent cells (Lukas et al. 1996; DeGregori et al. 1997). Thus, E2F4 and E2F5
have overlapping and distinct properties with the previously described E2Fs.
iv. E2F6
The conserved DNA binding and dimerization domains led to the isolation of E2F6 from
a yeast two hybrid assay and EST database searching (Figure 2) (Cartwright et al. 1998; Gaubatz
et al. 1998; Trimarchi et al. 1998). Like the other E2Fs, E2F6 requires DP dimerization for
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efficient DNA binding activity. Consistent with the lack of a pRB binding domain, E2F6 is
regulated independently of pocket protein binding. Yet, E2F6 has a role in E2F-dependent
repression during the cell cycle. Ectopic expression of E2F6 results in an accumulation of S
phase cells and E2F6 has been detected at E2F-responsive promoters during GO and S phases
(Cartwright et al. 1998; Ogawa et al. 2002; Giangrande et al. 2004). Despite such evidence for
E2F-related function, E2F6 loss does not have significant effects on murine development or on
cell cycle properties of MEFs (Storre et al., 2002; M. Courel and J. A. Lees, unpublished data).
Instead, the E2f6 mutant animals have a mild axial skeletal transformation, consistent with a role
for E2F6 in the Polycomb complex (Storre et al. 2002). In further support of this, E2F6
associates with Polycomb Group proteins, which are primarily involved in transcriptional
repression of the Hox genes during development (Trimarchi et al. 2001; Ogawa et al. 2002). In
addition, E2F6 has been implicated in gene silencing at GO in complex with histone
methyltransferases and other sequence-specific DNA binding transcription factors (Ogawa et al.
2002). Thus, the precise nature of E2F6 function remains unclear and further studies are needed.
v. E2F7 and E2F8
The most divergent E2F members, E2F7 and E2F8, were identified most recently (de
Bruin et al. 2003a; Di Stefano et al. 2003; Logan et al. 2004; Maiti et al. 2005). These two
proteins are homologous in structure, expression and function (Figure 2). They contain two
distinct conserved DNA binding domains, resembling the Arabidopsis E2F-like proteins.
Furthermore, DP dimerization is not required for DNA binding and they function as
transcriptional repressors independently of the pocket proteins. Their expression is cell cycle
regulated and ectopic expression leads to diminished cellular proliferation, as well as repression
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of some E2F-responsive genes. Further studies are necessary to determine the physiological role
of these novel E2F family members.
vi. DPI and DP2
DP1 (dimerization partner 1 or DRTF-P1) was isolated as a sequence-specific DNA
binding protein in association with DRTF1 (or E2F1) in murine cells (Girling et al. 1993).
Subsequently, the human DP1 ortholog was cloned and had 95% identity at the amino acid level
to the mouse protein (Helin et al. 1993b). DP1 has significant structural similarities to E2F1
(70% similar in the DNA binding domains), but does not have a pRB binding domain (Figure 2)
(Girling et al. 1993). Yet, DP1 is required for stable complex formation between pRB and E2F1
(Helin et al. 1993b). Although it was initially thought that E2F1 proteins homodimerized to bind
to DNA (Huber et al. 1993), heterodimerization of E2F1 and DP1 leads to enhanced DNA
binding in vivo (Helin et al. 1993b; Krek et al. 1993). DP2 was cloned by a variety of methods,
such as yeast two hybrid, library screening and degenerate oligonucleotide PCR (Ormondroyd et
al. 1995; Wu et al. 1995; Zhang and Chellappan 1995; Rogers et al. 1996). Dp2 gene has 68%
identity to Dpl. Although DP2 is expressed in most tissues, there is differential expression of
the different isoforms of DP2, which result from alternative splicing. To date, there are no
reported functional differences between DP1 and DP2 and they can bind to E2F1 to E2F6
indiscriminately.
It has been over a decade since the first E2F was cloned (Helin et al. 1992; Kaelin et al.
1992; Shan et al. 1992) and new family members are continuing to be discovered 13 years later
(Maiti et al. 2005). It is clear that E2F activity is not restricted to the G1/S transition of the cell
cycle, and E2F is involved in a number of cellular processes (discussed below). Thus, it is
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important to determine the individual physiological contributions of each E2F protein in order to
understand the intricacy of E2F function. Our understanding, however, may be incomplete in
that there may remain yet unidentified E2Fs.
C. The activating E2Fs versus the repressive E2Fs
The structural differences in the E2F transcription factors are partially reflective of their
differential activities in regulating cell division. As indicated by the presence or absence of a
pRB binding domain, the pocket proteins regulate E2F1, E2F2, E2F3a, E2F3b, E2F4 and E2F5,
but not E2F6, E2F7 or E2F8. The pocket protein regulated E2Fs can be further subdivided into
two classes: the activating E2Fs and the repressive E2Fs. For the most part, these two groups
have differential functions during the cell cycle. The remainder of Part II will focus on the
properties of these two distinct groups in cell cycle control, development and tumorigenesis.
i. Structural and functional properties
E2F1, E2F2, and E2F3a comprise the activating E2Fs and are most similar to each other
than to the other E2Fs in structure and function. These proteins have a high degree of structural
similarity, as previously described. They are strong activators of transcription (Helin et al. 1992;
Kaelin et al. 1992; Shan et al. 1992; Ivey-Hoyle et al. 1993; Lees et al. 1993) and induce
quiescent cells to enter the cell cycle when individually over-expressed (Lukas et al. 1996;
DeGregori et al. 1997). Accordingly, the absence of E2F3 in murine primary fibroblasts results
in delayed proliferation (Humbert et al. 2000b). MEFs lacking E2F1, E2F2 and E2F3 are further
impaired in cell division (Wu et al. 2001), supporting that the activating E2Fs have overlapping
roles in promoting cellular proliferation.
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The role of the activating E2Fs in the G1/S transition of the cell cycle depends upon their
ability to activate the transcription of E2F-responsive genes that are necessary for S phase
progression. Promoter occupancy experiments have confirmed that the activating E2Fs are
associated with E2F-responsive genes coincident with their activation in late G1 and S phases
(Takahashi et al. 2000; Rayman et al. 2002). Transcription of many of these genes is dependent
on an intact E2F DNA consensus site within the promoter and a functional E2F transactivation
domain (Lam and Watson 1993; Hsiao et al. 1994). Moreover, the reduced proliferative capacity
of murine primary fibroblasts lacking E2F3 or all of the activating E2Fs was associated with
deregulated expression of a number of classical E2F-responsive genes (Humbert et al. 2000b;
Wu et al. 2001). Thus, the activating E2Fs are critical for the transcriptional activation of target
genes that are necessary for S phase entry.
In contrast, E2F4 and E2F5, the repressive E2Fs, are important for transcriptional
repression during GO and early G1 phases of the cell cycle. Although these proteins can activate
transcription in reporter assays, over-expression in Ratl cells does not efficiently drive
progression through the cell cycle (Lukas et al. 1996; DeGregori et al. 1997). In addition, E2f4'
MEFs display normal cell cycle kinetics (Humbert et al. 2000a; Rempel et al. 2000). These
results indicate that the repressive E2Fs do not necessarily function in an analogous manner to
the activating E2Fs. Moreover, MEFs lacking both E2F4 and E2F5 are not able to arrest in G1
in response to p16NK4a expression (Gaubatz et al. 2000). Similar results are observed for p107'-
;p130-'- cells, suggesting a role for the repressive E2Fs and their associated pocket proteins in
maintaining growth arrest through negatively regulating E2F target genes (Hurford et al. 1997;
Classon et al. 2000). This model has been reinforced by chromatin immunoprecipitation
experiments demonstrating that E2F4-p130 and E2F4-p107 complexes recruit HDAC1 to E2F-
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responsive promoters in GO/early G1 and are replaced by the activating E2Fs in late G 1/S
(Takahashi et al. 2000; Rayman et al. 2002). E2F3b remains relatively uncharacterized;
however, initial studies suggest that it also acts as a transcriptional repressor, as demonstrated for
the p1 9 ARF gene (Aslanian et al. 2004). Further studies with targeted disruption of E2f3b will be
helpful to determine the precise nature of E2F3b function in vivo.
Although there is strong evidence to support that the activating and repressive E2Fs have
opposing functions in gene regulation, it is unclear whether both classes of E2Fs cooperate in the
regulation of each E2F target gene. For example, mutation of E2F binding sites in the B-myb
promoter results in increased transcription (Lam and Watson 1993). Promoter analysis by in
vivo footprinting found that E2F was bound to this promoter in GO and early G1, but not in late
G1 (Zwicker et al. 1996). Even though a subsequent study detected the activating E2Fs at this
promoter during the G1 to S transition (Takahashi et al. 2000), transcriptional activation of the
B-myb gene does not necessarily require E2F binding (Lam and Watson 1993). This suggests
that loss of E2F-pocket protein repressive complexes is sufficient to activate transcription.
Extending this concept, it is then unclear if the proliferative defects in the absence of the
activating E2Fs are due to the loss of activation or the gain of repression (by the repressive E2Fs)
at E2F target genes. In support of the latter, expression of a transactivation-deficient E2F1
mutant, which can bind DNA, was equivalent to the expression of wild-type E2F1 in that both
resulted in the derepression of target genes and cell cycle progression (Zhang et al. 1999a;
Rowland et al. 2002). On the other hand, activating E2F activity is important for the
transcription of certain E2F-responsive genes (e.g., DHFR) (Means et al. 1992) and this
correlates with entry into S phase (Johnson et al. 1993; Shan and Lee 1994; Qin et al. 1995).
Analysis of target gene expression in E2fl-'-;E2F2-;E2f3'- MEFs indicated that some genes were
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induced (e.g., PCNA and Cyclin El) and others were repressed (e.g., cdc6, DHFR and Mcm3),
suggesting that both activation and repression by the activating E2Fs are important (Wu et al.
2001). Therefore, regulation of E2F-responsive promoters by the activating and/or repressive
E2Fs appears to be gene-specific and the overall contribution of the activating and repressive
E2Fs to target gene expression may be important in regulating cell growth and division.
One way that the various E2F proteins achieve promoter specificity is through
interactions with other transcription factors. TFE3, an E-box binding factor, specifically binds to
E2F3a independently of DP to activate transcription of the DNA polymerase a p68 gene
(Giangrande et al. 2003). Moreover, E2F2 and E2F3 can bind to RYBP (Ring YY 1 binding
protein), which allows for combinatorial control of promoters that contain E2F and YY 1 binding
sites (e.g., cdc6) (Schlisio et al. 2002). In addition, the activating E2Fs cooperate with NF-Y
(nuclear factor Y) transcription factor to trigger transcription of cdc2 while repression of cdc2 by
E2F4 depends on different promoter elements (Zhu et al. 2004). Thus, these are alternative
mechanisms by which E2Fs can regulate transcriptional activity. Other factors that could affect
target gene specificity of the E2Fs are pocket protein binding, cell type and species-specific
differences.
ii. Regulation of E2F activity
The activity of the E2F transcription factors is tightly regulated by the coordinated action
of a number of factors, including pocket protein binding, subcellular localization, post-
translational modifications and ubiquitin-mediated proteolysis. The activating and repressive
E2Fs have distinct properties with respect to these types of regulation that contribute to their
differential functions in vivo.
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a. Regulation by pocket protein binding
Since mechanisms of repression by the pocket proteins have been described in Part I,
important differences between the activating and repressive E2Fs will be highlighted. The
activating E2Fs are exclusively regulated by pRB in vivo while the repressive E2Fs interact with
the entire pocket protein family. Specifically, E2F3b associates with pRB (Leone et al. 2000),
E2F4 binds to all three pocket proteins (Beijersbergen et al. 1994; Ginsberg et al. 1994; Moberg
et al. 1996) and E2F5 is primarily regulated by p130 (Hijmans et al. 1995; Sardet et al. 1995;
Moberg et al. 1996). As previously mentioned, pRB can repress E2F activity via two distinct
mechanisms, 'passive' and 'active' repression. Briefly, passive repression occurs when the
transactivation domain of E2F is physically masked upon pRB binding, thereby preventing
transcriptional activation of target genes. In contrast, the pocket proteins can recruit chromatin
remodeling enzymes to promoters in complex with E2F, resulting in active repression. While it
is believed that the activating E2Fs are primarily regulated by passive repression, this has not
been formally demonstrated in vivo since pRB is rarely detected at promoters (Takahashi et al.
2000; Wells et al. 2000). Active repression is widely thought to be a property of the repressive
E2Fs, since E2F4 and E2F5 are solely found in the nucleus in association with a pocket protein
(discussed below) (Muller et al. 1997; Verona et al. 1997). Furthermore, promoter occupancy
experiments have detected E2F4 with p107, p1 3 0 and HDAC1 at E2F-responsive promoters
coincident with transcriptional repression of the corresponding genes (Rayman et al. 2002).
Thus, the current models suggest that the pocket proteins differentially regulate the activating
E2Fs and the repressive E2Fs.
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b. Regulation by subcellular localization
The activating and repressive E2Fs can be distinguished based on their subcellular
localization patterns. E2F1, E2F2 and E2F3a, the activating E2Fs, contain a conserved nuclear
localization signal (NLS) in the amino terminal regions and are, therefore, exclusively found in
the nucleus (Muller et al. 1997; Verona et al. 1997). On the other hand, E2F4 and E2F5, the
repressive E2Fs, lack the amino terminal sequences that encode a NLS (Beijersbergen et al.
1994; Ginsberg et al. 1994; Hijmans et al. 1995; Sardet et al. 1995; Leone et al. 2000). Most of
the work detailing the subcellular localization of the repressive E2Fs has been done with E2F4,
the predominant E2F in vivo (Moberg et al. 1996). In GO and early G1 phases, E2F4 is primarily
found in the nucleus in association with p130 at E2F-responsive promoters (Muller et al. 1997;
Verona et al. 1997; Takahashi et al. 2000; Wells et al. 2000; Rayman et al. 2002). Upon entry
into S phase, E2F4-p107 complexes replace the nuclear E2F4-p130 complexes and the amount of
free E2F4 increases in the cytoplasm as cells reach S phase (Muller et al. 1997; Verona et al.
1997). Consistent with the absence of an NLS, E2F4 is found in the nucleus only when bound to
a pocket protein. Upon phosphorylation of the pocket protein, E2F4, which contains two
leucine/isoleucine-rich nuclear export signals, is subsequently exported from the nucleus through
a mechanism dependent on the CRM1 nuclear export receptor (Gaubatz et al. 2001).
The subcellular localization of the activating and repressive E2Fs largely supports their
distinct functions during the cell cycle. The expression pattern and nuclear localization of the
activating E2Fs parallel their transcriptional activity at the G1 to S transition of the cell cycle
(Magae et al. 1996; Muller et al. 1997; Verona et al. 1997). In contrast, E2F4 is found in the
nucleus in association with the pocket proteins during GO/G1, which are times when classic E2F-
responsive genes are repressed. Although the subcellular expression patterns of the other
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repressive E2Fs remain to be determined, it is likely that E2F5 will be analogous to E2F4 since
they share many structural and functional similarities.
c. Regulation by phosphorylation
Phosphorylation of the E2F proteins regulates E2F activity during the cell cycle. The
activating E2Fs and E2F3b contain a conserved cyclin A binding domain in the amino terminal
region (Figure 2) (Mudryj et al. 1991; Devoto et al. 1992; Pagano et al. 1992; Krek et al. 1994;
Xu et al. 1994; Leone et al. 2000). This region specifically binds to cyclin A/CDK2 and cyclin
A/CDC2 complexes. Stable complex formation results in phosphorylation of the DP subunit and
loss of E2F DNA binding and transactivation activities in S phase (Dynlacht et al. 1994; Xu et al.
1994; Krek et al. 1995). Mutation of the cyclin A binding domain or introduction of a non-
phosphorylatable DP leads to the accumulation of cells in S phase and subsequent apoptosis
(Krek et al. 1995), suggesting that phosphorylation of E2F-DP is required for cell cycle
progression through S phase. Yet, the exact role of DP phosphorylation remains unclear, since a
mutant DP lacking potential phosphorylation sites was only able to arrest cells in the presence of
ectopic E2F1 expression. Along the same lines, DP phosphorylation in serum deprived cells
corresponded with increased E2F binding (Bandara et al. 1994). There are additional studies
which demonstrated that E2F1 can be phosphorylated by cyclin A/CDK complexes in vitro
(Peeper et al. 1995; Adams and Kaelin 1996). Thus, phosphorylation seems to be an important
mode of E2F regulation and further work is necessary to elucidate the precise physiological role
of E2F and DP phosphorylation.
Although E2F4 and E2F5 lack the cyclin A binding domain, they associate with
cyclin/CDK complexes via p107 and p130 and are phosphorylated (Devoto et al. 1992; Faha et
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al. 1992; Lees et al. 1992; Shirodkar et al. 1992; Ginsberg et al. 1994). E2F-p107 complexes are
found in association with cyclin E/CDK2 in G1 while E2F-plO7-cyclin A/CDK2 complexes are
predominantly found in S phase (Lees et al. 1992). The functional significance of these
complexes is currently unknown. A few studies indicate that phosphorylation is important in
transcriptional activation by the repressive E2Fs. For example, phosphorylation of E2F5 by
cyclin E/CDK2 in late G1 leads to transcriptional activation and progression through S phase
(Morris et al. 2000). Furthermore, dephosphorylation of E2F4/DP1 complexes in human B
lymphocytes correlates with reduced DNA binding activity in S phase (van der Sman et al.
1999). While these data suggest that the repressive E2Fs function as transcriptional activators,
much of the work entailed over-expression and in vitro techniques. Thus, additional studies are
necessary to determine the biological significance of phosphorylation of the repressive E2Fs.
d. Regulation by acetylation
Transcriptional activation by the E2Fs has been associated with histone acetyl transferase
(HAT) activity. Acetylation of histone tails is widely thought to facilitate transcriptional
activation by weakening the interaction between histones and chromatin and, thus, enabling
transcription factor binding to DNA. p300 and CREB-binding protein (CBP) form a complex
with HAT activity (reviewed in Vo and Goodman 2001). CBP and p300, as well as an
associated factor P/CAF, can bind to the activating E2Fs to stimulate their transcriptional activity
(Trouche et al. 1996; Martinez-Balbas et al. 2000; Marzio et al. 2000). P/CAF acteylates E2F1
near the DNA binding domain on three lysine residues, which are conserved in E2F2 and E2F3
(Martinez-Balbas et al. 2000; Pediconi et al. 2003). Another HAT, Tip60, associates with
ectopically expressed E2F1 at E2F-responsive promoters (Taubert et al. 2004). Thus, acetylation
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may be an important mechanism for controlling the transcriptional activity of the activating
E2Fs.
It is unclear if acetylation also regulates the activity of the repressive E2Fs. In reporter
assays, E2F4 and E2F1 can promote transcriptional activation upon binding to GCN5, a HAT
(Lang et al. 2001). Furthermore, E2F5 has been found in association with p300 (Morris et al.,
2000). Although these studies demonstrate direct binding, the physiological relevance of these
interactions remains to be understood. In contrast, endogenous association of E2F4 and HDAC1
correlates with transcriptional repression in GO and early G1 (Takahashi et al. 2000; Rayman et
al. 2002). Perhaps E2F4 participates in transcriptional activation and repression during different
phases of the cell cycle. Further work is necessary to determine whether the repressive E2Fs
cooperate with HATs in vivo and at which promoters this interaction occurs.
iii. E2F target genes not involved in G1/S regulation
Classic E2F-responsive genes were initially identified by searching for E2F binding sites
in promoters of genes with known roles in the G1 to S transition. This type of analysis, while
fruitful in understanding the mechanism of E2F activity to promote cell cycle progression, is
incomplete. More recently, expression profiling by microarray analysis has been used to identify
additional E2F targets genes (Muller et al. 2001). E2F1, E2F2 and E2F3 expression was found
to induce the expression of previously identified E2F-responsive genes as well as previously
unidentified genes involved in additional pathways, including apoptosis and mitosis. In order to
determine direct targets, chromatin immunoprecipitation coupled with microarray analysis has
been used (Ren et al. 2002; Weinmann et al. 2002). These studies identified additional novel
targets involved in numerous biological processes, such as DNA damage checkpoint and DNA
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repair, mitotic spindle checkpoint and chromatin assembly. Thus, E2F functions at many stages
of the cell cycle and may coordinate proper cell cycle regulation with other cellular processes.
a. Apoptosis
E2F has a well-established role in apoptosis; however, it is unclear whether this is a
property of all the E2Fs or particular ones. Ectopic expression of E2F1 induces apoptosis, in
addition to cellular proliferation (Qin et al. 1994; Shan and Lee 1994; Wu and Levine 1994;
Kowalik et al. 1995; Vigo et al. 1999). Some studies have demonstrated that this is a specific
property of E2F1 (DeGregori et al. 1997; Kowalik et al. 1998; Lissy et al. 2000). In addition, the
loss of E2F1 in murine thymocytes results in defects in apoptosis (Field et al. 1996).
Furthermore, E2F1 deficiency prevents apoptosis induced by c-Myc expression in MEFs (Leone
et al. 2001). Other studies have argued that all of the activating E2Fs promote apoptosis (Vigo et
al. 1999; Moroni et al. 2001). Ectopic expression of E2F1, E2F2 or E2F3 can induce apoptosis,
though E2F2 and E2F3 were relatively less efficient.
There is also in vivo data to support that E2F1 and E2F3 contribute to programmed cell
death. As discussed in Part I, Rb loss in mice leads to increased levels of apoptosis in the
nervous system and the ocular lens (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992;
Morgenbesser et al. 1994). Despite findings that the apoptosis in the nervous system is a cell
non-autonomous effect of Rb loss, apoptosis in the lens is a cell intrinsic property (de Bruin et al.
2003b). Loss of either E2F1 or E2F3 in Rb-' animals results in suppression of the apoptosis in
the lens, suggesting that both E2F1 and E2F3 can regulate cell survival in vivo (Tsai et al. 1998;
Ziebold et al. 2001).
The mechanisms underlying E2F-induced apoptosis are incompletely understood. Most
studies focus on E2F1 action in apoptosis since it has an irrefutable role in this process. Ectopic
expression of E2F1 can induce p53-dependent (Qin et al. 1994; Wu and Levine 1994; Hiebert et
al. 1995) and p53-indendendent apoptosis (Hsieh et al. 1997; Phillips et al. 1997). pl14 A R F , an
upstream regulator of p53, was suggested to be an E2F1 target gene and provided a potential link
for the p53-dependent apoptosis (Bates et al. 1998). The disruption of pl9RF (murine homolog
of human pl4ARF), however, does not modulate the levels of p53-dependent apoptosis in the
absence of pRB (Tsai et al. 2002) or in the presence of increased E2F1 activity (Tolbert et al.
2002). Furthermore, recent work suggests that p1l9RF is primarily regulated by E2F3b, not E2F1
(Aslanian et al. 2004). Other apoptotic genes directly regulated by E2F1 are p73 (Lissy et al.
2000), Apaf-l (Moroni et al. 2001; Muller et al. 2001), Caspase 3 (Muller et al. 2001; Nahle et
al. 2002), as well as Caspase7 (Muller et al. 2001). Although transcriptional activation of these
apoptotic E2F target genes has been shown to be important for E2F1 function in apoptosis, the
transactivation domain of E2F1 is dispensable for apoptosis induced in Saos-2 cells (Hsieh et al.
1997; Phillips et al. 1997) and WI-38 cells (Moroni et al. 2001). Therefore, the apoptotic
response induced by E2F1 is complex and E2F1 may not function through a common mechanism
in different settings, such as cell type.
b. DNA damage and repair
There is an emerging role of the E2Fs in DNA damage checkpoint control and DNA
repair pathways. In response to DNA damage, E2F1 levels are stabilized (Blattner et al. 1999;
Hofferer et al. 1999; Meng et al. 1999) upon phosphorylation by ATM, a kinase activated by
DNA damage (Lin et al. 2001). It has been proposed that phosphorylation prevents E2F1
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degradation by p 4 5 SKP2 since the ATM phosphorylation site on E2F1 overlaps with the p45SKP2
binding site (Marti et al. 1999; Lin et al. 2001). Furthermore, E2F1 interacts with Nbsl at
origins of DNA replication, which is thought to recruit the Mrel 1 complex, another ATM
substrate (Maser et al. 2001). Expression profiling of human cells by microarray analyses have
identified several direct E2F target genes involved in DNA damage checkpoint (CHKI and
TP53) and DNA repair (MSH2, MLHI, RAD51, RAD54, BARDI) (Ren et al. 2002; Weinmann et
al. 2002). A number of these targets were specific for E2F4 (Ren et al. 2002), suggesting that
involvement in DNA damage checkpoint control and DNA repair may not be specific to E2F1.
There is evidence demonstrating that DNA checkpoint and repair genes also have functions
during the normal cell cycle. For example, CHK1 accumulates in S phase to guarantee the
completion of DNA replication prior to mitosis (Bartek and Lukas 2003). Thus, E2F regulation
of these genes may be a result of their roles in DNA synthesis rather than particular involvement
in the DNA damage response.
iv. Roles in development and differentiation
The physiological roles of the individual E2Fs have been probed by analyzing the
consequences of targeted gene disruption in mice. These studies have addressed whether the
different E2Fs have overlapping functions or separate tissue-specific roles. Consistent with in
vitro data, the activating and repressive E2Fs have distinct roles during development and
differentiation.
a. The activating E2Fs
E2fl-' (Field et al. 1996; Yamasaki et al. 1996) and E2f2 - (Murga et al. 2001) mice
survive to adulthood and display tissue-specific defects. E2f2-'- animals often develop
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autoimmunity-related defects in adulthood, including splenomegaly and glomerulonephritis
(Murga et al. 2001). E2fl '- mice exhibit exocrine gland dysplasia and have an increased
predisposition to develop tumors (Field et al. 1996; Yamasaki et al. 1996). Tumor development
in these animals was unexpected since loss of an activator was predicted to result in decreased
proliferation. The growth inhibitory properties of E2F1 result from its function in apoptosis. In
addition, E2fl-' thymocytes exhibit increased proliferation due to apoptotic defects during
negative selection (Field et al. 1996; Zhu et al. 1999; Garcia et al. 2000). Furthermore, transient
expression of E2F1 in the testes results in apoptosis in transgenic mice (Agger et al. 2005).
These data support that E2F1 and E2F2 are not essential for development and that E2F1 has dual
roles in cell division and apoptosis in vivo.
In contrast, E2F3 (E2F3a and E2F3b) is essential for embryonic development on a pure
129/Sv or C57B1/6 background (Humbert et al. 2000b; Cloud et al. 2002; Saavedra et al. 2002).
These animals die between E13.5 and postnatal day 1 and have reduced cardiomyocyte
proliferation (Cloud et al., 2002; J. Cloud and J. A. Lees, unpublished data). Yet, a small
proportion of E2f3 - - animals can survive to adulthood in a mixed genetic (129/Sv x C57B1/6)
background. The mice that endure have hypoplastic hearts and/or septal defects leading to
congestive heart failure in many cases (J. Cloud and J. A. Lees, unpublished data). Furthermore,
the surviving animals are not prone to develop tumors, as observed for E2F1 loss. Thus, the
activating E2Fs have tissue-specific functions during murine development.
The mild phenotypes associated with loss of an activating E2F are largely due to
functional compensation by the remaining activators. E2fl-'-;E2f3- - and E2f2'-;E2f3- - animals
die between E9.5 and E10.5 with exacerbated effects in some of the phenotypes described for the
single homozygous mutant animals (Wu et al. 2001; Cloud et al. 2002). In addition, E2fl-'-;E2f2-
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'- T cells have enhanced proliferation relative to the E2j2'- cells, which hyperproliferate in
response to T cell receptor activation (Zhu et al. 2001). Therefore, during murine development,
the activating E2Fs have redundant functions in some tissues and unique biological functions in
other tissues.
Dpl mutant mice also indicate that E2F activity is essential for murine development.
Since DP binding is required for E2F activity, loss of DP1 would effectively diminish the
activity of E2F1 through E2F6. Dpl -/- mice die in utero by E12.5 due to defects in the extra-
embryonic tissues (Kohn et al. 2003). Placental insufficiency in the absence of DP1 was due to
impaired proliferation of trophoblast precursors in the ectoplacental cone and defective
endoreduplication in the trophoblast giant cells, consistent with the critical role of E2F activity in
regulating DNA synthesis. Analysis of Dpl ';Dpl' - chimeras demonstrated that DP1 is not
required for the development of embryonic tissues from E10 to E17.5 (Kohn et al. 2004). Based
on the tissue-specific defects arising in the adult E2f mutant animals, it will be important to
establish whether these chimeric animals survive beyond birth and whether they have any
developmental defects at later times. Furthermore, in order to correlate DP1 loss with a
reduction in E2F activity, the relative levels of E2F DNA binding activity should be determined
as well as whether there is functional compensation by DP2.
b. The repressive E2Fs
Consistent with the in vitro data, the repressive E2Fs are dispensable for cellular
proliferation, but have important roles in differentiation during murine development. E2f4-' mice
are viable, but display decreased survival potential due to craniofacial defects that increase
susceptibility to bacterial infections (Humbert et al. 2000a). In addition, these animals have
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differentiation defects during intestinal development and hematopoiesis (Humbert et al. 2000a;
Rempel et al. 2000). More specifically, absence of E2F4 resulted in a failure in crypt formation
in the intestinal epithelium (Rempel et al. 2000) and cell autonomous defects during the end
stages of red blood cell maturation (Humbert et al. 2000a; Rempel et al. 2000). E2F4 has also
been implicated to have roles in adipogenesis (Fajas et al. 2002; Landsberg et al. 2003) and
neurogenesis in vitro (Persengiev et al. 1999). Ectopic expression of E2F4 enhanced neuronal
differentiation in PC12 cells (a pheochromocytoma cell line) and was important for maintaining
the differentiated state (Persengiev et al. 1999). In contrast, E2F4 loss predisposed MEFs to
differentiate into adipocytes spontaneously as well as in response to hormone induction (Fajas et
al. 2002; Landsberg et al. 2003). Adipogenesis entails a period of clonal expansion immediately
preceding terminal differentiation, which does not occur during neuronal development. Thus,
this difference may reflect the contrasting effects of E2F4 function in the two culture systems.
E2f5-' - mice also have a differentiation, not proliferation, defect (Lindeman et al. 1998).
These animals are born at the expected frequency and, on average, died by 6 weeks of age due to
hydrocephalus, which resulted from excessive cerebrospinal fluid production in the choroid
plexus. The tissue-specific defects associated with either E2F4- or E2F5 loss correspond with
their disparate expression patterns in mouse development (Dagnino et al. 1997). Yet, there is
some functional compensation between E2F4 and E2FS5. The characterization of the double
nullizygous animals has not been reported; however, viable mice are not detected at birth
(Gaubatz et al. 2000). These mouse model studies confirm that the activating E2Fs and
repressive E2Fs regulate different processes during murine development.
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v. Roles in tumorigenesis
The activating E2F transcription factors have a well-established role in the regulation of
cellular proliferation. As a result, understanding the contribution of the activating E2Fs to
tumorigenesis has been a major focus in the field.
Deregulation of E2F1 activity can have oncogenic consequences. Ectopic expression of
E2FI can induce cellular transformation in cooperation with activated Ras expression, as
assessed by the ability for form tumors in immunocompromised mice (Johnson et al. 1994).
Expression of E2fl under the keratin 5 promoter leads to skin tumors in mice (Pierce et al.
1999). In skin tumors induced by chemical carcinogenesis, however, E2F1 expression resulted
in an increase in apoptosis and consequently a reduction in tumor size (Pierce et al., 1999).
Thus, the net effect of E2F1 functions in proliferation and apoptosis largely dictates its
oncogenic properties.
Since the E2F transcription factors are important downstream effectors of the pocket
proteins, the requirement for E2F1 activity in tumor promotion has been assessed in tumor
mouse models resulting from pocket protein inactivation. SV40 large T antigen inactivates the
pocket proteins and p53. A truncation mutant containing the first 121 amino acids of the amino
terminus of SV40 large T antigen (T1 2 1) specifically targets the pocket proteins, and not p53
(DeCaprio et al. 1989; Dyson et al. 1989; Ewen et al. 1989). Tumor development results from
expression of Ti2, in a variety of murine tissues, including the choroid plexus (Saenz Robles et
al. 1994), astrocytes (Xiao et al. 2002) and the mammary epithelium (Simin et al. 2004).
Although loss of E2F1 did not affect the lifespan of the transgenic mice expressing T121 in the
choroid plexus, the balance of proliferation and apoptosis was altered in the resulting tumors
(Pan et al. 1998). In particular, there was a significant decrease in the levels of apoptosis
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accompanied by a decrease in the levels of proliferating cells in the E2fl-'-;T 2 tumors compared
to those from the T 12 1 animals. Thus, these opposing effects did not drastically alter the timing of
tumor development. Regardless of the final outcome, it is clear that deregulated E2F1 activity in
the absence of the pocket proteins contributes to tumor development through its apoptotic and
proliferative roles.
The contribution of the activating E2Fs (E2F1 and E2F3) has also been investigated in
tumors arising in Rb+'- mice. Rb' - mice die around one year of age due to pituitary tumor
development (Jacks et al. 1992; Hu et al. 1994; Williams et al. 1994b). In addition, the animals
form thyroid tumors at approximately 70% penetrance. This model is analogous to the T 121
mouse model since they both result in deregulated E2F activity. Loss of an activating E2F,
E]2F1 (Yamasaki et al. 1998) or E2F3 (see Appendix C), in the Rb+'-background results in an
extension of lifespan due to a delay in pituitary tumor formation. With regard to thyroid tumor
development, loss of E2F1 results in significant suppression while loss of E2F3 increases thyroid
tumorigenicity and frequently leads to metastasis. The differential effects in the thyroid may be
due to tissue-specific functions of E2F1 and E2F3. Another possibility is that the opposing
effects in the pituitary and thyroid tissues in Rb+ - ;E2f3-' animals are reflective of the differential
functions of E2F3a and E2F3b,which are both inactivated in E2f3 -' - mice. In any case, the tumor
suppressive properties of pRB are largely dependent upon its ability to regulate the activating
E2Fs.
The roles of the activating E2Fs in the phenotypes caused by homozygous loss of Rb
have also been determined. Rb-'- mice die in mid-gestation by E15.5 and exhibit defective
erythropoiesis in the fetal liver and widespread inappropriate proliferation and apoptosis in the
ocular lens and the nervous system (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992). Loss
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of an activating E2F, E2F1 or E2F3, led to prolonged survival of the Rb -'- mice to E17 (Tsai et al.
1998; Ziebold et al. 2001). Moreover, the ectopic proliferation and apoptosis were significantly
suppressed in the Rb-deficient animals with concomitant absence of E2F1, E2F2, or E2F3,
though ablation of E2F2 did not rescue as efficiently as the other activating E2Fs (Tsai et al.
1998; Ziebold et al. 2001; Saavedra et al. 2002). Recently, it has been demonstrated that
embryonic lethality in the Rb-'- animals is due to a primary placental defect (Wu et al. 2003). In
fact, the defect in the extra-embryonic tissues is responsible for the apoptosis in the nervous
system and for a significant portion of the erythropoietic defect in the Rb mutants (de Bruin et al.
'2003b). Notably, the ectopic proliferation is a cell autonomous effect of pRB, as is the apoptosis
in the lens. In light of these results, the roles of the activating E2Fs in the placenta need to be
examined. It is entirely possible that loss of E2F1 or E2F3 suppressed the placental defect in the
Rb-'- mice and, thus, resulted in the observed extension in lifespan. In spite of this, it is clear that
E]2F1 and E2F3 participate in apoptosis in the lens and in the inappropriate proliferation that
arise from pRB loss (Tsai et al. 1998; Ziebold et al. 2001).
Mutant mouse models have significantly extended our understanding of the molecular
signals involved in tumorigenesis. With respect to the mechanism through which pRB loss
promotes inappropriate proliferation, E2F1 and E2F3, for the most part, have overlapping
functions in promoting the phenotypes caused by pRB deficiency. The repressive E2Fs are also
downstream effectors of pRB function. Yet, the biological significance of these interactions
remains unclear. Therefore, this study is aimed at determining the contribution of E2F4, the
major repressive E2F in vivo, to the growth suppressive functions of pRB in the contexts of
tumor formation (Chapter 2) and normal development (Chapter 3).
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ABSTRACT
The E2F transcription factors mediate the activation or repression of key cell cycle
regulatory genes under the control of the retinoblastoma protein (pRB) tumor suppressor and its
relatives, p107 and p130.' Here we investigate how E2F4, the major 'repressive' E2F,
contributes to pRB's tumor suppressive properties. Remarkably, E2F4 loss suppresses the
development of both pituitary and thyroid tumors in Rb+/- mice. Importantly, E2F4 loss also
suppresses the inappropriate gene expression and proliferation of pRB-deficient cells.
Biochemical analyses suggest that this tumor suppression occurs via a novel mechanism: E2F4
loss allows p107 and p130 to regulate the pRB-specific, activator E2Fs. We also detect these
novel E2F complexes in pRB-deficient cells suggesting that they play a significant role in the
regulation of tumorigenesis in vivo.
SIGNIFICANCE
Understanding how the E2F and pRB family members contribute to the regulation of
tumorigenesis is a key goal. Our finding of tumor suppression in the Rb+/';E2f4-/ mice through
the formation of novel E2F complexes in Rb+/-;E2f4-/-, Rb/-;E2f4 /-, and Rb-/- cells strongly
suggests tumor formation is critically and exclusively dependent upon the inactivation of pRB,
rather than p 107 or p130, because it triggers the release of the normally pRB-specific, activator
E2Fs. However, p107 and p130 assume significant tumor suppressive properties in pRB-
deficient cells because they can substitute for pRB in the regulation of these activator E2Fs. This
model suggests a novel strategy for the generation of chemotherapeutics that would act by
increasing the available pools of p107 and p130.
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INTRODUCTION
The retinoblastoma protein (pRB) was the first identified tumor suppressor, and it is
mutated in approximately one third of all human tumors. pRB blocks cells in G1 by inhibiting
the activity of a cellular transcription factor, E2F, that controls the expression of key
components of the cell cycle and DNA replication machinery (reviewed in Dyson 1998;
Trimarchi and Lees 2002). pRB regulates E2F through two distinct mechanisms. First, its
association is sufficient to block E2F transcriptional activity. Second, the pRB-E2F complex can
recruit histone deacetylases (HDACs) to the promoters of E2F-responsive genes and thereby
actively repress their transcription. Cell cycle entry requires the phosphorylation of pRB and its
subsequent dissociation from E2F. This phosphorylation is mediated by cell cycle dependent
kinase complexes, cyclin D-CDK4/6 and cyclin E-CDK2. Importantly, tumors that retain wild-
type pRB almost always carry activating mutations in cyclin D1 or CDK4 or inactivating
mutations in the cdk4-inhibitor, p1 6 (reviewed by Bartek et al. 1996; Sherr 1996). This suggests
that the functional inactivation of pRB, and the resulting de-regulation of E2F, is an essential step
in tumorigenesis.
pRB belongs to a family of proteins, called the pocket proteins, that also includes p1 07
and p130 (reviewed by Dyson 1998; Trimarchi and Lees 2002). p107 and p130 share many
properties with pRB: they bind to E2F in vivo, inhibit E2F transcriptional activity and recruit
HDACs to mediate the active repression of E2F-responsive genes. However, there are dramatic
differences in the tumor suppressive properties of the individual pocket proteins (reviewed by
Mulligan and Jacks 1998). Inheritance of a single Rb mutant allele predisposes both mice and
humans to tumors with 100% penetrance. The tumors consistently lose the wild-type Rb allele,
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confirming that pRB behaves as a classical tumor suppressor. In contrast, the loss of p1 07
and/or p130 does not appear to promote tumorigenicity in mice or cells (Cobrinik et al. 1996; Lee
et al. 1996). Yet there is growing evidence that mutation of p107 and/or p130 promotes tumor
formation when pRB is also inactivated. This is exemplified by Rb - -; p l07 '-chimeric mice, which
develop an additional tumor type, retinoblastoma, compared to Rb-' chimeras (Robanus-Maandag et
al. 1998), and Rb -'; p10l 7' -; p1 30-'- mouse embryonic fibroblasts (MEFs), which are more
tumorigenic than Rb-' controls (Dannenberg et al. 2000; Sage et al. 2000). Biochemical and
mechanistic studies in cells deficient for different pocket protein family members should help to
identify the critical, tumor suppressive function(s) of pRB.
To date, eight genes have been identified as components of the E2F transcriptional
activity (reviewed by Dyson 1998; Helin 1998). These genes have been divided into two distinct
groups: the E2fs (E2fl through E2f6); and the DPs (DPi and DP2). The protein products from
these two groups heterodimerize to give rise to functional E2F activity (Bandara et al. 1993;
Helin et al. 1993; Krek et al. 1993). The functional specificity of the E2F-DP complex is
primarily determined by the identity of the E2F subunit. The pocket protein-binding E2Fs can
be divided into two subgroups that appear to have opposing roles in vivo (reviewed by Trimarchi
and Lees 2002).
The first E2F subgroup includes E2F 1, 2 and 3. These E2Fs play a key role in promoting
the activation of E2F-responsive genes, and thereby cell cycle entry. Chromatin
immunoprecipitation (ChIP) experiments confirm that these E2Fs associate with the promoters
of known target genes coincident with their activation in late G1 (Takahashi et al. 2000; Rayman
et al. 2002). MEFs lacking E2F3 or E2F 1, E2F2, and E2F3 exhibit reduced E2F target gene
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expression and significant proliferative defects (Humbert et al. 2000b; Wu et al. 2001).
Furthermore, the ectopic expression of E2F1, 2 or 3 is sufficient to induce quiescent cells to
initiate E2F-responsive gene expression and cell cycle re-entry (Lukas et al. 1996; DeGregori et
al. 1997). Importantly, these so-called 'activator' E2Fs are specifically regulated by pRB but not
by p107 or p130 in vivo (Moberg et al. 1996).
E2F4 and E2F5 represent the second E2F subgroup. The transcriptional properties of
these E2Fs are largely determined by their subcellular localization (Magae et al. 1996; Muller et
al. 1997; Verona et al. 1997; Gaubatz et al. 2001). The endogenous E2F4-DP and E2F5-DP
complexes are localized in the cytoplasm and are therefore unable to contribute to the activation
of E2F-responsive genes. However, pocket protein binding enables the nuclear localization of
E2F4 and E2F5. As a result, E2F4 and E2F5 appear to be primarily involved in the active
repression of E2F-responsive genes. E2F4 associates with pRB, p107 and p130 in vivo and
accounts for the majority of the repressive-pocket protein complexes (Moberg et al. 1996).
E2F5 is expressed in Go cells and is primarily regulated by p130 (Hijmans et al. 1995; Sardet et
al. 1995). ChIP assays confirm that E2F4, p107, p130, and HDAC specifically associate with
E2F-responsive promoters in Go/G1 cells under physiological conditions (Takahashi et al. 2000;
Rayman et al. 2002). Importantly, MEFs deficient for E2F4 and E2F5 are unable to arrest in G1
in response to a variety of growth arrest signals, suggesting that the repressive E2Fs promote cell
cycle arrest (Gaubatz et al. 2000).
Considerable attention has focused on understanding how the growth suppressive
properties of pRB relate to its role in the inhibition of the activating E2Fs versus its participation
in repressive E2F-pRB complexes. The analysis of Rb;E2f and Rb,E2f3 compound mutant mice
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has shown that the absence of E2F1 or E2F3 is sufficient to suppress both the ectopic S-phase
entry and p53-dependent apoptosis arising in pRB-deficient embryos (Tsai et al. 1998; Ziebold
et al. 2001). Moreover, E2F1 deficiency significantly diminishes the development of tumors in
Rb+/- mice (Yamasaki et al. 1998). These data suggest that the inappropriate release of the
activator E2Fs makes a significant contribution to the phenotypic consequences of pRB
deficiency. However, these experiments do not rule out a role for the repressive pRB-E2F
complexes in tumor suppression. Indeed, numerous over-expression studies have led to the
conclusion that regulation of E2F-responsive genes, and therefore cell cycle entry, is largely
controlled by the repressive, and not activating, E2Fs (Zhang et al. 1999; Zhang et al. 2000;
Dahiya et al. 2001). In this study, we use Rb;E2f4 compound mutant mice to investigate
whether repressive E2F complexes contribute to tumor suppression. This analysis shows that
the absence of E2F4 suppresses the formation of pRB-deficient tumors by promoting the
formation of novel complexes between the activating E2Fs and p107 and p130 as well as
correcting inappropriate target gene expression and cell growth. Most significantly, these data
provide support for a model in which pocket proteins function as tumor suppressors by
controlling activator E2Fs rather than by forming repressive E2F complexes.
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RESULTS
Loss of E2F4 extends lifespan and alters tumorigenesis in Rb mutant mice
Over-expression studies strongly suggest that the repressive E2F-pocket protein
complexes play a critical role in controlling the expression of E2F-responsive genes. Given this
finding, we wished to establish whether these repressive E2F-pocket protein complexes
contribute to tumor suppression. E2F4 is the major repressive E2F in vivo, accounting for the
majority of the endogenous pRB-, p107- and p130-associated E2F activity. Thus, if the
repressive E2F complexes are important, E2F4 loss should exacerbate the formation of pRB-
deficient tumors. To test this hypothesis, we intercrossed Rb and E2f4 mutant mouse strains
with the same C57BL/6 X 129/Sv mixed background. We then compared the lifespan and tumor
phenotype of Rb+/', Rb+/-;E2f4+/- and Rb+/-;E2f4-/ littermates.
The phenotype of the Rb +/' mice was entirely consistent with previous studies (reviewed
by Mulligan and Jacks, 1998). All mice died between 8.5 and 13.9 months of age (Figure 1A).
Histological examination confirmed that the cause of death was intermediate lobe pituitary
tumors and that the vast majority of the Rb+/' animals (23/27) also displayed c-cell thyroid
tumors (Figure 1A and B; data not shown). Mutation of a single E2f4 allele did not significantly
alter the lifespan of Rb +/' animals (Figure 1A). Moreover, the Rb+/-;E2f4+/ - mice developed
pituitary (55/57) and thyroid (47/57) tumors that were comparable to those arising in the Rb+/'
controls with respect to both incidence and size (Figure B; data not shown). Thus, a reduction
in the levels of E2F4 had no notable effect on tumorigenicity in the Rb mutant mice.
Remarkably, the phenotype of Rb+/-;E2f4-/' animals diverged considerably from those of
their littermate controls. First, there was a significant difference (p=0.0033) in lifespan of
81
A0 5
B ;Rb E2f4+/-22.0 months
Rb +l;E2f4-l-
10 15 20 25 30
Age (Months)
Rb+l/-;E2f4+/+
10.4 months
Rb+l';E2f4-l-
Rb+l-;E2f4+ /"
12.7 months
Rb+/-;E2f4-l-
26.6 months
Figure 1. Loss of E2F4 extends the lifespan of Rb ÷ adults by reducing the tumor
incidence.
A, Survival curves for Rb"+;E2f4'1+ (blue, n=27), Rb+-;E2f4+- (green, n=61), and Rb +-
;E2f4- (red, n= 15) mice. Rb +;E2f4- mice with no evidence of tumor formation (open
circles) and those with tumors (closed circles) are shown, but the animals that were
prematurely sacrificed are not included. B, Representative H&E stained median sections
of adult heads including the pituitary (marked with an arrow) from (i) control
Rb ';E2f4 animal, (ii) Rb -;E2f4 +, (iii) Rb ;E2f4 , and (iv-vi) Rbl ;E2f4- mice.
The older Rb +-;E2f4- mice have a variety of pituitary phenotypes including (iv) small,
early pituitary tumors, (v) normal pituitaries, and (vi) medium intermediate lobe pituitary
tumors. Magnification, 20x.
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the Rb+/-;E2f4-/' versus the Rb+/ animals (Figure 1A; Table 1). Two of the Rb+ / ;E2f4- /- mice died
at early ages (2.7 and 5.4 mo.) as a result of an increased susceptibility to infections. This is a
characteristic phenotype of the E2f4-/- mice and was therefore an anticipated outcome for a
fraction of the Rb+/';E2f4-/ - mice. However, we unexpectedly found that neither of these animals
had any evidence of tumorigenic lesions (data not shown), even though such lesions are routinely
observed in the pituitaries of Rb+/- mice by 3 months of age (Nikitin and Lee 1996). Most
importantly, the majority of the Rb+/-;E2f4-/- mice (17/19) survived at least until the window of
lethality of the Rb+/- littermate controls (8.5-13.9 mo.). Moreover, 4 months after the death of
the oldest surviving Rb+/ animal, half of the Rb+/-;E2f4-/- mice remained alive and healthy. Indeed,
a significant fraction of the Rb+/-;E2f4-/- animals lived to an age (20-27 months) comparable to
wild-type controls (Figure 1A; Table 1). Thus, the absence of E2F4 actually extended the
lifespan of the Rb+/ mice.
Consistent with the prolonged lifespan, E2F4 loss greatly suppressed the formation of
tumors in the Rb+/- mice (Table 1). Histological examination showed that the vast majority of the
Rb+/';E2f4-/- animals died as a result of defects typical of the E2f4-/- mice. Indeed, prior to 16
months of age none of the Rb+/-;E2f4-/ - mice displayed any evidence of pituitary tumors, although
they were detected in some of the older Rb+/-;E2f4-/- mice (Table 1). However, the incidence of
pituitary tumors was significantly lower than in the Rb+/- controls (p=0.000092), and there was a
considerable range in size in the tumors that did arise in the Rb+/-;E2f4-/' animals (Table 1; Figure
lB; data not shown). Three of the older Rb+/-;E2f4-/- animals (16.2, 20.5, and 23 mo.) eventually
developed tumors comparable to those seen in the Rb+/ - mice (8.5-13.9 mo.), but others
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Table 1. Histological Analysis of Rb'-;E2f4 -- Mice
Age
(Months)
2.7
5.4
8.7
9.3
9.4
10.7
12.6
15.6
16.2
16.5
18.2
18.5
18.6
20.5
20.8
23.0
Pituitary Thyroid Cause of Death
Tumor Tumor
++++
+
+++ +
++
++++
26.0 nd
26.6 +++
27.0 nd
nd = not determined
Tumor size is indicated as fc
tumors comparable to those c
- Sinusitis
- Pylonephritis
- Sacrificed early
- Unknown
- Severe dermatitis
- Dermatitis, Aspiration
- Severe dermatitis
- Sacrificed early
- Pituitary tumor
++++ Thyroid tumor and metastasis
Histiocytic sarcoma
- Sacrificed early
- Sacrificed early
- Pituitary tumor
- Hemangiosarcoma
Pituitary tumor and
pheochromocytoma
nd Alive
- Infection of reproductive organs
nd Alive
)Ilows:
if Rb +'-
"+" indicates very early tumor growth and "++++" indicates
mice.
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-
developed very early lesions or mid-sized tumors (16.5 and 26.6 mo.), and two animals had
completely normal pituitaries (18.2 and 18.5 mo.).
E2F4 loss had an even greater effect on the development of thyroid tumors in Rb+/- mice
(p=0.00000034). Despite the extremely high incidence of c-cell thyroid tumors in the Rb+/-
(23/27) and Rb+/;E2f4 +/ (47/57) animals, only 1/17 of the Rb+/;E2f4 -/- mice developed a thyroid
tumor (Table 1; data not shown). Indeed, there was no evidence of thyroid hyperplasia in the
remaining 16/17 Rb+/-;E2f4-/' animals. Thus, we conclude that the absence of E2F4 dramatically
suppresses the development of both pituitary and thyroid tumors in the Rb+/- mice and thereby
greatly extends their lifespan.
Loss of E2F4 induces profound rearrangement of E2F-pocket protein complexes
We initiated the tumor studies with the expectation that E2F4 loss would either have no
effect on, or would exacerbate, the formation of pRB-deficient tumors depending on whether or
not the repressive E2F-pocket protein complexes were important for tumor suppression.
Instead, our data clearly show that E2F4 loss inhibits the formation of tumors. To establish the
underlying mechanism, we characterized the effect that E2F4 loss had on the remaining E2F-
pocket protein complexes. Initially, we compared the E2F complexes present in extracts from
wild-type, Rb+/', and Rb+/';E2f4-/ - MEFs by immunoprecipitating specific E2Fs and then western
blotting to identify the associated pocket proteins. Consistent with previous studies, E2F1 and
E2F3 bound specifically to pRB in wild-type and Rb+/- cells (Figure 2 and data not shown). In
contrast, in Rb+/-;E2f4-/- MEFs, activating E2Fs participated in novel pocket protein complexes in
addition to binding to pRB. Specifically, E2F1 bound to p130, and E2F3 associated with p107.
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Figure 2. E2F complex rearrangement in Rb+ ; E2f4/ MEFs.
Western blot detection of pRB, p107, and p130 after immunoprecipitation of lysates from
wild-type and Rb ; E2f4/ MEFs with anti-E2F I and E2F3 antibodies. Input lysate (10%
of total) is shown at right.
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This was not due to an alteration of E2F 1 or E2F3 levels, since steady state amounts of these
proteins were not affected in cells deficient for either pRB or pRB and E2F4 relative to wild-
type MEFs (Figure 3 and data not shown). Thus, E2F4 loss allows p107 and p130 to substitute
for pRB by binding E2F 1 and E2F3:
Since the activating E2Fs are known to be important downstream targets of the pRB
tumor suppressor, the formation of novel complexes between activating E2Fs and p 107 and p130
could account for the suppression of tumors in the Rb+/;E2f4-/ mice. To address this issue, we
used electrophoretic mobility shift assays to establish whether these novel complexes were
present in Rb+/-;E2f4-/ tissues. For these experiments, we immunoprecipitated p107 from
extracts derived from several tissues, including the pituitary, which is prone to tumors in Rb+/-
animals. The associated E2F species were released by the addition of the detergent deoxycholate
(DOC) and then identified in electrophoretic mobility shift assays (Figure 4). Regardless of the
tissue examined, p107 associated specifically with E2F4 in the wild-type and Rb+/- mutant mice
(Figure 4A, B, D). In contrast, p107 bound at least three distinct E2F complexes in the tissues
derived from the Rb+/';E2f4-/ mice (Figure 4C, D). An anti-E2F5 antibody recognized one of
these species, and the other E2F complexes were completely retarded by a combination of
antibodies against E2F1 and E2F3. E2F1 and E2F5 were also observed when the
immunoprecipitations were conducted with anti-p130 antibodies (data not shown). Thus, the
absence of E2F4 enables p107 and p130 to bind activator E2Fs in a variety of tissues, including
the tumor-prone pituitary.
It is well documented that the formation of tumors in Rb+/ - mice is dependent upon the
inactivation of the wild-type Rb allele. Therefore, we also determined the nature of the E2F
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Figure 3. plO7/pl30 association with activator E2Fs in E2f4' MEFs is further enhanced
in E2f4';E2f5' MEFs.
A, E2f4' and E2f4';E2f5' MEFs were lysed with E2F extraction buffer and were
subjected to immunoprecipitation with anti-p 107 and/or p130 antibodies, DOC release,
and EMSA. B, Coupled Immunoprecipitation-DOC release with anti-pl07 antibodies in
E2fl' and E2F3' 3T3s to test the specificity of the antibodies. C, Western blot analysis
of E2F I1 and E2F3 proteins in Rb - and Rb-/-;E2f4- MEFs.
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Figure 4. p107 associates exclusively with E2F4 in organs of wild type and Rb
but associates with E2F 1, 3, and 5 in Rb +/-;E2f4- mice.
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A-C, Immunoprecipitation, DOC release, and EMSA were performed with anti-pl07
antibody, using homogenates of adrenal glands (A, C, 500 [ag; B, 300 lag), liver (A-C, 2
mg), lymph nodes (L.N.)(A, C, 500 ýtg; B, 250 [tg), and spleen (A, C, 200 pLg; B, 100 [tg)
of wild-type, Rb- -, and Rb÷ -;E2f4-1- mice. D, Coupled immunoprecipitation-DOC
release of E2F proteins in pituitary homogenates of wild-type (130 Gig) and Rb' :,E2f4-
(200 [tg) mice with anti-pl07 antibody. Specific E2F-DNA complexes in the absence of
antibody retardation are indicated. The identities of each of the distinct p I07/E2F
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complexes in Rb-/- versus Rb-'-;E2f4- /- cells. Since the Rb- /- and Rb-/-;E2f4/- animals both die in
utero (reviewed by Mulligan and Jacks, 1998; E.Y.L. and J.A.L., see chapter 3), these
experiments were conducted using MEFs (Figure 5A). DOC release and electrophoretic mobility
shift assays confirmed that E2F4 and E2F5 accounted for all of the p107- and p130-associated
E2F activity in wild-type cells (Figure 5A). In agreement with our analysis of Rb+/ -;E2f4 '/ -
samples, some of the p107- and p130-associated E2F species in Rb-/-;E2f4-/ - MEFs were
unaffected by anti-E2F4 and anti-E2F5 antibodies. The remaining complexes corresponded to
E2F 1, E2F3a and E2F3b (data not shown). Importantly, we found that the spectrum of E2F
complexes in the Rb-/-MEFs was a composite of those of the wild-type and Rb-/;E2f4-/ MEFs.
Specifically, whereas E2F4 accounted for either all or a large fraction of the p107-associated E2F
activity in wild-type and Rb-/- cells, respectively, p107 bound significant quantities of activator
E2Fs in Rb' and Rb-/';E2f4-/ - MEFs. Further, p130 associated almost exclusively with E2F4 in
Rb-/ - cells, but in the doubly deficient cells, it associated to a large extent with E2F1 and E2F5
(Figure 5A and see below).
This analysis raised the possibility that p107 and p130 might act in pRB-deficient cells
to bind to E2F1 and E2F3 even in the presence of physiological levels of E2F4. To further test
this hypothesis, we examined the pocket protein binding properties of E2F1 and E2F3 in Rb /
and Rb/-;E2f4/- MEFs by immunoprecipitating the activator E2Fs and western blotting for
associated pocket proteins (Figure 5B). These experiments confirmed that there was a robust
association between the activating E2Fs and p107 and p130 in Rb-/' cells. Furthermore, the
absence of both E2F4 and pRB strikingly increased the level of E2F I-associated p130 when
compared to Rb-/' cells. Taken together, these data yield two important conclusions. First, in
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pRB-deficient cells, p107 and p130 appear to substitute for pRB in the regulation of the
activating E2Fs. Second, E2F4 loss enhances the formation of these novel complexes,
presumably by increasing the levels of the free pools of p 107 and p 130.
Loss of E2F4 suppresses inappropriate E2F target gene expression and cell proliferation
in pRB-deficient cells
Our experiments indicated that tumor suppression in animals lacking both pRB and E2F4
resulted from the reassortment of complexes such that p 1 07/p130 associated with activating
E2Fs. Given these findings, we investigated whether loss of E2F4 had an impact on the
proliferative capacity of Rb-deficient MEFs. To address this issue, we compared the levels of
proliferation in wild-type, Rb-/-, and Rb-/-;E2f4-/-MEFs grown to confluence. Wild-type cells
incorporated BrdU at low levels, as expected for a quiescent population (Figure 6A and B). In
contrast, Rb-/- cells largely failed to arrest in response to confluent growth, and approximately
40% of the cells entered S-phase. Remarkably, loss of E2f4 completely suppressed this
inappropriate proliferation and restored the low levels of BrdU incorporation observed in wild-
type cells.
The abnormal proliferation observed in confluent Rb-/- MEFs has been shown to correlate
with the inappropriate expression of known E2F-responsive genes, cyclin E and p 107 (Herrera et
al. 1996; Hurford et al. 1997). Given the apparent rescue of the Rb-/- proliferation defect in Rb-/'
;E2f4-/- MEFs, we hypothesized that the loss of E2F4 might also modulate the expression of
E2F-responsive genes. We investigated this possibility by examining expression of the cyclin E
gene in wild-type, Rb-/- and Rb-/-;E2f4-/- MEFs grown to confluence. As expected from previous
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Figure 6. Loss of E2F4 restores confluence arrest and regulation of target genes in Rb-
MEFs.
A, Immunofluorescence for BrdU (red) and DAPI (blue) on wild-type, Rb'- and Rb-'
;E2f4- MEFs treated with BrdU 2 days after reaching confluence. B, Quantification of
BrdU incorporation. For each genotype, the percentage of BrdU positive nuclei was
calculated. The graph depicts the average of two experiments with standard deviation.
C, RT-PCR analysis of E2F target genes, cyclin E and B-myb (not deregulated in Rb -'
MEFs), and actin (loading control) on day 2 confluent cells. Wild-type 3T3 cells were
used as a positive control. D, Western blot analysis of E2F target genes, cyclin E and
p107, and P-tubulin (loading control) on day 2 confluent cells. Asynchronously growing
pl07';pl30' MEFs were used as a negative control for the p107 blot.
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studies (Hererra et al. 1996; Hurford et al. 1997), cyclin E was expressed at very low levels in
confluent, wild-type cells but was markedly elevated in cells deficient for Rb (Figure 6C). In
striking contrast, cyclin E RNA levels were dramatically and consistently reduced in cells
deficient for both Rb and E2f4 to levels that approximated those observed in wild-type cells. We
demonstrated that each of these effects was specific, since expression of a second E2F target
gene, B-myb, known to be under the control of pl07/p130 but not pRB (Hurford et al., 1997;
Rayman et al., 2002), was not affected by mutation of Rb or Rb and E2f4 (data not shown).
To extend these findings, we performed western blotting on extracts derived from wild-
type and mutant MEFs and examined expression of several E2F target genes. These experiments
confirmed our RT-PCR studies and showed that expression of cyclin E and a second established
pRB target, p 107, was markedly elevated in Rb-deficient cells. Furthermore, simultaneous loss
of E2f4 largely reversed this de-regulation in two independent preparations of doubly null MEFs
(Figure 6D). These findings strongly suggest that loss of E2f4 suppresses tumorigenic growth of
Rb deficient cells by restoring both appropriate levels of expression of critical E2F target genes
and a normal response to cues that limit cell proliferation.
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DISCUSSION
The goal of these studies was to establish whether the formation of repressive E2F
complexes contributes to the tumor suppressive properties of pRB. Since E2F4 cooperates with
the pocket proteins in gene repression, we anticipated that E2F4 loss would either exacerbate or
have no effect on the tumor phenotype of the Rb+/- mice depending upon whether or not
repression was important. Instead, we found that the absence of E2F4 greatly inhibited the
formation of both pituitary and thyroid tumors, enabling a significant fraction of the Rb+/ ;E2f4-/ -
mice to live as long as wild-type controls. Indeed, the degree of tumor suppression significantly
exceeded that resulting from the loss of the activating E2Fs, E2F1 or E2F3, in an Rb+/-
background (Yamasaki et al. 1998). Furthermore, we demonstrated that loss of E2f4 in Rb-
deficient cells restored the control of E2F-responsive genes and the inhibition of DNA synthesis
characteristic of wild-type, confluence-arrested cells. Since the loss of contact inhibition is one of
the hallmarks of a cancer cell, we suggest that this finding could explain the tumor suppression
we observe in pituitaries and thyroids of Rb+/-; E2f4 /' mice. Thus, this study provides the first
evidence for a critical role of E2F4 in pRB function.
E2F4 loss could be exerting its tumor suppressive effects via several possible
mechanisms. The simplest model is that E2F4 contributes to the activation of E2F-responsive
genes and is therefore a key downstream target of pRB in a similar manner to E2F 1 and E2F3.
This conclusion is supported by early studies that showed that E2F4 has significant
transcriptional activity in over-expression experiments (Beijersbergen et al. 1994; Ginsberg et al.
1994). However, analysis of the endogenous E2F4 protein does not support this conclusion.
First, the predominant cytoplasmic localization of the free E2F4-DP complexes is inconsistent
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with their role in transcriptional activation (Magae et al. 1996; Muller et al. 1997; Verona et al.
1997; Gaubatz et al. 2001). Second, ChIP assays strongly suggest that E2F4 specifically
occupies E2F-responsive promoters in association with p107 and p130 during the GO/G1 stages
of the cell cycle when these targets are transcriptionally repressed (Takahashi et al. 2000;
Rayman et al. 2002). Finally, primary cells that are deficient for E2F4 and E2F5 are defective in
cell cycle arrest but not proliferative functions (Gaubatz et al. 2000). Clearly, these data do not
rule out the possibility that E2F4 could contribute to the activation of E2F-responsive genes in
pRB-deficient tumor cells, and experiments that investigate both expression profiles and
promoter occupancy of target genes will be needed to address this issue further. Moreover, it is
important to note that although it is widely assumed that E2F 1 and E2F3 contribute to the
formation of tumors through this mechanism, this has not yet been demonstrated. Therefore,
experiments with Rb;E2fcompound mutant cells will be critical in testing this hypothesis as well.
An alternative model arising from our data suggests that E2F4 loss could increase the
apoptotic potential of pRB-deficient cells. Under these conditions, cells in the Rb'-;E2f4-'- mice
that lose the wild-type Rb allele might be eliminated by apoptosis rather than become
tumorigenic. This a reasonable concern because there is considerable evidence supporting a role
for the E2F proteins in the regulation of many apoptosis genes (reviewed by Trimarchi and Lees
2002). We have not observed any obvious difference in the apoptotic potential of Rb-/-;E2f4-/-
versus Rb-/- MEFs (our unpublished observations). However, since this does not address the
consequences of E2F4 loss in the adult pituitary and thyroid, we are attempting to establish Rb-/-
;E2f4-/- ES cell lines that can be used to generate chimeric mutant mice. Such mutant animals will
be invaluable because they will allow us to establish whether Rb-/-;E2f4-/- cells can contribute to
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adult tissues. Since it is well established that the formation of tumors in Rb+/ mice depends upon
the inactivation of the wild-type Rb allele, it is also possible that the rearrangement in pocket
protein complexes in the Rb+/-;E2f4-/ - tissues somehow diminishes the selective pressure for loss
of heterozygosity. In addition, our data do not rule out that the observed tumor suppressive
effect of E2F4 loss is cell non-autonomous. Thus, the generation of both conditional and
chimeric mice will also be essential in allowing us to address these two issues.
A final model suggests that E2F4 loss suppresses tumors by simply altering the spectrum
of the remaining E2F complexes. We currently favor this hypothesis, based on our biochemical
analysis. Specifically, our data show that E2F4 loss promotes the formation of novel E2F
complexes in which p107 and p130 associate with the normally pRB-specific E2Fs, E2F1 and 3
(Figure 7). Previous studies have shown that inappropriate release of the activating E2Fs makes
a major contribution to the phenotypic consequences of pRB loss (Tsai et al. 1998; Yamasaki et
al. 1998; Ziebold et al. 2001). We therefore propose that E2F4 loss suppresses tumorigenesis by
increasing the free pools of p107 and p130 and thereby enabling them to substitute for pRB in
the inhibition of the activating E2Fs (Figure 7). This could also account for the observed
suppression of inappropriate E2F-responsive gene expression and cell cycle entry of confluence-
arrested Rb-/- MEFs (Figure 6B and C). Additional tumor studies will be required to distinguish
between these models. However, regardless of the precise mechanism by which E2F4 loss is
operating, our studies do not provide any support for a role of repressive E2F-pocket protein
complexes in tumor suppression. Instead, they strongly suggest that the critical tumor
suppressive role of pRB is to inhibit E2F family members that mediate the activation of E2F-
responsive genes.
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Figure 7. Model for tumor suppression resulting from simultaneous deficiency of E2f4
and Rb.
In wild-type cells, the activator E2Fs are specifically regulated by pRB while E2F4
associates with pRB, p107 and p130. In the absence of Rb, E2F1 and E2F3 activators are
released, activating inappropriate S-phase target gene expression and thereby promoting
uncontrolled proliferation and tumor formation. The simultaneous deficiency of Rb and
E2f4 in Rb -;E2f4- -mice results in the association of p107 and p130 with the activator
E2Fs, conferring tumor suppressive functions on p107 and p130. Loss of pRB alone also
promotes some binding of pl07 and p130 to E2FI and E2F3. Thus, the levels of
available p107 and p130 in individual tissues may account for the tissue specificity of
Rb-/- tumor formation.
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Importantly, we also detected p130-E2F1 and p107-E2F3 complexes in cells that had
physiological levels of E2F4, but lacked the pRB tumor suppressor. Since the generation of Rb -
cells is a key step in the development of many naturally occurring tumors, we believe that the
formation of novel E2F-pocket protein complexes has significant in vivo relevance. There is
extensive evidence from both human tumors and mutant mouse models that the pocket proteins
play non-overlapping roles in the suppression of tumors (Cobrinik et al. 1996; Lee et al. 1996;
Robanus-Maandag et al. 1998; Dannenberg et al. 2000; Sage et al. 2000). Specifically, pRB is a
classical tumor suppressor, but mutation of p107 and/or p130 promotes tumor formation only
when pRB is also inactivated. We believe that our observations can account for these differential
properties. First, we propose that tumor formation is dependent upon the inappropriate release of
the activating E2Fs. Since these E2Fs are specifically regulated by pRB in normal cells, their
release can only be triggered by the loss of pRB and not p107 and/or p130, explaining why pRB
is the key tumor suppressor in vivo. Second, our data suggest that pRB loss causes p107 and
p130 to substitute for pRB in the regulation of the activating E2Fs. In this manner, p107 and
p130 become significant tumor suppressors in pRB-deficient cells. Consistent with this
hypothesis, Rb - ;p 07'- chimeric mice develop an additional tumor type, retinoblastoma, compared
to Rb-" chimeras (Robanus-Maandag et al. 1998), and the combined mutation of pRB, p107 and
p130 has been shown to be highly tumorigenic (Dannenberg et al. 2000; Sage et al. 2000).
Moreover, p O07 and/or p130 mutations have been detected at a low frequency in certain pRB-
deficient human tumors (Helin et al. 1997; Claudio et al. 2000a; Claudio et al. 2000b).
It is important to note that mutation of pl07 and/orpl30 is not required for the formation
of most pRB-deficient tumors. We must therefore conclude that p107 and p130 are unable to
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compensate for the loss of pRB in tumor-prone tissues. Inheritance of germline Rb mutations
results in a highly tissue-specific tumor spectrum in both humans (retinoblastoma) and mice
(pituitary and thyroid tumors). Since pRB is believed to play a key role in all tissue types, the
underlying basis for this tissue-specific spectrum is not understood. We believe that our
observations could also explain this phenomenon. Our data show that the absence of E2F4
increases the levels of p107 and p130 that associate with the activating E2Fs in Rb-/-cells,
suppressing the formation of both pituitary and thyroid tumors in Rb-/- mice. This raises the
possibility that the tumor-prone tissues may simply be those where the levels of available p107 and
p130 are insufficient to substitute fully for pRB in the inhibition of the activating E2Fs (Figure 5).
By extension of this logic, a relatively modest increase in the free pools of p107 and p130 may be
sufficient to prevent the formation of tumors. This suggests a novel strategy for the generation of
chemotherapeutic agents that would either release free pools of p107 and p130 by depleting cells
of E2F4 (as in this study) or increasing intracellular p107/p130 levels.
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EXPERIMENTAL PROCEDURES
Generation, genotyping, and analysis of mice and MEFs
The Rb+/-;E2f4+/- strain was generated by intercrossing Rb+/- and E2f4+/- 129/Sv x
C57BL/6 mice carrying germline mutations in Rb or E2f4. Genotyping was conducted as
previously described (Jacks et al. 1992; Humbert et al. 2000a). Soft tissues were fixed in 10%
formalin, stained with hematoxylin and eosin, and scored for tumors histologically and/or
macroscopically. For comparison, the tumors were measured at the widest diameter. MEFs
were generated using embryos between 10.5 and 13.5 days post coitum from Rb+/-;E2f4+/-
intercrosses as previously described (Humbert et al. 2000b). MEFs were used before passage 7.
The statistical significance of the differential lifespan and tumor incidence of the Rb+/ - versus the
Rb+/-;E2f4-/- animals was determined by the log-rank test and 2-tailed Fisher's exact test (as
previously described by Yamasaki et al. 1998), respectively.
Immunoprecipitation, deoxycholate release, and electrophoretic mobility shift assays.
Asynchronously growing MEFs were lysed in ELB buffer (50 mM Hepes pH 7.0, 250
mM NaCl, 5 mM EDTA, 0.1 % NP-40, and 10 % glycerol containing a protease inhibitor
cocktail). Immunoprecipitation using ELB buffer and western blotting were conducted using anti-
E2F1 (sc-193, Santa Cruz Biotech), anti-E2F3 (AB) (sc-878), anti-pRB (G3-245, PharMingen),
anti-pl07 (sc-318) and anti-p 30 (sc-317) antibodies. Whole organs were lysed in E2F extraction
buffer (20 mM Hepes pH 7.8, 450 mM NaCl, 0.2 mM EDTA pH 8.0, 0.1% NP-40, 25%
glycerol) by three rounds of freeze-thaw and then homogenized in 1.5 ml Eppendorf tubes with a
tight-fitting pestle. Deoxycholate (DOC) release and electrophoretic mobility shift assays were
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conducted as described (Woo et al. 1997) using anti-E2F1 (KH129, Neomarkers), anti-E2F3 (sc-
878), anti-E2F4 (sc-1082), and anti-E2F5 (sc-1083) antibodies. The specificity of these
antibodies was confirmed by performing electrophoretic mobility shift assays with extracts from
various E2F-deficient MEFs.
Confluence arrest, BrdU incorporation, and target gene expression assays
MEFs were grown to confluence, and two days later, cells were labeled with 10 ~IM 5-
bromo-2'-deoxyuridine (BrdU; Sigma) for 8 hours. Incorporation was quantified by indirect
immunofluorescence with anti-BrdU (347580, Becton Dickinson) antibodies and DAPI. The
percentage of BrdU positive cells was determined by counting more than 875 cells per genotype.
Whole cell extracts from day 2 confluent MEFs were prepared as previously described (Moberg
et al., 1996), and western blotting was performed using anti-cyclin E (sc-481), anti-p 107 (sc-
318)(each from Santa Cruz Biotech), and anti-f-tubulin (T-4026, Sigma) antibodies. RT-PCR
assays were carried out as described in Ren et al., 2002 using an Invitrogen RT-PCR Superscript
One Step kit.
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Chapter Three
E2F4 cooperates with pRB in the development of extra-embryonic
but not embryonic tissues
Eunice Y. Lee, Jing Zhang, Tina Yuan, Harvey F. Lodish and Jacqueline A. Lees
The author contributed all the text, Tables 1-4 and Figures 1-6. Jing Zhang, from Harvey F.
Lodish's laboratory, performed the erythroid cell analyses represented in Tables 5 and 6 and
Figure 8 through a collaborative effort with the author. Tina Yuan and the author contributed
Figure 7. Most of the work was performed in the laboratory of Jacqueline A. Lees.
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ABSTRACT
Homozygous mutation of the murine retinoblastoma tumor suppressor gene, Rb, causes
embryonic lethality between E13.5 and E15.5 with defects in cellular proliferation, differentiation
and apoptosis. Many of these defects are suppressed by mutation of the activating E2Fs, E2fl or
E2f3, indicating that they are key downstream targets of the retinoblastoma protein, pRB. We
have previously shown that loss of E2F4, a repressive E2F, suppresses tumor formation in the Rb*'
background. In this study, we have assessed how E2F4 contributes to the developmental
consequences of pRB loss. In stark contrast to the activating E2fs, homozygous mutation of E2f4
shortened the lifespan of Rb-' embryos. This resulted from an exacerbation of the extra-embryonic
tissue defect of the Rb'- mice, indicating that E2F4 and pRB cooperate in the development of this
tissue. To determine the relative roles of E2F4 and pRB in the embryo, we provided Rb- -;E2f4-'
embryos with a normal functioning placenta. Under these conditions, the Rb-';E2f4 - - mice
survived to birth and exhibited all of the defects that were observed in the E2f4 and Rb single
mutant embryos. This was most striking in the hematopoietic compartment, which displayed both
the stress erythropoiesis and Howell-Jolly body phenotypes of the E2f4-'- embryos and the
excessive levels of nucleated erythrocytes characteristic of Rb' - embryos. Thus, we conclude that
pRB and E2F4 play non-overlapping roles in the development of many embryonic tissues.
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INTRODUCTION
The retinoblastoma gene, RB-I, was the first tumor suppressor to be identified. The E2F
transcription factors are the most extensively studied downstream effectors of the retinoblastoma
protein, pRB, and they make a key contribution to its growth inhibitory activities (reviewed in
Trimarchi and Lees 2002). In the G1 phase, hypophosphorylated pRB binds to E2F and
consequently inhibits the activation of E2F-responsive genes, which are required for cell cycle
progression. Upon mitogenic stimulation, pRB is phosphorylated by cyclin D/CDK4 and cyclin
E/CDK2 complexes. This leads to the release of transcriptionally active E2F and entry into S
phase. The importance of this pathway is highlighted by the fact that tumors with wild-type pRB
typically have mutations in Cyclin Dl, CDK4 or p1 6 NK4" , a cyclin dependent kinase inhibitor
(reviewed in Sherr 1996). Therefore, functional inactivation of pRB, which leads to deregulated
E2F activity, is a critical event in tumorigenesis.
E2F transcriptional activity is conferred by a heterodimer of one E2F protein and one DP
protein. To date, there are eight mammalian E2F genes (E2fl through E2f8) and two DP genes
(DPi and DP2) (reviewed in Attwooll et al. 2004; Maiti et al. 2005). The DP moiety enhances
DNA binding and the E2F subunit confers functional specificity. Based on structural and
functional differences, the E2Fs that are regulated by pRB and its relatives, p107 and p130,
(collectively known as the pocket proteins) can be divided into two distinct subgroups: the
activating E2Fs (E2F1, E2F2, E2F3a) and the repressive E2Fs (E2F3b, E2F4, E2F5). The
activating E2Fs are primarily involved in the transcriptional activation of E2F target genes and
when over-expressed each of these E2Fs induces quiescent cells to enter S phase (Lukas et al.
1996; DeGregori et al. 1997). Coincident with the transcription of E2F-responsive genes and
initiation of DNA synthesis, the activating E2Fs are bound to E2F-responsive promoters
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(Takahashi et al. 2000; Rayman et al. 2002). In addition, the activating E2Fs are solely regulated
by pRB in vivo and can induce apoptosis when ectopically expressed (Lees et al. 1993; Moberg et
al. 1996; Vigo et al. 1999).
In contrast, the repressive E2Fs have pivotal roles in transcriptional repression of E2F
target genes. They are constitutively expressed throughout the cell cycle and their subcellular
localization largely influences their transcriptional activity (Magae et al. 1996; Muller et al. 1997;
Verona et al. 1997; Gaubatz et al. 2001). E2F4 and E2F5 are found in the nucleus when bound to
the pocket proteins. E2F4, the major E2F species in vivo, interacts with all of the pocket proteins
and E2F5 predominantly binds to p130 (Beijersbergen et al. 1994; Ginsberg et al. 1994; Ikeda et
al. 1996; Moberg et al. 1996). Promoter occupancy experiments show that E2F4 and E2F5 are
found at classic E2F target genes in association with pocket proteins and chromatin remodeling
factors during GO/G1 (Takahashi et al. 2000; Rayman et al. 2002). Consistent with this
observation, cells lacking both E2F4 and E2F5 are unable to arrest in G1 in response to p16INK4a
expression (Degregori et al., 1997; Gaubatz et al., 2000; Lukas et al., 1996). E2F3b is less well
understood, but it also associates with classic E2F-responsive promoters during GO/G1 and it is
required to maintain the appropriate repression of the pl9ARF tumor suppressor in primary mouse
cells (Aslanian et al. 2004). Taken together, these findings indicate a role for the repressive E2Fs,
and their associated pocket proteins, in enforcing the repression of critical growth regulatory
genes.
Mutant mouse models have been an important tool in defining the role of pRB during
tumorigenesis and development. Consistent with human genetics, Rb+' mice develop tumors
associated with loss of the remaining wild-type allele (Hu et al. 1994; Williams et al. 1994). pRB
is also essential for murine development. Rb-' mice die in mid-gestation by E15.5 and exhibit
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defective erythropoiesis in the fetal liver and widespread inappropriate proliferation and apoptosis
in the central nervous system (CNS), peripheral nervous system (PNS) and ocular lens (Clarke et
al. 1992; Jacks et al. 1992; Lee et al. 1992). Studies with chimeric and conditional animals have
demonstrated that the programmed cell death in the CNS and a considerable fraction of the
erythroid defects are cell non-autonomous effects of pRB loss (Maandag et al. 1994; Williams et
al. 1994; Lipinski et al. 2001; Ferguson et al. 2002; de Bruin et al. 2003; Wu et al. 2003). In fact,
they are secondary consequences of a primary placental defect that is responsible for the
embryonic death of the Rb-' mice (Wu et al. 2003). The loss of pRB leads to uncontrolled
proliferation of trophoblast stem cells in the labyrinth layer of the placenta, which results in
decreased nutrient and gas exchange between the mother and developing fetus. When the early
lethality of the Rb- -animals is circumvented by providing a wildtype placenta, the rescued animals
continue to exhibit ectopic proliferation in the lens, CNS and PNS and also display abnormalities
in erythrocyte maturation and myogenesis (de Bruin et al. 2003; Wu et al. 2003). Taken together,
these data show that pRB plays critical roles in cell cycle regulation, terminal differentiation and
cell survival.
Studies with compound Rb;E2f mutant mice have illustrated that the activating E2Fs have
significant roles in mediating the developmental phenotypes associated with pRB deficiency.
Homozygous mutation of either E2fl or E2f3 leads to an extension in lifespan in the Rb -'- mice. It
also suppresses both the apoptosis and the unscheduled proliferation that occurs in the lens, CNS
and PNS of the Rb-' embryos, although the abnormalities in erythrocyte maturation or myogenesis
persist (Tsai et al. 1998; Ziebold et al. 2001). These studies do not assess the roles of E2fl and
E2f3 in the extra-embryonic relative to the embryonic tissues of the Rb-' animals. The phenotypes
of the compound mutant mice, however, are widely interpreted to indicate that the activating E2Fs
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act in a cell autonomous manner to promote the inappropriate proliferation of both the placental
trophoblast stem cells and the embryonic lens, CNS and PNS.
We have investigated the functional relationship of E2F4, the major repressive E2F, and
pRB. We previously reported that the absence of E2F4 in the Rb' - mice results in a dramatic
suppression of tumor formation (Lee et al. 2002). Our analysis reveals that, in contrast to the
tumor setting, the absence of E2F4 decreases the lifespan of the Rb-deficient mice due to an
exacerbation of the placental defect. Furthermore, E2F4 does not cooperate with pRB within the
developing embryo. These findings clearly indicate that E2F4 functions in a distinct manner from
the activating E2Fs in mediating the effects of pRB loss during normal development.
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RESULTS
Loss of E2F4 causes earlier lethality in Rb-deficient mice
Over-expression and promoter occupancy studies strongly suggest that the repressive E2F-
pocket protein complexes play a critical role in regulating the expression of E2F-responsive genes
in GO and early G1 phases of the cell cycle (Lukas et al. 1996; DeGregori et al. 1997; Takahashi et
al. 2000; Rayman et al. 2002). Our recent data demonstrated that E2F4, which accounts for the
majority of the endogenous pRB-, p107- and p130-associated E2F activity, significantly
contributes to tumor formation in Rb' - mice (Lee et al. 2002). We propose that the oncogenic
activity of E2F4 reflects its ability to restrict the levels of p107 and p130 that are available to bind,
and suppress, the activating E2Fs in place of pRB. It is formally possible, however, that E2F4 can
act as a transcriptional activator in a manner analogous to the activating E2Fs. In order to better
define the role of E2F4 in the growth suppressive properties of pRB, we have assessed the
developmental consequences of E2F4 loss in Rb-- mice.
Rb-'- animals die in mid-gestation from E13.5 to E15.5 (Clarke et al. 1992; Jacks et al.
1992; Lee et al. 1992). To analyze the effects of E2F4 deficiency on the Rb mutant mice, we set
up double heterozygous crosses on a mixed C57B1/6 x 129/Sv background. Since E2f4-'- mice are
viable to adulthood, we began to assess embryo viability at E13.5, the beginning of the window of
lethality for the Rb'- mice. Consistent with previous findings, the Rb-' mice were present at the
expected frequency with most of the animals found alive (Table 1). We also detected the Rb-'-
;E2f4' embryos at the expected Mendelian ratio, indicating that the loss of one wild-type allele of
E2f4 has no effect on the survival of Rb-'- animals at this developmental stage. In contrast, the Rb -'
;E2f4-'- embryos were clearly underrepresented at E13.5; arising at approximately one-third of the
expected frequency. The high mortality rate of the double knockout animals is specifically
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attributed to the additional loss of E2F4 since the vast majority of the Rb homozygous mutants are
alive at this age. Thus, the combined loss of pRB and E2F4 results in early embryonic death prior
to E13.5.
To ascertain the timing of lethality for the Rb-';E2f4-' mice we looked at progressively
earlier times in development. At El 11.5, the Rb-';E2f4-'- embryos arose at roughly the expected
frequency, but slightly more than half of the embryos were found dead, as assessed by the absence
of a heartbeat (Table 1). All other genotypes were present at the expected frequency, confirming
that loss of E2F4 reduces the lifespan of the Rb-'- embryos. At E10.5, a larger proportion (70%)
of the double knockout animals had a detectable heartbeat and at E9.5 viable Rb-';E2f4 -' embryos
were present at the expected frequency. Therefore, the Rb-';E2f4-'- animals die between E10 and
E14, significantly earlier than the Rb-'- mice (E13.5-E15.5).
Although homozygous loss of E2F4 dramatically shifted the window of lethality of the Rb
homozygous mutant animals, the phenotypic consequences on embryonic development were
negligible. First, gross morphological and histological examination detected the same spectrum of
defects in the Rb-'-;E2f4-' animals that had previously been reported for each of the single
homozygous mutants. The Rb-' and E2f4-'- embryos appear paler than their wild-type littermates at
E13.5 as a result of erythrocyte differentiation defects (Jacks et al. 1992; Humbert et al. 2000;
Rempel et al. 2000). The Rb'-;E2f4 -' animals showed a similar pallid coloration. Furthermore, Rb-
'-;E2f4-'- embryos were smaller than littermate controls as previously reported for the E2f4 mutants
(Figure 1A) (Humbert et al. 2000; Rempel et al. 2000). Apart from these characteristic Rb-'- and
E2f4-'- phenotypes, the compound mutant mice did not display any novel morphological defects.
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Table 1. Offspring viability from Rb+'E2f4+' intercrosses
Total # Rb-';E2f4 +' + Rb-';E2f4 +'- Rb-/-;E2f4- '-
Age
Embryos # alive/obs # expected # alive/obs # expected # alive/obs # expected
E13.5 201 11/14 13 24/26 25 3/4 13
E11.5* 366 15/18 23 46/49 46 14/26 23
E10.5* 386 24/27 24 43/53 48 13/19 24
E9.5* 103 2/2 6 13/15 13 7/9 6
* Offspring viability was assessed by the presence of a heartbeat under a stereomicroscope.
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We also examined the Rb- ';E2f4' embryos for evidence of the inappropriate S phase entry
and apoptosis, which are well established features of the E13.5 Rb-'- embryos (Lee et al. 1994;
Morgenbesser et al. 1994; Macleod et al. 1996). For these experiments, we assayed the level of
BrdU incorporation and TUNEL staining in wildtype, E2f4-'-, Rb' - and Rb-';E2f4 -'- embryos (Figure
IB, C). At E11.5, a time when a significant proportion of the double knockouts are viable, the Rb-
/' embryos have elevated levels of BrdU-positive cells in the intermediate zone of the hindbrain
(CNS) and the dorsal root ganglia (PNS) compared to control and E2f4 - ' animals (Figure 1D and
data not shown). There was no alteration in the levels of BrdU-positive cells between the Rb-'- and
Rb'-;E2f4 -' - mice. We also quantified the number of proliferating cells in the lens vesicle. There
was no change among control, Rb-' and Rb-'-;E2f4-'-animals, which is most likely indicative of the
fact that the lens is actively developing and cells are just beginning to withdraw from the cell cycle
around E11.5 (Kaufman 1995). Taken together, these findings suggest that E2F4 does not
contribute to the inappropriate proliferation observed in the absence of pRB.
We also assessed the levels of apoptosis in the animals. At E11.5, there were increased
numbers of apoptotic cells in the hindbrain in the Rb mutant embryos relative to control
littermates. This elevated level of apoptosis persisted to the same extent in the Rb-'-;E2f4-'- mice
(data not shown). These findings were confirmed at E13.5, a developmental stage when this
phenotype is considerably enhanced in the Rb-' mice. Consistent with previous studies, there were
significant amounts of programmed cell death in the hindbrain near the fourth ventricle, trigeminal
ganglia (PNS) and ocular lens of the Rb-' mice, compared to control and E2f4-'- littermates
(FigurelC and data not shown). We found that the degree of apoptosis was relatively unchanged
in the Rb'-;E2f4-'- mice from the Rb homozygous mutants. Thus, increased
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Figure 1. Loss of E2F4 does not affect inappropriate proliferation and apoptosis in the
Rb' embryos.
A) Control, Rb /' and Rb';E2f4' mice at El 1.5. B) Sagittal sections of the hindbrain near
the fourth ventricle in control and mutant embryos at E11.5 are stained for BrdU
incorporation to identify S phase cells. In the control, BrdU-positive cells are restricted
to the ventricular zone while in the Rb-' and Rb'-;E2f4' sections BrdU-positive cells are
present in the intermediate zone, indicating ectopic proliferation. Magnification, 40x. C)
Transverse sections of the hindbrain near the fourth ventricle in control and mutant
embryos at E13.5 are stained for apoptotic cells. There are increased levels of TUNEL-
positive cells in the Rb' and Rb';E2f4'- sections. Magnification, 40x. D) Quantitation
of BrdU-positive cells in control and mutant animals at El 1.5. The elevated levels of
proliferating cells in the PNS (trigeminal ganglia) and CNS (hindbrain) in the Rb mutants
are unchanged with the additional loss of E2F4. In contrast, the amounts of S phase cells
in the developing lens are similar in control and mutant animals. For the PNS and lens,
the overall percentage of BrdU-positive cells was quantified. For the CNS, BrdU-
positive cells in the intermediate zone were counted. E) Quantitation of TUNEL-positive
cells in control and mutant animals at E13.5. The elevated levels of apoptotic cells in the
PNS (dorsal root ganglia), CNS (hindbrain), and ocular lens in the Rb mutants are
unchanged with the additional loss of E2F4. All data are represented relative to the
percentages observed in Rb mutants (+ standard deviation), which were set to 1.
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programmed cell death does not contribute to the reduced survival potential of the double
knockout animals.
Extra-embryonic tissue defect in Rb'';E2f4 ' embryos
Since there were no clear indications as to the cause for early lethality of the Rb-'-;E2f4-'-
animals upon examination of the embryos, we analyzed the extra-embryonic tissues. pRB has
been found to have a critical role in placental development (Wu et al. 2003). Loss of pRB results
in hyperproliferation of trophoblast stem cells in the labyrinth layer of the placenta, leading to
reduced nutrient and gas delivery to the embryo. Consistent with this finding, the Rb-related
defect was highly penetrant at E13.5 in our crosses (Figure 2A, B). At earlier times, E10.5 and
E11.5, the defect in the labyrinth was variable and subtle in many instances (Figure 3B).
Histological examination at E11.5 revealed that loss of E2F4 enhanced the labyrinth layer defect in
the Rb-deficient background and had no discernable effect on the other placental layers (Figure
3B). In contrast to the Rb-' extra-embryonic tissues, a considerable proportion (about 60%) of Rb-'-
;E2f4-'- placentas had a decreased villous appearance of the labyrinth layer. In addition, the yolk
sacs of the compound mutants were not well vascularized (Figure 3A). At E13.5, the placental
defect was more apparent and was detectable in every Rb'-;E2f4-'- placenta examined (Figure 2A,
B). There was a profound reduction in size and number of fetal and maternal blood cavities, which
was associated with a smaller and more compacted labyrinth layer in the double mutant placentas.
Since the Rb-'-;E2f4-' embryos are as small as E2f4-'- mice at E13.5, we compared the sizes of their
placentas and found that the labyrinth layer of the double mutants was smaller than those of E2f4-'-
littermates (data not shown). Therefore, the decrease in placental size is not just a consequence of
growth retardation, but also reflects the defective nature of the placenta. Taken together, these
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Figure 2. The defect in the RbV extra-embryonic tissues is exacerbated in Rb';E2f4'l
mice at E13.5.
A and B) Hematoxylin and eosin stained placental sections of control and mutant
littermates at a magnification of 10x and 20x, respectively. The labyrinth layer (L) is
highly villous in control sections while the loss of pRB results in a compact appearance.
In the Rb';E2f4' placentas, this layer is denser and has a further reduction in blood
spaces when compared to the Rb' sections. C) In situ hybridization for 4311 (Tpbp)
indicates that the spongiotrophoblast layer (Sp) is relatively normal in the mutant
placentas. Magnification, 10x. MD, maternal decidua.
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Figure 3. Loss of E2F4 aggravates the placental defect in the Rb mice at E 11.5.
A) Control yolk sacs are highly vascularized. In contrast, there is a decrease in the
number of blood vessels in the Rb mutant yolk sacs and loss of E2F4 further impairs
vascularization in the yolk sac. B) Hematoxylin and eosin stained placental sections of
control and mutant littermates at a magnification of 10x. The labyrinth layer (L) defect in
the Rb' placenta is subtle. In the Rb';E2f4' placentas, this layer is slightly smaller and
has a noticeably compact appearance. C) In situ hybridization for 4311 (Tpbp) indicates
that the differentiation of the cells in the spongiotrophoblast layer (Sp) is relatively
unaffected in the mutant placentas. Magnification, 10x. D) In situ hybridization for
placental lactogen-1 indicates that trophoblast giant cell (GC) differentiation is
comparable in the control and mutant placentas. Magnification, 2x. MD, maternal
deciduas; C, chorionic plate.
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data reveal that the early lethality of the Rb-'-;E2f4-'- embryos is due to placental insufficiency since
E2F4 loss aggravates the labyrinth layer defect in the Rb-'- placentas.
In order to determine whether the compact appearance of the labyrinth layer is a result of
excessive cell division, we assessed the levels of proliferation in the placentas at E11.5. The
percentage of cells undergoing DNA synthesis was unchanged in all of the genotypes examined
(data not shown). Yet, inappropriate proliferation may not be detectable at this time due to the
active formation of the labyrinth layer at this stage. The extremely low frequency with which
viable Rb-';E2f4-' embryos arise at E13.5 did not allow us to assess the levels of proliferating cells
in the compound mutant placentas. We further determined the levels of apoptosis in the E11.5
placentas. There were no alterations in the number of TUNEL-positive cells between wild-type,
Rb-'-, and Rb-';E2f4-' placentas (data not shown). These results indicate that the placental defect in
the Rb--;E2f4-'- animals at E11.5 does not result from an overall change in the levels of
proliferation or apoptosis within the labyrinth.
To further dissect the placental defect, we compared the expression of several placental
layer specific differentiation markers in the, various genotypes. Due to the small number of Rb-'-
;E2f4- '- embryos at E13.5, our analysis of these samples was limited to in situ hybridization. In
contrast, the E13.5 Rb-' and control littermates, and all pertinent E11.5 genotypes were examined
by both quantitative real-time PCR and in situ hybridization. There was no significant difference
in the expression levels of two trophoblast giant cell markers, placental lactogen-1 (PI-1) and
proliferin-l (Plf-1), in Rb-' and Rb--;E2f4-'- placentas versus the wildtype or E2f4-' control
littermates by real-time PCR (Figure 4A, B and data not shown). This finding was confirmed by
in situ hybridization, which further showed that the spatial expression of PI-1 was equivalent in all
of the genotypes examined (Figure 3D). Similarly, there was no difference in either the expression
122
A
Co
0
@3
*0
PI-1 Fit-i Esx-1
e-
yo
O-
oX0@3@3
*0
PI-1 Fit-1 Esx-1
Figure 4. mRNA expression levels for placental layer-specific markers are unchanged in
mutant placentas.
A and B) At E13.5 and E11.5, respectively, wild-type and mutant placentas expressed
equivalent levels of placental lactogen-1 (PI-1, trophoblast giant cell layer marker), Fit-i
(spongiotrophoblast layer marker), and Esx-1(labyrinthine layer marker), as assessed by
quantitative real-time PCR. Gene expression levels are normalized to ubiquitin
expression levels. Standard deviation is represented by the error bars.
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levels of two spongiotrophoblast markers, 4311 (Tpbp) and Flt-1 (Figure 4A, B and data not
shown), or the in situ hybridization pattern of 4311 (Figure 2C and Figure 3C), between the
various genotypes. We were unable to detect a good in situ hybridization signal for a labyrinth
marker. Yet, quantitative real-time PCR showed that Esx-1, a labyrinth trophoblast marker, was
expressed at similar levels in wildtype, E2f4-'-, Rb-', and Rb--;E2f4-' embryos (Figure 4A, B). In
combination with the hematoxylin and eosin staining of the placentas, these results confirm that
the trophoblast giant cell and spoingiotrophoblast layers are not adversely affected by the loss of
E2F4 and/or pRB. Moreover, the defect in the Rb-';E2f4-'- placentas is not associated with a
defect in trophoblast differentiation in the labyrinth layer.
Expression profile of mutant placentas
To determine the molecular basis of the placental defect, we analyzed the transcriptional
expression profiles of the Rb' - and Rb-'-;E2f4- - extra-embryonic tissues. We began by comparing
the expression profiles of wild-type and Rb-'- placentas at E13.5, the time when the placental defect
is clearly evident in most of Rb-'- samples. Using the Affymetrix whole mouse genome (430 2.0)
microarray, we identified 135 differentially expressed genes with a 2> 2-fold difference and an
adjusted p-value < 0.05 in the Rb-'- tissues. Of these genes, 71 were induced while 64 were
repressed (Table 2A and 2B). As an internal control, Rb was detected as a significantly repressed
gene.
Consistent with the classical view that pRB loss promotes E2F transcriptional activity, a
number of classic E2F-responsive genes were significantly upregulated in the Rb mutant placentas.
These included MCM2, MCM3, MCM6, MCM7, cyclin El, cyclin E2 and E2F1. Importantly, we
were able to confirm the induction of all of these E2F-target genes using real-time PCR (Figure 5A
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and data not shown). These results provide direct support for the previous conclusion that loss of
pRFB results in increased proliferation at E13.5 (Wu et al., 2003). Due to the small amount of
E13.5 Rb-'-;E2f4-' - animals, we compared the transcript levels of the same cell cycle genes in wild-
tylpe, E2f4 -/-, Rb-'- and Rb-'-;E2f4-'- placentas at E11.5. At this earlier time point, we did not detect
any significant differences (Figure 5B). This finding is entirely consistent with our BrdU
immunohistochemistry data, which did not detect any difference on the level of proliferating cells
between wild-type and mutant placentas at E1 1.5.
The most induced gene in Rb-' - placentas, compared to wild-type tissues, was not a classic
E2F-responsive gene. Instead, it was developmental pluripotency associated 5 (Dppa5), which is
also known as embryonal stem cell specific gene 1 (Esg-1). This gene is specifically expressed in
embryonic stem (ES) cells and in the trophoectoderm, which gives rise to most cell lineages in the
placenta (Astigiano et al. 1991; Bierbaum et al. 1994; Tanaka et al. 2002; Bortvin et al. 2003; Ahn
et al. 2004). In contrast, Dppa5 is not expressed in lineage-committed stem cells (i.e., neural stem
cells and trophoblast stem cells) or somatic cells. Thus, the expression pattern of Dppa5 denotes it
as a marker for pluripotency, but its function is currently unknown. Quantitative real-time PCR
corroborated our microarray data, as there was approximately 10 times more Dppa5 mRNA in Rb-'-
placentas than in wild-type tissues (Figure 5C). Furthermore, Dppa5 was barely expressed in wild-
type trophoblast stem cells, in accordance with previous reports (data not shown; Tanaka et al.,
2002). Importantly, the levels of DppaS were also increased (approximately 4 fold) in extra-
embryonic tissues derived from Rb -' - and Rb-'-;E2f4-'- versus wild-type and E2f4 -'- animals at E11.5
(Figure 5D). Thus, the upregulation of DppaS is detected at, or before, the placental defect can be
consistently observed in the Rb -' - embryos. Based on these observations, we conclude that there is
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Table 2A. Significantly induced genes in E13.5 Rb-'- placentas identified by microarray analysis
Probe set
1418199_at
1447360_at
141.6552_at
1420773 at
1420720 at
1438239_at
1450555_at
1460570_at
1433623_at
14 1.9014_at
1444454_at
1442334_at
1427603_at
1425753 a at
14.35998 at
1418283_at
1419348_at
14-38852 x at
1443961_at
1458659_at
1452590 a at
1419571_at
1456005 a at
1422628_at
1419570_at
1435275_at
1449061 a at
1420719_at
1431554 a at
1452458 s at
1418203_at
1449960_at
142.3809_at
Gene Title
hemogen
transforming growth factor beta 1 induced
transcript 4
developmental pluripotency associated 5
deubiquitinating enzyme 1
neuronal pentraxin 2
midline 1
testis expressed gene 13
RIKEN cDNA 2900019M05 gene
zinc finger protein 367
Rhesus blood group-associated A glycoprotein
Transcribed sequences
Transcribed seq, similarity to sp:095522
(H.sapiens) YA02_HYPOTHETICAL PROTEIN
DJ1198H6.2
cDNA sequence BC018510
uracil-DNA glycosylase
Similar to chromosome 14 open reading frame 18
isoform a; enhancer of invasion 10 (LOC239083)
claudin 4
parotid secretory protein
minichromosome maintenance deficient 6 (MIS5
homolog, S. pombe) (S. cerevisiae)
expressed sequence AU017962
Transcribed sequences
hypothetical LOC211623
solute carrier family 28 (sodium-coupled
nucleoside transporter), member 3
BCL2-like 11 (apoptosis facilitator)
RIKEN cDNA 4632417K18 gene
solute carrier family 28 (sodium-coupled
nucleoside transporter), member 3
cytochrome c oxidase subunit VIb, testes-specific
DNA primase, p49 subunit
testis expressed gene 15
annexin A9
peptidylprolyl isomerase (cyclophilin) like 5
phorbol- 12-myristate- 13-acetate-induced protein 1
neuronal pentraxin 2
transcription factor 19
Fold change
4.733
4.636
4.197
3.859
3.451
3.061
2.786
2.547
2.473
2.289
2.237
2.179
2.158
2.133
2.104
2.087
2.048
1.980
1.956
1.935
1.932
1.819
1.770
1.727
1.725
1.713
1.706
1.658
1.641
1.629
1.608
1.574
1.561
Adj p-value
1.71 E-19
1.71E-19
1.7 1E-19
1.71E-19
1.71E-19
1.71E-19
1.95E- 11
6.58E-08
6.48E-09
1.30E-04
5.23E-07
4.06E-07
3.88E-05
3.53E-05
1.29E-05
1.05E-11
3.18E-10
4.65E-08
1.31E-04
1.60E-08
6.12E-07
9.30E-04
2.85E-03
3.87E-05
3.88E-05
7.22E-03
3.82E-07
7.82E-03
5.09E-03
1.60E-03
1.11E-06
2.46E-04
2.63E-03
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- -
- -
Probe set
1436708_x_at
1424638_at
1419172_at
1416326_at
1434734_at
1449052_aat
1417938_at
1420028_s at
1418600_at
1416251_at
1416641_at
1449708_s_at
1418369_at
1423877_at
1418719_at
1426652_at
1422944 aat
1456280_at
1428304_at
1416492_at
1434695_at
1448899_s_at
1452598 at
1415945_at
1449705_x_at
1425837_a_at
1417541_at
1428738_a_at
1422535_at
1439269_x_at
1435114_at
1435217_at
1452912_at
1424608 aat
Gene Title
minichromosome maintenance deficient 4 homolog
(S. cerevisiae)
cyclin-dependent kinase inhibitor 1A (P21)
dihydrofolate reductase
cysteine-rich protein 1 (intestinal)
RIKEN cDNA E130016E03 gene
DNA methyltransferase 3B
RAD51 associated protein 1
minichromosome maintenance deficient 3 (S.
cerevisiae)
Kruppel-like factor 1 (erythroid)
minichromosome maintenance deficient 6 (MIS5
homolog, S. pombe) (S. cerevisiae)
ligase I, DNA, ATP-dependent
checkpoint kinase 1 homolog (S. pombe)
DNA primase, p49 subunit
chromatin assembly factor 1, subunit B (p60)
RIKEN cDNA 2410004L22 gene
minichromosome maintenance deficient 3 (S.
cerevisiae)
diaphanous homolog 3 (Drosophila)
RIKEN cDNA E130314M08 gene
RIKEN cDNA 2410004I17 gene
cyclin El
RIKEN cDNA 2810047L02 gene
RAD51 associated protein 1
RIKEN cDNA 2810418N01 gene
minichromosome maintenance deficient 5, cell
division cycle 46 (S. cerevisiae)
minichromosome maintenance deficient 3 (S.
cerevisiae)
CCR4 carbon catabolite repression 4-like (S.
cerevisiae)
helicase, lymphoid specific
DNA segment, Chr 14, ERATO Doi 449, expressed
cyclin E2
MCM7 (S. cerevisiae)
RIKEN cDNA D630024B06 gene
up-regulated in Myc liver
RIKEN cDNA 2600005003 gene
xanthine dehydrogenase
Fold change Adj p-value
1.542
1.530
1.515
1.504
1.495
1.488
1.487
1.486
1.483
1.479
1.475
1.464
1.439
1.434
1.432
1.425
1.416
1.414
1.410
1.406
1.373
1.373
1.369
1.368
1.347
1.346
1.345
1.339
1.338
1.335
1.331
1.327
1.322
1.321
1.74E-04
1.27E-02
5.06E-05
6.7 1E-04
4.41E-02
2.59E-03
4.73E-03
3.1 OE-05
1.67E-02
3.55E-05
1.66E-04
6.78E-03
2.5 3E-05
1.82E-02
2.62E-02
2.87E-04
5.98E-03
2.98E-03
2.58E-02
2.12E-04
6.65E-03
2.22E-02
1.06E-02
3.46E-04
5.03E-04
6.90E-04
4.35E-04
1.15E-04
1.75E-04
5.79E-03
4.8 1E-03
4.62E-02
2.37E-02
5.09E-03
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Probe set
1436808 x at
1432566_at
1452715_at
1423653_at
14-34079 s at
1422430_at
1421278 s at
14-17926_at
1418281_at
1450677_at
1418264_at
1416915_at
1439562_at
144191.0 x at
1448777_at
1424953_at
143571.0 at
1437:309 a at
1416802 a at
1445849_at
14.24607 a at
1426687_at
1426242_at
1455990_at
1426473_at
14.2,1731 a at
1426817_at
1438'320_s_at
1439012 a at
14.2,2016 a at
142.4143 a at
1424609 a at
1436'390 a at
14161[18_at
1439436 x at
Gene Title
minichromosome maintenance deficient 5, cell
division cycle 46 (S. cerevisiae)
RIKEN cDNA 1700129115 gene
RIKEN cDNA 2310022K01 gene
ATPase, Na+/K+ transporting, alpha 1 polypeptide
minichromosome maintenance deficient 2 mitotin
(S. cerevisiae)
fidgetin-like 1
spectrin alpha 1
RIKEN cDNA 5830426105 gene
RAD51 homolog (S. cerevisiae)
checkpoint kinase 1 homolog (S. pombe)
SoxLZ/Sox6 leucine zipper binding protein in testis
mutS homolog 6 (E. coli)
RIKEN cDNA F730047E07 gene
cyclin El
minichromosome maintenance deficient 2 mitotin
(S. cerevisiae)
cDNA sequence BC021614
expressed sequence AI661384
replication protein Al
RIKEN cDNA 2610036L13 gene
RIKEN cDNA A430089119 gene
xanthine dehydrogenase
mitogen activated protein kinase kinase kinase 3
polymerase (RNA) II (DNA directed) polypeptide
A
kinesin family member 23
DnaJ (Hsp40) homolog, subfamily C, member 9
flap structure specific endonuclease 1
antigen identified by monoclonal antibody Ki 67
minichromosome maintenance deficient 7 (S.
cerevisiae)
deoxycytidine kinase
centromere autoantigen H
retroviral integration site 2
xanthine dehydrogenase
Mid-l-related chloride channel 1
RIKEN cDNA 2310035M22 gene
inner centromere protein
Fold change Adj p-value
1.302
1.301
1.299
1.297
1.296
1.294
1.266
1.258
1.256
1.238
1.229
1.226
1.224
1.212
1.210
1.207
1.203
1.201
1.185
1.170
1.168
1.156
1.153
1.149
1.141
1.138
1.130
1.126
1.121
1.117
1.101
1.095
1.094
1.065
1.056
3.48E-05
1.50E-03
4.58E-02
1.46E-02
4.17E-03
2.37E-03
1.78E-02
2.50E-02
1.13E-03
4.09E-02
1.3 3E-02
1.18E-02
3.29E-02
1.99E-03
3.33E-03
3.76E-02
1.16E-02
8.86E-04
1.36E-02
6.25E-03
4. 11 E-05
2.66E-02
4.5 l1E-06
8.76E-03
5.75E-03
1.93E-03
5.91E-03
6.36E-03
2.30E-02
2.39E-02
6.78E-03
2.27E-05
2.34E-02
1.82E-02
4.60E-02
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__
- -
Probe set Gene Title Fold change Adj p-value
minichromosome maintenance deficient 7 (S.
1416031_s_at cerevisiae) 1.055 2.31E-02
1452543_a_at secretoglobin, family 1A, member 1 (uteroglobin) 1.054 1.78E-02
1426731_at desmin 1.050 1.45E-03
1423293_at replication protein Al 1.046 2.64E-02
1424144_at retroviral integration site 2 1.030 2.43E-02
1436459_at G protein-coupled receptor 161 1.024 1.77E-02
minichromosome maintenance deficient 7 (S.
1416030_a_at cerevisiae) 1.014 1.00E-02
1436454_x_at flap structure specific endonuclease 1 1.006 7.36E-03
tumor necrosis factor receptor superfamily, member
1449033_at 1 lb (osteoprotegerin) 1.004 2.66E-02
1448393_at claudin 7 1.001 3.34E-02
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Table 2B. Significantly repressed genes in E13.5 Rb-' placentas identified by microarray analysis
Probe set
1416646_at
1416645_a_at
1459737_s_at
1454608_x_at
1438840 x at
1436879 x at
1419232_a_at
1455201 x at
1435648_at
1419233 x at
1455913_x_at
1419725_at
1451580_a_at
1417761_at
1418282 x at
1458070_at
1417950 a at
1426990_at
1452270_s_at
1418689_at
1418310_a_at
1424265_at
1436504 x at
1426082_a_at
145641.8_at
1416025_at
1434354_at
1415938_at
1418916 a at
1455593_at
1428079_at
1424279_at
1432198_at
1431701_a_at
1448680_at
1421063_sat
Gene Title
alpha fetoprotein
alpha fetoprotein
transthyretin
transthyretin
apolipoprotein A-I
alpha fetoprotein
apolipoprotein A-I
apolipoprotein A-I
RIKEN cDNA B430119L13 gene
apolipoprotein A-I
transthyretin
solute carrier family 26, member 4
transthyretin
apolipoprotein A-IV
serine (or cysteine) proteinase inhibitor, clade A,
member la
cDNA sequence BC032925
apolipoprotein A-II
cubilin (intrinsic factor-cobalamin receptor)
cubilin (intrinsic factor-cobalamin receptor)
cathepsin 6
retinaldehyde binding protein 1
N-acetylneuraminate pyruvate lyase
apolipoprotein A-IV
solute carrier family 16 (monocarboxylic acid
transporters), member 4
Transcribed seq, sim to protein pir:A55119
(H.sapiens) A55119 protein romk-1
fibrinogen, gamma polypeptide
monoamine oxidase B
serine protease inhibitor, Kazal type 3
secreted phosphoprotein 2, 24kDa
apolipoprotein B
fibrinogen, B beta polypeptide
fibrinogen, alpha polypeptide
RIKEN cDNA 6330414G02 gene
PDZ domain containing 1
serine (or cysteine) proteinase inhibitor, clade A,
member la
SNRPN upstream reading frame
Fold change
-5.226
-4.071
-4.002
-3.917
-3.787
-3.784
-3.709
-3.588
-3.191
-3.089
-3.077
-2.909
-2.726
-2.466
-2.462
-2.445
-2.441
-2.367
-2.361
-2.346
-2.333
-2.277
-2.273
-2.203
-2.200
-2.182
-2.174
-2.107
-2.065
-2.053
-2.003
-1.993
-1.993
-1.990
-1.980
-1.968
Adj p-value
1.71 E-19
1.71E-19
1.71E-19
1.7 1E-19
1.71 E-19
1.7 1E-19
1.71E-19
1.7 1E-19
1.84E-10
6.00E-17
1.13E-14
1.7 1E-19
3.13E-10
1.65E-09
1.71E-19
7.90E- 12
3.19E-06
1.OOE-17
8.44E-12
1.28E-09
6.90E-08
1.61E-05
8.89E-12
5.44E-12
1.54E-06
4.90E-16
1.OOE-17
3.00E-17
7.03E-13
1.03E-13
1.81E-10
1.60E-16
1.37E-08
1.47E-05
1.71E-19
5.80E-03
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Probe set
1424338_at
1420553 x at
1451513 x at
1423436_at
1425260_at
1417850_at
1436101 at
1429379 at
1431226_aat
1418724_at
1418370_at
1419095 a at
1422837_at
1426547_at
1435578_s_at
1439111 _at
1452424_at
1425841_at
1425546 a at
1426260_aat
1460541_at
1418880_at
1458401_at
1431142 s at
1436279_at
1440409_at
1424808_at
1424901_at
1416776_at
1437259_at
1455193_at
1451297_at
1432418 a at
Gene Title
solute carrier family 6 (neurotransmitter
transporter, GABA), member 13
serine (or cysteine) proteinase inhibitor, clade A,
member la
serine (or cysteine) proteinase inhibitor, clade A,
member la
glutathione S-transferase, alpha 3
albumin 1
retinoblastoma 1
RIKEN cDNA 2810473M14 gene
extra cellular link domain-containing 1
fibronectin type III domain containing 4
complement component factor i
troponin C, cardiac/slow skeletal
apolipoprotein M
sciellin
group specific component
RIKEN cDNA C630028C02 gene
16 days neonate cerebellum cDNA, RIKEN full-
length enriched library, clone:9630032E14
product:unknown EST, full insert sequence
G protein-coupled receptor 23
solute carrier family 26, member 7
transferrin
UDP-glucuronosyltransferase 1 family, member 2
expressed sequence AI643885
glial cell line derived neurotrophic factor family
receptor alpha 3
RIKEN cDNA 4932438A13 gene
apoptosis-inducing factor (AIF)-like
mitochondrion-associated inducer of death
solute carrier family 26, member 7
RIKEN cDNA 2210401J11 gene
laminin, alpha 4
glucosaminyl (N-acetyl) transferase 3, mucin type
crystallin, mu
solute carrier family 9 (sodium/hydrogen
exchanger), member 2
zinc finger and BTB domain containing 8
gulonolactone (L-) oxidase
creatine kinase, mitochondrial 1, ubiquitous
Fold change Adj p-value
-1.941
-1.924
-1.889
-1.863
-1.813
-1.813
-1.792
-1.788
-1.783
-1.770
-1.747
-1.714
-1.631
-1.600
-1.576
-1.570
-1.568
-1.566
-1.552
-1.536
-1.536
-1.447
-1.445
-1.442
-1.427
-1.425
-1.407
-1.376
-1.376
-1.365
-1.356
-1.345
-1.327
2.3 1E-03
3.33E-11
5.39E-14
2.47E-09
3.63E-10
7.15E-06
2.78E-03
2.38E-05
6.90E-04
3.10E-11
2.45E-03
1.69E-06
3.55E-05
3.18E-10
9.78E-03
1.28E-02
6.26E-07
1.78E-02
7.69E-05
9.83E-07
6.23E-04
2.76E-04
2.63E-05
1.73E-02
1.79E-02
7.76E-07
4.80E-02
2.38E-05
8.35E-04
6.1 OE-03
4.94E-02
3.65E-02
8.61E-04
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Probe set Gene Title Fold change Adj p-value
1435292_at
1425875 a at
1417079_s_at
1450770_at
1451426_at
1421641_at
1424649_a_at
1451738_at
1428223_at
1425644_at
1449077_at
1451657_a_at
1439163_at
1427975_at
1442025_a_at
1429523_a_at
1426697 a at
1416842_at
1433514_at
1422852_at
1418352_at
1437213_at
1418069_at
1449043_at
1429901_at
1419403_at
1439995_at
1422723 at
Transcribed sequence with moderate similarity to
protein pir:T00261 (H.sapiens) T00261
hypothetical protein KIAA0603 - human
leptin receptor
lectin, galactose-binding, soluble 2
RIKEN cDNA 3632451006 gene
DNA segment, Chr 11, Lothar Hennighausen 2,
expressed
solute carrier family 6 (neurotransmitter
transporter, noradrenalin), member 2
transmembrane 4 superfamily member 3
O-linked N-acetylglucosamine (GlcNAc)
transferase (UDP-N-
acetylglucosamine: polypeptide-N-
acetylglucosaminyl transferase)
RIKEN cDNA 1700018018 gene
leptin receptor
erythroid associated factor
cytosolic ovarian carcinoma antigen 1
Transcribed sequence with weak similarity to
protein ref:NP_079268.1 (H.sapiens)
hypothetical protein FLJ12547 [Homo sapiens]
RIKEN cDNA 2210403B10 gene
expressed sequence A1467657
solute carrier family 39 (metal ion transporter),
member 5
low density lipoprotein receptor-related protein
associated protein 1
glutathione S-transferase, mu 5
ethanolamine kinase 1
calcium and integrin binding family member 2
hydroxysteroid (17-beta) dehydrogenase 2
Transcribed sequence with moderate similarity to
protein ref:NP_008937.1 (H.sapiens) cleavage
and polyadenylation specific factor 5, 25 kD
subunit; pre-mRNA cleavage factor Im
apolipoprotein C-II
N-acetyl galactosaminidase, alpha
RIKEN cDNA 6330571D19 gene
cDNA sequence BC017612
expressed sequence C80638
stimulated by retinoic acid gene 6
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-1.298
-1.295
-1.289
-1.286
-1.275
-1.268
-1.259
-1.252
-1.248
-1.221
-1.220
-1.214
-1.196
-1.190
-1.187
-1.183
-1.176
-1.169
-1.149
-1.139
-1.113
-1.093
-1.089
-1.084
-1.052
-1.038
-1.037
-1.031
3.65E-02
5.34E-03
1.OOE-02
7.17E-03
2.71E-03
1.34E-02
4.50E-03
4.81 E-02
1.25E-02
4.41E-02
6.78E-03
3.21E-02
4.01E-03
1.76E-02
3.62E-02
1.83E-03
4.44E-02
3.66E-02
7.04E-03
1.45E-02
2.30E-02
2.00E-02
6.61E-03
1.78E-02
1.96E-02
1.76E-03
9.64E-03
1.03E-02
Probe set Gene Title Fold change Adj p-value
1459034_at RIKEN cDNA D330023L08 gene -1.026 2.50E-03
1421261 at lipase, endothelial -1.019 9.32E-03
1455093_aat alpha-2-HS-glycoprotein -1.018 4.25E-02
1457551_at Transcribed sequences -1.016 3.23E-05
Transcribed sequence with moderate similarity to
protein ref:NP_008937.1 (H.sapiens) cleavage
and polyadenylation specific factor 5, 25 kD
1455966 s_at subunit; pre-mRNA cleavage factor Im -1.009 2.40E-02
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Figure 5. Confirmation of microarray data by quantitative real-time PCR analysis.
A) Cell cycle genes are expressed at increased levels in E13.5 Rb / placentas compared to
wild-type placentas. B) At E11.5, wild-type and mutant placentas express cell cycle
genes at similar levels, indicating that loss of pRB and/or E2F4 does not affect
proliferation in this tissue at this time. C and D) Expression of Eomes (a trophoblast
stem cell marker) and Dppa5 (a pluripotency marker) in wild-type and mutant placentas
at E13.5 and E11.5, respectively. Eomes is expressed at similar levels among the various
genotypes while Dppa5 expression is significantly elevated in Rb' and Rb';E2f4'
placentas relative to wild-type and E2f4-' tissues. Gene expression levels are normalized
to ubiquitin expression levels and error bars represent standard deviation.
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a population of pluripotent cells in the Rb mutant placentas, which is absent or very minimally
present in the wild-type placentas.
Wu et al. (2003) previously concluded that placental insufficiency in the Rb mutants results
from the uncontrolled proliferation of trophoblast stem cells within the labyrinth layer. This was
based on their ability to detect increased expression of Eomes, a trophoblast stem cell marker. In
contrast with this finding, we did not detect any significant difference in Eomes expression
between Rb-' (either single or double mutant) and control placentas at either E11.5 and E13.5, as
assessed by real-time PCR (Figure 5C, D). Moreover, Eomes was not identified as a differentially
expressed gene in our microarray studies. Although these results indicate that Eomes is
equivalently expressed in wild-type, Rb-', E2f4- '-, and Rb- -;E2f4-/- placentas we cannot rule out the
possibility that the localization of Eomes expressing cells is altered in the mutant tissues. Our
data, however, suggest that the labyrinth layer defect of Rb-' and Rb-';E2f4- ' placentas results from
the presence of a misplaced pool of pluripotent cells rather than an increased population of
trophoblast stem cells.
For a number of the differentially expressed genes that were analyzed, the mRNA
expression levels in the double knockout placentas paralleled those in the Rb mutants while the
wild-type and E2f4- '- placentas exhibited comparable levels (Figure 4, 5 and data not shown).
These findings suggest that these genes are influenced by pRB and not E2F4. Presumably,
different genes are affected by the simultaneous loss of pRB and E2F4 and cause the intensified
placental defect. In order to identify these genes, we performed microarray analyses on wild-type
and Rb'-;E2f4 -'- placentas at E11.5. We chose this time point because a significant proportion of
viable double mutant animals can be recovered at this stage. Using the same arrays and thresholds
as before, we identified 14 significantly induced genes and 30 repressed genes in the Rb-'-;E2f4-'
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placentas compared to wild-type tissues. Of the 14 induced genes, 3 were also induced in
expression profiles from the E13.5 Rb-'- placentas. Furthermore, 4 of the 30 repressed genes were
in the previous array. The complete table of differentially expressed genes is listed in Table 3A
and 3B. None of the E2F-responsive cell cycle genes were differentially expressed in the El 1.5
Rb-'-;E2f4-'-, placentas, supporting our real-time PCR and proliferation index results. Dppa5 was
still one of the most induced genes in the compound mutant placentas, which is also consistent
with our real-time PCR analysis (Figure 5D). Further analysis is necessary to validate the
candidates that arose from these microarrays, as well as to determine whether differential
expression is a consequence of losing pRB and/or E2F4.
Early lethality is rescued in conditionally mutant animals
In order to determine whether the placental defect is the primary cause of death in the Rb-/-
;E2f4-'- embryos, we generated conditional mice resulting in double mutant embryos provided with
normal functioning placentas. Using a similar strategy employed by (Wu et al. 2003), we bred
Rb 2 1ox/ 2 lox;E2f4+/- mice to an epiblast-specific Cre line, MORE (Mox2Cre) (Tallquist and Soriano
2000; MacPherson et al. 2003). Although Cre expression from the Mox2 promoter is detectable in
the embryo proper by E6, recombination efficiency is variable (Tallquist and Soriano 2000;
Hayashi et al. 2002). Despite the possibility for embryo-specific genetic mosaics, the majority of
extra-embryonic tissues do not exhibit Cre activity, allowing us to establish whether early lethality
associated with simultaneous loss of pRB and E2F4 results from an aggravated placental defect.
Rbl°x/l°x;Mox2cre+ mice are found dead at birth (Wu et al. 2003). We also found that all
Rb"' 'x""/;Mox2"' mice, irrespective of the E2f4 genotype, were underrepresented at birth. We
believe this is partially due to episodes of cannibalism, since the Rb mutant animals have a
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Table 3A. Significantly induced genes in E11.5 Rb-'-;E2f4-'- placentas identified by microarray
analysis
Probe set Gene Title
1429287_aat prolactin
Similar to THO complex subunit 4 (Tho4) (RNA
and export factor binding protein 1) (REFI-I) (Ally
1443961_at of AML-1 and LEF-1) (Aly/REF)
1416552_at developmental pluripotency associated 5
1460613_xat growth hormone
1427346_at ovary testis transcribed
1437522_xat growth hormone
1456595_xat growth hormone
1420773_at deubiquitinating enzyme 1
1436936_s_at inactive X specific transcripts
1415897_a_at microsomal glutathione S-transferase 1
1427262_at inactive X specific transcripts
14:23859_aat prostaglandin D2 synthase (brain)
T-cell immunoglobulin and mucin domain
1418766_s_at containing 2
14:2.5220_x_at cDNA sequence AF067061
14:56655_at
14:2'7263_at
14:38512_at
14:53287_at
14:20720_at
14'21(41 s at
14:35217_at
14'29982_at
1416676 at
Exostoses (multiple) 1
inactive X specific transcripts
epididymal protein Av381126
RIKEN cDNA 5730557B15 gene
neuronal pentraxin 2
glutathione S-transferase, alpha 2 (Yc2)
Hypothetical LOC236262 /// Hypothetical
LOC'385178
RIKEN cDNA 4933426K21 gene
kininogen 1
Fold change
3.247
2.679
2.441
2.208
2.207
2.119
2.019
1.954
1.871
1.618
1.613
1.578
1.565
1.498
1.437
1.387
1.313
1.285
1.128
1.096
1.068
1.048
1.025
Adj p-value
0.OE+00
0.OE+00
0.OE+00
0.OE+00
0.OE+00
0.0E+00
0.OE+00
0.OE+00
0.OE+00
5.9E-04
0.OE+00
0.OE+00
1.5E-04
3.6E-02
0.OE+00
0.OE+00
1.9E-03
0.OE+00
5.OE-02
1.6E-03
3.2E-02
0.OE+00
2.0E-05
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Table 3B. Significantly repressed genes in E11.5 Rb-'-;E2f4-' - placentas identified by microarray
analysis
Probe set
1417850. at
1426438_at
14-25182_ x
14-52077_at
14-26439_at
14-24749_at
1419725_at
1417210 at
1424903_at
1418310 a
1435648_at
1426225_at
1425841_at
1438325_at
1427308_at
1448291_at
1450188 s,
14.2,6598_at
14.23135_at
1437093_at
1452656_at
1421262_at
1451933 a_
1426263_at
1453485_ s 
1435577_at
1451862_ a
1424477 at
1436544_at
1452655_at
1452417_x_
1455735_at
1452424_at
1448729_ a
1455422 x_,
Gene Title
retinoblastoma 1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked
at kallikrein 9 /// kallikrein 22
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked
WD repeat and FYVE domain containing 1
solute carrier family 26, member 4
eukaryotic translation initiation factor 2, subunit 3,
structural gene Y-linked
jumonji, AT rich interactive domain D (Rbp2 like
at retinaldehyde binding protein 1
RIKEN cDNA B430119L13 gene
retinol binding protein 4, plasma
solute carrier family 26, member 7
ecotropic viral integration site 1
RIKEN cDNA C630028C02 gene
matrix metalloproteinase 9
it lipase, endothelial
ubiquitously transcribed tetratricopeptide repeat
gene, Y chromosome
thymus cell antigen 1, theta
dynein, axonemal, intermediate chain 1
zinc finger, DHHC domain containing 2
lipase, endothelial
it cathepsin 7
immunoglobulin superfamily, member 4C
it RIKEN cDNA 1110005A03 gene
RIKEN cDNA C630028C02 gene
it perforin 1 (pore forming protein)
cDNA sequence BC019731
ATPase, Class V, type 10D
zinc finger, DHHC domain containing 2
at immunoglobulin kappa chain, constant region
adaptor-related protein complex AP-1, sigma 3
G protein-coupled receptor 23
it septin 4
at septin 4
Fold Change Adj p-value
-2.849 0.OOE+00
)
-2.417
-2.314
-2.272
-2.243
-2.063
-2.026
-1.931
-1.923
-1.754
-1.695
-1.573
-1.530
-1.511
-1.507
-1.496
-1.489
-1.459
-1.435
-1.419
-1.400
-1.399
-1.390
-1.338
-1.320
-1.291
-1.276
-1.272
-1.232
-1.202
-1.195
-1.151
-1.114
-1.093
-1.084
0.OOE+00
0.OOE+00
0.OOE+00
0.OOE+00
1.OOE-10
0.OOE+00
0.OOE+00
0.OOE+00
2.72E-04
2.61E-04
3.28E-03
4.07E-02
1.46E-04
1.41E-02
1.20E-09
1.02E-03
0.OOE+00
2.34E-07
1.OOE-10
8.18E-03
1.75E-03
5.00E-10
4.61E-02
7.93E-04
0.OOE+00
1.15E-08
3.59E-02
2.3 1E-02
2.75E-02
3.73E-05
4.16E-02
1.30E-02
7.91E-04
5.95E-04
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Probe set Gene Title Fold Change Adj p-value
1422643_at monooxygenase, DBH-like 1 -1.044 4.1 1E-02
142,9566 a at homeodomain interacting protein kinase 2 -1.039 7.66E-03
142,3669_at procollagen, type I, alpha 1 -1.037 3.40E-02
1450792 at TYRO protein tyrosine kinase binding protein -1.013 3.19E-02
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reduced survival potential once born. To confirm that the RblO°xl°X;Mox2cre/+ animals and the
RbJlox/ilx;E2f4-/-;Mox2cre+ mice developed to term, we assessed the frequency with which they arose
at E18.5, one day prior to birth, as well as at earlier time points. Consistent with previous
findings, the Rb'l°XllO°;Mox2cre+ mice were present at the expected Mendelian ratio at E13.5, E15.5.
and E18.5 (Table 4.). In contrast to the germline mutants, loss of E2f4 did not reduce the viability
of the Rbo°X]°ox;Mox2cre/+ animals since the Rb°Oxl°Ox;E2f4+/';Mox2cre+ and the RblO°X"°X;E2f4-' -
;MAox2c" e/+ mice were recovered at the expected numbers. All of the RbJ°lx/°ox;Mox2cre'+ mice,
regardless of E2f4 status, were not able to survive upon removal from the uterus, because they
could not begin or sustain breathing. Thus, the RbO°X/°l;E2f4-/-;Mox2cre+ mice had the same timing
of lethality as the Rb'°X/l°x;Mox2cre/+ mice. Moreover, these results support our findings that the
reduced viability of the Rb-'-;E2f4-/- embryos is indeed due to an acute placental defect.
Since the conditional double mutant mice survive beyond E13.5, we were able to assess the
consequences of pRB- and E2F4 loss on later stages of embryonic development. We assessed the
efficiency of recombination in the mutant animals by western blot analysis, which confirmed that
pRB expression was undetectable in Rbllox/lox;Mox2cre/+ and Rb'llOx1l°X;E2f4-/-;Mox2cre/+ mouse
embryonic fibroblasts (data not shown). Consistent with our analysis of the germline mutant
embryos, gross morphological examination revealed that the rescued double knockout mice
exhibited defects reminiscent of both the E2f4-'- and the RbbOx/lOx;Mox2re+ littermates. In general,
the: phenotypes were detectable in most animals by E13.5 and continued to birth. The
Rbo xlox;E2f4f--;Mox2cre animals were similar in coloration, size and weight to the E2f4 -'-
littermates, which were paler and smaller than the control and Rb°x/ l°X;Mox2cre+ littermates
(Figure 6A; data not shown). The Rb""lOo;E2f4--;Mox2cre+ animals also had a hunched
appearance as seen in the RblOX/lXx;Mox2creI+ mice, which was reflective of the altered spinal
140
Table 4. Offspring viability from Rb2 "'x/2l° ;E2f4+/- x Rb lox+ ;E2f4+/- ;Mox2+ crosses*
Age Total # RbRlox/loxE2f4+/+ Rblox/lox;E2f4+1A Rb l lox/lox;E2f4 -/ -
Embryos # observed # expected # observed # expected # observed # expected
]E18.5 258 19 16 39 32 12 16
]E15.5 100 6 6 15 12 4 6
]E13.5 65 6 4 9 8 5 4
* All animals represented in this table are Mox2cre+.
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curvature of the skeletons (Figure 6B). Furthermore, all of the rescued Rb-deficient animals had
misshapen ribs and absence of a muscle attachment site on the humerus, both consequences of
abnormal musculature. The Rb""°X°X;Mox2cr '+ animals had decreased muscle density associated
with myoblast apoptosis (assessed by TUNEL staining), shortened myotubes and reduced muscle
fibers in the skeletal muscle (Figure 6C). The extent of the defect was unchanged in the compound
mutants. Finally, as discussed below, we analyzed the peripheral blood from the E18.5 animals
since both E2F4 and pRB have been implicated to have roles in erythropoiesis (Figure 6E). Taken
together, our data demonstrates that loss of E2F4 does not modulate the phenotypes of the
Rb°xal°lx;Mox2cre+ embryos and does not lead to additional phenotypes in the Rb-deficient
background.
Although unscheduled proliferation is a cell autonomous effect of pRB loss, it has been
demonstrated that the apoptosis observed in the nervous system, but not in the lens, is secondary to
the placental defect in Rb'- embryos (de Bruin et al. 2003). To determine if E2F4 participates in
cell cycle control and cell survival associated with pRB, we analyzed the levels of proliferation
and apoptosis in the conditional double mutant animals. As determined from BrdU incorporation
assays at E18.5, the levels of ectopic proliferation in the ocular lens and in the hindbrain (CNS)
were unchanged in the Rb"oxl"Ox;E2f4-l-;Mox2cre animals compared to the RblOXI°X;Mox2cre/+ mice
(Figure 6D and data not shown). Furthermore, the degree of apoptosis in the lens paralleled that
observed in the Rb single mutant embryos at E18.5 (data not shown). There were also significant
levels of TUNEL-positive cells in the retina of Rb°IOx°lO;Mox2cre/+ and the concomitant loss of
E2F4 had no effect (data not shown). Consistent with our analyses of the Rb-'-;E2f4-1- embryos,
E2F4 loss had no influence on the levels of ectopic proliferation and apoptosis in the Rb'°IOX°IOX;
Mox2re/+ mice, suggesting that E2F4 does not participate in these processes regulated by pRB.
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Figure 6. Conditional Rb';E2f4-' mice exhibit a combination of Rb and E2f4 mutant
phenotypes at E18.5.
A) Control, E2f4', Rbox"'lOx,;Moxcre"+ (Rb noxIn ox) and Rblo11xilx;E2f4 ;Mox re'/+ (DKO)
embryos. DKO embryos are growth retarded, as seen in the E2f4- mice, and have a
hunched appearance similar to the Rb noxinox animals. B) Skeletal staining with Alcian
blue (cartilage) and Alizarin red (bone) of control and mutant embryos. The Rb " oxi"Jx and
DKO embryos have altered curvatures of the spine and ribcage. C) Hematoxylin and
eosin stained skeletal muscle sections at a magnification of 40x. There is a decrease in
muscle density and organization in the Rb mutants, which is unchanged with the
additional loss of E2F4. D) Transverse sections of the ocular lens in control and mutant
embryos are stained for BrdU incorporation to identify S phase cells. Darkly stained
BrdU-positive cells were detected in the lens fiber cell compartment (indicated by the
black arrows) in the Rb "oxIox and DKO lenses, but not in the control and E2f4' lenses.
Magnification, 40x. E) Giemsa stained peripheral blood smears indicates the presence of
abnormal erythrocytes in the absence of E2F4 and/or pRB. There is a considerable
amount of erythroblasts containing Howell-Jolly bodies (white arrows) with the loss of
E2F4 and the loss of pRB leads to a number of immature nucleated erythroblasts
(outlined arrows).
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E2F4 and pRB in erythropoiesis
E2F4 and pRB have demonstrated roles in erythroid differentiation. E2f4-' - mice exhibit
severe fetal anemia from E13.5 to E16.5 (Humbert et al. 2000; Rempel et al. 2000). Analysis of
the peripheral blood smears reveals a significant proportion of abnormal erythrocytes, including
nucleated erythrocytes and cells containing Howell-Jolly bodies, which are remnants of DNA that
have not been completely extruded during enucleation. Rb-' - mice also have an erythroid defect.
They have a pale appearance, reduced cellularity in the fetal livers and an increase in immature
nucleated erythrocytes (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992). Analyses of
conditional mice and chimeras composed of Rb-deficient and wild-type cells have shown that a
considerable amount of the red blood cell defect in Rb-' - animals is cell non-autonomous (Maandag
et al. 1994; Williams et al. 1994; de Bruin et al. 2003). Despite the significant rescue,
abnormalities in erythrocyte maturation persist in the conditional and chimeric animals, indicative
of a cell autonomous role for pRB in erythropoiesis (de Bruin et al. 2003; Spike et al. 2004). Thus,
the nature of pRB function in this process is not entirely clear. In order to determine whether pRB
acts cell autonomously or non-autonomously in red blood cell development, we have investigated
the effects of pRB deficiency in our conditional system. Furthermore, we have analyzed the
effects of simultaneous loss of E2F4 and pRB with the aim of understanding whether these two
proteins cooperate during erythroid differentiation.
To confirm that the erythroid defects in the E2f4 and Rb mutants, we analyzed the
peripheral blood of E18.5 embryos. Consistent with previous findings, the E2f4-' - animals were
anemic at E18.5, as evidenced by a 30% reduction in hematocrit levels compared to those of wild-
type littermates (p-value < 3x10-6; Figure 7A). The Rblo°X°ox;Mox2cre/+ mice had a similar decrease
in hematocrits (p-value < 0.02), supporting that pRB loss has a significant effect on erythrocyte
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Figure 7. Loss of E2F4 and pRB results in anemia in E18.5 mice.
A) Hematocrits of peripheral blood from control and mutant mice. Loss of E2F4 or pRB
leads to similar decreases in the volume of packed red blood cells and the conditional
double mutants have a further reduction compared to wild-type embryos. Each data point
represents the hematocrit value from a single animal and black bars (-) reflect the average
hematocrit levels. B) Quantitation of abnormal erythrocytes from control and mutant
Giemsa stained peripheral blood smears. The conditional double knockout animals have
increased levels of nucleated red blood cells and erythrocytes containing Howell-Jolly
bodies, which are additive effects of E2F4- and pRB-loss.
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development. There was a further decrease (approximately 60%) in hematocrits of the
RbJ°xI/l;E2f4-/-;Mox2cre+ mice relative to wild-type animals (p-value < 5x10-6 ).
Cytological investigation of the peripheral blood cells at E18.5 revealed that the
Rboxl°x;E2f4-/-;Mo.x2re+ animals had additive phenotypes of the Rb'°x/Jl°X;Mox2cre+ and E2f4 -' -
mice (Figure 6E; Figure 7B). The vast majority of red blood cells in the wild-type animals are
mature enucleated erythrocytes with a very low amount of immature nucleated cells (0.02% +
0.05) and mature erythrocytes containing Howell-Jolly bodies (0.42% + 0.13). In contrast, there
was a modest increase in the level of erythrocytes containing Howell-Jolly bodies in the
Rb°xJl°Xr;Mox2ce+ mice (0.9% + 0.33) while there was a greater elevation in the number of
nucleated red blood cells (1.7% + 1.03). On the other hand, the E2f4-'- animals exhibited the
converse (0.41% + 0.12 nucleated erythrocytes and 5.1% + 2.7 with Howell-Jolly bodies). We
found that the double mutant animals had a high preponderance of both nucleated immature
erythrocytes (2.8% + 1.4) and red blood cells with Howell-Jolly bodies (6.3% + 2.3), suggesting
that there may be synergy between E2F4 and pRB during erythropoiesis.
Since erythrocyte defects are first evident during embryonic development in the E2f4 and
Rb single mutant mice, we analyzed erythropoiesis in the fetal livers, the site of the first wave of
definitive erythropoiesis from E12 to late gestation (Car and Eng 2001). Colony formation assays
revealed that the E2f4 -/- and Rblx/0x;E2f4-/-;Mox2ce+ fetal livers had a significant, and
comparable, increase in erythroid progenitor cells, colony forming units (CFU-Es) and burst
forming units (BFU-Es), compared to the wild-type fetal livers at E13.5 and E15.5 (data not
shown). Yet, there was no difference in the number of progenitor cells in the Rbloxlx ;Mox2cre+
fetal livers compared to that in wild-type littermates. This is in contrast to the initial
characterization of the erythropoietic defect in the Rb-' embryos, which demonstrated that there
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was an increase in erythroid progenitors in Rb-/' fetal livers (Jacks et al. 1992). Although the
increased erythropoiesis in the Rb germline mutants is secondary to the placental defect, the
cytological analysis of E18.5 peripheral blood smears indicated that an erythrocyte maturation
defect is present in the conditional Rb mutant animals.
In order to determine the precise stage at which red blood cell development is affected by
E2F4 and/or pRB loss, we used a flow cytometry-based analysis to quantify the erythroblasts at the
various differentiation states in E15.5 fetal livers (Zhang et al. 2003). As committed progenitor
cells differentiate into erythrocytes, expression of the non-erythroid specific transferrin receptor
(CID71) is induced initially and repressed thereafter, while the expression of the erythroid specific
marker TERI 19 is very low at first and induced upon differentiation (Ikuta et al. 1990; Kina et al.
2000). This allows the stages of erythroid differentiation to be monitored by double labeling
freshly isolated fetal liver cells for CD71 and TER119.
Consistent with our in vitro progenitor assays, the E2f4 -/- and Rbll°x/Ox;E2f4-/-;Mox2cre+ fetal
livers had a modest elevation in the CD71meTER1 191°w population, which is highly enriched for
CFUJ-E progenitor cells, compared to wild-type controls (Table 5). Rbt°Ox/]°OX;Mox2cre+ fetal livers
had normal levels of progenitor cells, but there was a significant decrease in the proportion of
basophilic erythroblasts (CD71hiTER1 19 hi population) and a considerable increase in the level of
ortlhochromatophilic erythroblasts (CD71medTER1 19 hi population). This indicates that there is a
block in the end stage of erythroid differentiation in the absence of pRB. Surprisingly, the
erythroid differentiation profile of the Rbxl/+ fetal livers was similar to that observed for the
Rb Itx/ll°;Mox2 c re+fetal livers, which may reveal that pRB functions in a haploinsufficient manner
during erythrocyte development (data not shown). We observed the same trend, though to a lesser
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Table 5. Flow cytometric analysis of erythrocyte development in E15.5 fetal livers
Genotype CD71m"'TER1 19' CD71 h'TER1 19" CD71'hTER 19h
i CD71m'TER1 19hi CD711TER1 19
h '
(%) (%) (%) (%) (%)
Differentiatio Unipotent stem cell Proerythrocyte Basophilic Orthochromatic Reticulocyte
Stage+ erythroblast erythroblast
Wild-type 2.6 + 0.4 2.9 + 1.8 72.1 + 8.7 16.4 + 8.4 1.1 + 0.6
n=19
E2f4'/- 3.6 + 1.1 * 4.6 + 2.5 72.3 + 3.3 11.3 + 3.0 0.8 + 0.5
n=8
Rb-° 1'~" 2.5 + 0.5 2.4 + 1.0 60.9 + 13.0 ** 28.0 + 13.1 ** 1.3 + 0.9
n=20
Rb1'-lOX-;E2f4-'- 3.7 + 0.5 2.8 + 1.3 64.0 + 12.0 22.3 + 12.0 0.6 + 0.2
n=3
+ The majority of cells represented by each population are in the indicated stage of erythrocyte development.
* denotes statistical significance, p-value = 0.03, compared to wild-type.
** denotes statistical significance, p-value < 0.005, compared to wild-type.
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extent, in the Rb""°X/°;E2f4-/;Mox2cre/+ fetal livers. In general, the double mutants exhibited
characteristics of both E2f4 and Rb single mutant mice.
We next used an in vitro culture system that closely resembles erythrocyte development in
vivo to determine whether erythroblast proliferation defects are associated with the differentiation
abnormalities (Zhang et al., 2003). TER119- cells were purified from individual E15.5 fetal livers
and cultured on fibronectin-coated plates in the presence of erythropoietin, which specifically
supports the survival of erythroid cells, for one day. By two days in culture, most of the wild-type
cells are in the end stages of erythropoiesis. Accordingly, cell cycle analysis demonstrated that the
vast majority of wild-type cells had exited the cell cycle after two days, and there were low levels
of cells in S and G2/M phases (Table 6). As previously demonstrated, there was a considerable
increase in the Rb °/°X ;Mox2re/+ cells in S phase and a mild, though significant, increase in the
G2/M population. In conjunction with the erythroid differentiation profile of the
Rb°X1l°x;Mox2re/+ fetal livers, our data is consistent with the notion that the significant
accumulation of late stage erythroblasts results from a defect in terminal cell cycle exit. The
failure to exit the cell cycle in the absence of pRB is concomitant with their failure to enucleate
properly (data not shown).
Unexpectedly, we found that loss of E2F4 also resulted in a significant decrease in the
proportion of cells in GO/G1 phases of the cell cycle relative to the wild-type erythroblasts (Table
6). In contrast to the Rbo°X/°X;Mox2cre/+ cells, there was more than twice the number of E2f4-/-
erythroblasts in both S and G2/M phases. Cytological analysis of the cultured erythroid cells
showed that enucleated red blood cells formed in the absence of E2F4, but with increased cell size,
consistent with the macrocytosis identified in vivo (data not shown; Humbert et al. 2000). Our
data suggest that E2F4 is not necessarily acting in an analogous manner to pRB.
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Table 6. Cell cycle analysis of erythroid cells isolated from E15.5 fetal livers
Genotype GO/G1 (%) S (%) G2/M (%)
Wild-type, n=17 87.4 + 3.1 7.5 + 1.9 5.1 + 1.7
E2f4-'-, n=9 72.2 + 6.0 ** 15.5 + 4.9 ** 12.4 + 3.1 **
RblOX/l°Ox, n=16 76.4 + 5.1 ** 16.8 + 3.8 * 6.9 + 2.2 **
Rb1'°o/x'°XE2f4-/-, n=2 46.5 + 1.4 ** 37.6 + 0.1 ** 16.1 + 1.5 **
* denotes statistical significance, p-value = 0.019, compared to wild-type.
** denotes statistical significance, p-value < 0.001, compared to wild-type.
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This is further supported by the relatively normal differentiation profiles of the E2f4-/- fetal livers
(Table 5). Taken together, these findings indicate that the absence of E2F4 does not result in an
erythrocyte defect at a particular differentiation stage, but rather may be in cell cycle progression.
Currently, we have only been able to analyze erythroblasts from two Rb"I"""°X;E2f4-'
;Mox2re/+ embryo. Undoubtedly, further samples will be needed, but our initial findings indicate
that there are additive effects of E2F4- and pRB loss in the erythroid compartment. Therefore,
these results suggest that E2F4 and pRB have distinct functions in erythropoiesis.
Recently, it has been proposed that the Rb-null defects in erythropoiesis are secondary to
abnormalities in fetal liver macrophages (Iavarone et al. 2004). In order to determine if the
erythrocyte abnormalities in the Rbl°x°X;Mox2cre/+ embryos are indeed a cell non-autonomous
effect of improper differentiation of the macrophages, we quantitatively assessed the population of
macrophages in E15.5 fetal livers by flow cytometric analysis. Among all of the genotypes
examined, there was no difference in the distribution of macrophage progenitor cells, as
determined by expression of CD31, an antigen on endothelial cells and macrophage progenitors
(Figure 8A). We also found that there were no differences in the granulocyte and macrophage
progenitors by colony formation assays with Rb'°O/L"O°X;Mox2cre/+ and wild-type fetal livers at E13.5
and E15.5 (data not shown). Upon analysis of F4/80 expression, a mature macrophage marker,
there was a slight decrease in the proportion of F4/80-positive cells in the Rbl°OXO°X;Mox2cre/+ fetal
livers compared to wild-type cells (Figure 8B). Although the mild reduction was statistically
significant compared to wild-type littermates (p-value = 0.006), it is not nearly as dramatic as
previously described in the germline Rb mutant fetal livers (Iavorone et al., 2004). Thus, the
macrophage differentiation defect in the Rb' - embryos appears to be largely due to the primary
placental defect. Moreover, it does not seem likely that a minimal reduction in the amount of fully
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Figure 8. Macrophage differentiation is minimally affected in conditional Rb mutant
animals.
A and B) Histogram representations of flow cytometry analysis of TER119- cells
immunostained with Allophycocyanin (APC)-conjugated anti-CD3 land
phycoerythrin(PE)-conjugated anti-F4/80 antibodies, respectively. Among the various
genotypes, there was no alteration in the proportion of macrophage progenitor cells, as
determined by expression of CD31 (an antigen on endothelial cells and macrophage
progenitors). There was a slight decrease in the proportion of F4/80-positive cells (a
mature macrophage marker) in the Rb°x/°lx;Mox2ce/+ fetal livers compared to wild-type
littermates (*p-value = 0.006). All data represented as average values + standard
deviation.
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differentiated macrophages is entirely responsible for the observed erythrocyte abnormalities in the
conditional Rb mutant animals, since our erythroblast differentiation culture system is performed
in the absence of macrophages. These findings support that pRB has a cell autonomous function
in red blood cell development.
We performed the same analyses on E2f4'- fetal livers and found that the
microenvironment of the erythroblasts in these fetal livers was normal. Despite previous findings
that there is an increase in monocyte and granulocyte populations in E2f4 -' bone marrow (Rempel
et al. 2000), we did not detect any changes within the fetal livers, as judged by the expression of
Macl (a monocyte and granulocyte differentiation marker) and Gr-1 (primarily a granulocyte
differentiation marker, but also expressed on monocytes) (data not shown). When we examined
the Rb1 OX/OX;E2f4-;Mox2cre+ fetal livers, they recapitulated the results for the Rb"I°x"°X;Mox2Cre/+
embryos. Thus, all of the erythroid defects associated with E2f4 and conditional Rb single mutant
animals manifest in the conditional double homozygous mutants in a purely additive manner,
illustrating that E2F4 and pRB do not cooperate during erythrocyte differentiation.
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DISCUSSION
The E2F transcription factors are the most well studied downstream effectors of pRB.
Compound mutant mouse models have been used to determine the specific roles of the individual
E2Fs to the growth suppressive properties of pRB. In general, the phenotypic effects of pRB
deficiency are largely dependent on the activating E2Fs (Tsai et al. 1998; Ziebold et al. 2001),
consistent with their role in promoting cell cycle progression. In this study, we have assessed the
contribution of E2F4, a repressive E2F, to the developmental consequences of pRB loss. We
found that E2F4 is critical during development of the Rb-' mice and the functional significance of
the interaction between pRB and E2F4 was tissue-specific. Our analysis clearly supports that
E2F4 has distinct properties from the activating E2Fs in mediating the effects of pRB loss during
normal development.
pRB and E2F4 do not cooperate in the developing embryo
We previously demonstrated that E2F4 considerably contributes to tumor formation in Rb+'-
mice (Lee et al. 2002). We proposed that E2F4 indirectly influences tumor progression by limiting
the levels of p107 and p130 that can compensate for the absence of pRB. It is formally possible,
however, that E2F4 could promote cellular proliferation by activating the transcription of E2F-
responsive genes in a manner analogous to the activating E2Fs. E2F4 can act as a strong
transcriptional activator when ectopically expressed and E2F4 has been found at some murine
promoters during the G1 to S transition of the cell cycle (Beijersbergen et al. 1994; Ginsberg et al.
1994; Wells et al. 2000). Thus, if E2F4 functions to activate gene transcription, then E2F4 loss
should suppress the developmental defects arising in the Rb-'- mice and result in a significant
extension in lifespan, as observed in mice with simultaneous loss of an activating E2F and pRB
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(Tsai et al. 1998; Ziebold et al. 2001). Instead, we found that the absence of E2F4 accelerated
embryonic lethality in the Rb- ' mice. Furthermore, there was minimal, if any, cooperation between
E2F4 and pRB in the developing embryo. Loss of E2F4 had no effect on the levels of
inappropriate proliferation and apoptosis in the ocular lens, CNS and PNS in the Rb-deficient
animals. Moreover, using a conditional deletion strategy, we found that loss of E2F4 did not
modulate any defects associated with the absence of pRB in later stages of development, including
inappropriate proliferation and apoptosis in the lens, as well as differentiation defects in the
skeletal muscle and in erythroid cells. Thus, E2F4 does not have overlapping properties with the
activating E2Fs in promoting the phenotypes in the embryo proper caused by pRB loss.
There is currently serious debate as to the nature of the role of pRB in erythrocyte
development. Early studies demonstrated that Rb-null mice had defective definitive erythropoiesis
in the fetal livers (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992). Subsequent analyses of
Rb-' ;Rb+' chimeras showed that the presence of wild-type cells alleviated the erythroid
abnormalities and, thus, the erythroid defect in the absence of pRB is a cell non-autonomous effect
(Maandag et al. 1994; Williams et al. 1994). This was confirmed by the recent finding that the
placental defect is largely responsible for the incomplete erythropoiesis in the Rb mutant mice (de
Bruin et al. 2003; Wu et al. 2003). Although these results indicate that pRB loss in the erythroid
compartment does not have as great an influence as initially believed, there are several lines of
evidence to suggest that there is indeed a cell intrinsic function of pRB during red blood cell
maturation. First, Rb-'- cells fail to differentiate properly in irradiated wild-type mice reconstituted
with Rb' - or Rb-' ;R b +'+ chimeric fetal liver cells (Hu et al. 1997; Spike et al. 2004). Second, the
end stages of differentiation are perturbed in Rb-'- erythroid progenitors in the presence of wild-
type cells, as well as upon acute deletion of Rb in vitro (Clark et al. 2004; Spike et al. 2004).
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Third, Rb mutant mice provided with a normal placenta have a persistence of nucleated immature
erythrocytes in the peripheral blood (de Bruin et al. 2003; Wu et al. 2003).
In the process of determining the interplay between pRB and E2F4 in erythrocyte
development, we characterized the defects arising in the single and compound mutants. Although.
there was no data to suggest that pRB and E2F4 cooperate during this process, our analysis led to
some new insights into pRB and E2F4 function. Our characterization of the erythroid defect in the
conditional Rb mutant animals support the view that pRB has a cell autonomous function in
erythrocyte development. In accordance with previous studies, we found that the increase in
immature erythrocytes (at the normoblast stage) in the absence of pRB is linked to a cell cycle exit
defect. These defects appear to be a cell intrinsic effect of pRB in the erythroblasts, and not
entirely a consequence of abnormal macrophage differentiation as recently suggested by Iavarone
et al. (2004). There was a substantial decrease in the proportion of mature macrophages in the
conditional Rb mutant cells compared to wild-type cells. This indicates that the previously
described reduction in macrophages in Rb-'- fetal livers is largely influenced by the placental defect
and the Rb'- macrophages that were previously analyzed had already acquired a defect from the
hypoxic environment in utero. These data support that there is a cell autonomous effect of pRB in
the erythroid cells. Future studies using macrophage-specific conditional deletion strategies will
be helpful to clarify the role of pRB in this cell lineage and to determine the extent to which
erythroid cell development is affected.
Unexpectedly, the Rb° x/+ fetal livers had erythroid differentiation defects similar to those
observed in the conditional Rb mutants, suggesting that pRB can act in a haploinsufficient manner.
Along the same lines, Rb+' fetal liver cells had a diminished reconstitution potential compared to
wild-type cells in adoptive transfer experiments (Spike et al. 2004). Yet, when we cultured the Rb
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heterozygous cells, they became indistinguishable from wild-type cells. Since the erythroid
differentiation profile is obtained from freshly isolated fetal liver cells and the cell cycle profile
relies on erythroblasts that differentiate in culture, the properties may be affected by the varying
differentiation environments. On the other hand, the cells completely lacking pRB have defects in
both differentiation and cell cycle control, suggesting that these defects can be uncoupled in the
Rb+'- fetal liver cells.
In contrast to pRB, E2F4 loss does not result in an erythrocyte defect at a particular
differentiation stage, but rather seems to affect cellular proliferation. A significantly greater
proportion of E2f4-' erythroblasts were in the cell cycle at a time when most wild-type cells had
undergone terminal cell cycle exit. This was not anticipated since the loss of E2F4 in MEFs does
not lead to defects in cellular proliferation (Humbert et al. 2000; Rempel et al. 2000). It will be
important to determine whether loss of E2F4 promotes cellular proliferation of the erythroblasts or
causes a delay in cell cycle progression. Coupled with the increase in erythrocytes containing
Howell-Jolly bodies, DNA fragments that have not been properly extruded from mature
erythrocytes, lack of cell cycle control in the absence of E2F4 could be responsible for these
abnormal red blood cells. Promoter occupancy experiments have shown that Mad2 and Bub3,
mitotic spindle checkpoint components, are specific targets of E2F4 (Ren et al. 2002). Thus, E2F4
deficiency may lead to the derepression of these genes and result in abnormal chromosome
separation at the mitotic spindle, giving rise to red blood cells containing Howell-Jolly bodies.
Alternatively, Howell-Jolly bodies can arise from a defect in enucleation, a process that has not
been well characterized. Further work will be needed to explore these possibilities.
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pRB and E2F4 are essential for extra-embryonic development
Recently it has been demonstrated that the Rb homozygous mutant mice die from placental
insufficiency caused by a defect in the labyrinthine layer of the extra-embryonic tissues (Wu et al.
2003). We found that additional loss of E2F4 aggravated this phenotype as the labyrinth had a
more compact appearance in the Rb-';E2f4' placentas compared to Rb-' littermate placentas.
Based on placental layer specific marker analysis, trophoblast differentiation in the three layers of
the Rb-'-;E2f4-'- placentas was not affected, consistent with findings for Rb-' - placentas. We also
determined the expression levels of Eomes, a trophoblast stem cell marker, since loss of pRB leads
to its increased spatial expression and consequent hyperproliferation of trophoblast stem cells (Wu
et al. 2003). We were unable to detect any significant differences in Eomes expression in wild-
type, E2f4 --, Rb-'- and Rb'-;E2f4 -'- placentas by microarray and real-time PCR analyses. Since the
previous report of increased Eomes expression was assessed by in situ hybridization, it is possible
that the pattern of Eomes expression is merely altered in the mutant placentas while the overall
expression levels are equivalent.
Although we found no evidence for an expanded trophoblast stem (TS) cell population, our
data suggest that there is an atypical population of pluripotent cells in the Rb mutant placentas.
We found that Dppa5 (Esg-1), a marker for pluripotency, was one of the most differentially
expressed genes in the Rb mutant placentas compared to wild-type tissues. The function of Dppa5
is currently unknown, but its expression is limited to ES and trophoectoderm cells, but repressed in
lineage-restricted stem cells and terminally differentiated cells (Astigiano et al. 1991; Bierbaum et
al. 1994; Tanaka et al. 2002; Bortvin et al. 2003; Ahn et al. 2004). Since we did not detect any
alterations in the expression of other markers that are unique to pluripotent ES cells, such as
Oct3/4 and FGF4, the cell population expressing Dppa5 is not necessarily equivalent to ES cells.
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In fact, the trophoectoderm, which only contributes to the placental tissues, has been reported to
express equivalent levels of Dppa5 as observed in the inner cell mass (ICM), which gives rise to
the embryo proper (Tanaka et al., 2002). Yet, in contrast to the ICM, Dppa5 induction in the
tro.phoectoderm was not accompanied by expression of Oct3/4 and FGF4, indicating that the
trophoectoderm is not analogous to the ICM. Thus, placental insufficiency due to loss of pRB may
result from increased proliferation or atypical persistence of cells resembling the trophoectoderm
within the labyrinth layer. Further support that loss of pRB leads to an increased pool of stem cell-
like cells comes from observations with Id2, a transcriptional repressor that interacts with pRB. In
the placenta, the human ortholog of Id2 is highly expressed in the cytotrophoblasts, the equivalent
of murine trophoblast stem cells, and is repressed as the cells differentiate (Jen et al. 1997;
Janatpour et al. 2000). Loss of Id2 results in a significant extension in lifespan and a general
suppression of defects in the Rb- ' - mice (Lasorella et al. 2000). The requirement for Id2 was not
assessed in the Rb'- placentas; however, it is very likely that Id2 has an opposing effect to pRB in
the undifferentiated trophoblasts, and, thus, the loss of Id2 results in developmental rescue of the
Rb mutant embryos. Further work will be needed to determine the role of Id2 in the murine
placenta, as well as to establish the functional consequences of increased expression of Dppa5 in
Rb mutant placentas.
We expected that the genes differentially expressed in the Rb mutants would be further
affected by the simultaneous loss of E2F4, if E2F4 and pRB are cooperating during placental
development. E2f4 deficiency does not influence the expression levels of Dppa5 in the Rb-
deficient background. In general, we found that mRNA expression levels of genes with enhanced
or diminished expression in the Rb mutants were unchanged in the double knockout placentas, as
assessed by real-time PCR. In order to assess the gene expression changes in the Rb--;E2f4-'- extra-
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embyronic tissues more systematically, we used microarray analysis to determine the differential
expression profiles from the double mutant placentas relative to the wild-type placentas. There
were a number of potentially interesting candidates with demonstrated roles in placental
development, such as Growth Hormone, Prolactin, and Matrix Metalloproteinase 9. Further work
is required to determine whether their expression is regulated by pRB and/or E2F4 and how their
deregulation contributes to placental insufficiency.
Our data is consistent with the notion that E2F4 and pRB may have independent roles in
the placenta. In this case, accelerated placental failure due to concomitant loss of E2F4 and pRB
would result from a combination of distinct defects. This is supported by our findings in the
compound mutant embryos. First, in many tissues in the embryo proper, E2F4 was dispensable for
the phenotypes caused by pRB loss. Furthermore, during erythropoiesis, a process where both
E2F4 and pRB are documented to have functions, we found no evidence for crosstalk and the
double mutant animals simply displayed additive defects. Second, expression analysis suggests
that the pRB-related defect in the placenta is associated with an increase in a stem cell-like
population which is unaffected by the additional loss of E2F4. Third, E2f4 homozygous mutant
embryos are growth retarded and exhibit fetal anemia with an increase in erythroid progenitor
cells, which are characteristics often associated with inefficient placental function.
While it is formally possible that loss of E2F4 disturbs extra-embryonic tissue
development, it remains unclear whether E2F4 in fact functions in the placenta. There were no
obvious histological abnormalities in the E2f4-' placentas. In addition, the erythropoietic defect in
the E2f4 mutant mice is a cell intrinsic effect (Humbert et al. 2000). Ultimately, these data do not
rule out the possibility that E2F4 has a significant impact on placental development. Conditional
deletion experiments with E2F4 would determine whether the reduced embryo size is a
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consequence of E2f4 loss in the placenta. Moreover, further analysis of our microarray results
may yield E2F4-regulated target genes, which may also be helpful to establish a requirement for
E2F4 in the placenta.
Alternatively, E2F4 and pRB may function in the same pathway during the development of
the extra-embryonic tissues. The phenotype of the Rb'; E2f4'/- animals is highly reminiscent of
that observed for the Rb-'-,p107' embryos. For example, the window of lethality for the Rb-' ;p l07
/' embryos is between E10.5 and E13 (Lee et al. 1996), which is comparable to that for the Rb'-
;E2f4-'- mice. Although the cause of death in the Rb-'-pl07 - - animals was not determined, the
elevated levels of CNS apoptosis, the lack of defects in the embryo and the yolk sac abnormalities
suggest a more severe defect in the extra-embryonic tissues compared to the Rb-' embryos. The
placentas from the Rb-'-,p107' mice need to be examined; however, loss of E2F4 appears to have
analogous effects as p107 deficiency in the Rb-' - embryos, suggesting that there is a critical
requirement for repressive pocket protein-E2F complexes in the extra-embryonic tissues.
Despite the mechanism by which E2F4 and pRB promote embryonic development, it is
clear that the pRB pathway plays a major role in the extra-embryonic tissues. In addition to our
study, others have identified upstream and downstream regulators of pRB activity that have
profound effects in the placenta upon targeted inactivation. p5 7K'I P 2 and p2 7PKI, cyclin dependent
kinase inhibitors, regulate the proliferation and differentiation of trophoblasts (Zhang et al. 1998;
Takahashi et al. 2000). Furthermore, mice mutant for cyclin El and cyclin E2 exhibit
endoreduplication defects in the trophoblast giant cells (Geng et al. 2003; Parisi et al. 2003). Mice
mutant for DP1, the dimerization partner for E2F proteins, die in mid-gestation and have a
significant reduction in trophoblast precursors (Kohn et al. 2003). The absence of DPi would be
expected to indirectly inactivate the E2Fs that require DP binding for E2F activity. Thus, by
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extension, the E2Fs would be expected to function in the placenta as well. While we have
demonstrated that E2F4 does indeed function in the placenta in association with pRB, it is very
likely that the activating E2Fs also contribute to the development of the extra-embryonic tissues.
Loss of an activating E2F may suppress, to some extent, the placental defect in the Rb-'- embryos,
since the double mutant animals survive longer than the Rb-null mice and have an amelioration of
the cell non-autonomous apoptosis in the CNS (Tsai et al. 1998; Ziebold et al. 2001). Studies
addressing the role of the activating E2Fs in the placentas will be needed.
Many pathways regulating the development of the embryo proper are conserved in extra-
embryonic development (reviewed in Cross et al. 2003). The pRB pathway is no exception and,
thus, it will be important to understand whether pRB and its regulators have retained their
established functions in cell cycle control and differentiation or whether they have novel functions
in the placenta.
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EXPERIMENTAL PROCEDURES
Mouse strains
E2f4+'" and Rb +' mice were crossed to generate Rb'-;E2f4 +'- mice on a mixed C57BL/6 x
129/Sv background (Jacks et al. 1992; Humbert et al. 2000). Rb+'-;E2f4+'- mice were interbred to
obtain Rb-'-;E2f4-'- animals. The detection of a vaginal plug was considered E0.5. Embryos were
harvested at the indicated times and viability was determined by the presence of a heartbeat under
a stereomicroscope. Embryos and placentas were fixed in 10% formalin or 4% paraformaldehyde,
embedded in paraffin and sectioned at 4-6/m. Sections were stained with hematoxylin and eosin
for histological analysis.
Genetic rescue experiments were carried out by breeding E2f4 +'-, RbO'x2°Ox, and Mox2cre'+
mice (Humbert et al. 2000; Tallquist and Soriano 2000; Sage et al. 2003). Mox2re/+ transgenic
mice were obtained from Jackson Laboratories. Timed Rb2 ox/2lox ;E2f4 1/- x RboX+ ;E2f4/-;Mox2cre/+
crosses were set up to obtain Rb"X't°x;E2f4'/-;Mox2cre/+ mice at the indicated developmental ages.
At E18.5, the ability to breathe was assessed upon removal from the yolk sac. Mice were fixed in
Bouin's fixative or 10% formalin, embedded in paraffin and sectioned at 4-6ym. Sections were
stained with hematoxylin and eosin for histological analysis.
Immunohistochemistry and skeletal staining
For bromodeoxyuridine (BrdU) incorporation analysis, pregnant mice were injected
intraperitoneally with a BrdU and fluorodeoxyuridine mixture 1 hour prior to sacrifice. Staining
for BrdU was performed as previously described (Tsai et al. 2002) and hematoxylin was used for
counterstain. Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL)
assays were performed to assess levels of apoptosis. Sections were deparaffinized, rehydrated,
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blocked in 3% H202, treated with proteinase K, and incubated with biotin-16-dUTP (Roche) and
recombinant terminal deoxynucleotidyltransferase (Invitrogen). Biotin-dUTP was detected with
ABC peroxidase detection kit (Vector Labs) followed by DAB (Vector Labs). Methyl green was
used for counterstain. The number of BrdU- and TUNEL-positive nuclei over the total number of
nuclei in a given area was determined for 2-4 independent samples per genotype. Average values
were then adjusted relative to the percentages observed in Rb mutants, which were set to 1.
Quantification of ectopically proliferating cells in the CNS was determined by counting cells in the
intermediate zone in the hindbrains. Skeletal stainings were performed as previously described
(Humbert et al. 2000).
In situ hybridization
In situ hybridization was performed on 4% paraformaldehyde (PFA) fixed, paraffin
embedded sections. Sections were deparaffinized, rehydrated, treated with proteinase K, refixed
with 4% PFA, incubated in 2x SSC, dehydrated and air dried. Prehybridization was carried out for
1 hour followed by overnight hybridization with digoxygenin-labeled riboprobes for Pl-l (Colosi
et al. 1987) and 4311/Tpbp (Lescisin et al. 1988). Washes were done in 50% formamide/lx
SSC/0.1%Tween-20 followed by washes in MABT. Sections were blocked in10% sheep
serum/2% blocking reagent (Roche) and then incubated with an anti-digoxigenin antibody
conjugated to alkaline phosphatase at 4°C overnight. Sections were washed in MABT/levimasole
(Sigma) and BM purple (Roche) was used for detection.
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Oligonucleotide microarray analysis and real time PCR
Extra-embryonic tissues were separated from the maternal deciduas under a
stereomicroscope. Total RNA was prepared with Trizol reagent (Invitrogen). RNA quality and
concentration were determined using an Agilent 2100 Bioanalyzer. For microarray analysis, 2-3
biological replicates per genotype were used at E13.5 and 3 independently prepared samples per
genotype were used at E11.5. Target preparation and hybridization to GeneChip® Mouse Genome
430 2.0 arrays (Affymetrix) were performed according to the manufacturer's instructions. The
microarrays were scanned with GeneChip® Scanner 3000 and images were analyzed with
GeneChip® Operating Software. Data was normalized using GCRMA normalization method
(Wu and Irizarry 2004). LPE test was applied for variance stabilization between the biological
replicates (Jain et al. 2003) and statistical significance was determined using Benjamini-Hochberg
False Discovery Rate rule (Benjamini et al. 2001). Differential expression of a gene was
considered significant if the adjusted p-value < 0.05 and the fold change > 2.0.
For real-time PCR analysis, cDNA synthesis was performed using 2 pg total RNA and
SuperScriptIII (Invitrogen). At E13.5, 2-4 independently prepared samples were used per
genotype while at E11.5 3-4 biological replicates were tested per genotype. Reactions were
carried out with 50 ng cDNA, 16 pM primers, and SYBR Green PCR Master Mix in 20 pl total
volume (Applied Biosystems). Reactions were carried out in the ABI Prism 7000 Sequence
Detection System. Gene expression was normalized against ubiquitin expression. Primer
sequences are available upon request. For each gene, reactions were performed 2-6 times per
sample.
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Purification and in vitro culture of erythroid progenitors
Fetal liver cells (FLC) were isolated from individual E15.5 embryos. FLC were
mechanically dissociated by pipetting in PBS containing 2% fetal bovine serum (FBS). Single cell
suspensions from each individual embryo were prepared by passing the dissociated cells through a
25 m cell strainer. Alive cells were counted using 0.4% Trypan Blue (Cellgro). TER1 19- cells
were purified and cultured as previously described (Zhang et al., 2003).
Immunostaining, cell cycle and flow cytometry analyses of erythroid differentiation
Freshly isolated FLC and cultured Day 2 cells were stained for CD71 and TERI19
simultaneously as previously described (Zhang et al., 2003). For macrophage analysis, TER119-
cells purified from individual embryos were immunostained with phycoerythrin(PE)-conjugated
anti-F4/80 (1:100; Caltag Laboratories) and Allophycocyanin (APC)-conjugated anti-CD31
(1:100; BD Pharmingen) antibodies simultaneously. For cell cycle analysis, cultured erythroid
cells were harvested on Day 2 and stained in hypotonic Propidium Iodide (PI) solution (0.1%
sodium citrate and 50 mg/ml PI). Flow cytometry was carried out on a Becton Dickinson
FACSCalibur (Franklin Lakes, NJ) and collected data was analyzed by ModFit software (Verity
Software House, Inc., Topsham, ME).
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Chapter Four
Conclusions
174
Our understanding of the extent to which the E2F family of transcription factors
contributes to the growth suppressive properties of pRB is limited to the activating E2Fs. This
study is the first demonstration of the biological significance of the interplay between pRB and
E2F4, a repressive E2F, in cell cycle regulation during normal development and tumorigenesis.
In chapter two, we established that E2F4 loss has profound effects on tumor formation in the
Rb'- mice. Our molecular and biochemical analyses suggest a novel mechanism through which
E2F4 may influence tumor progression. In chapter three, we found that E2F4 is critical during
development of the Rb- -mice and the functional impact of the interaction between pRB and
E2F4 is tissue-specific. Our findings further indicate that E2F4 does not act in an equivalent
manner to the activating E2Fs in mediating the effects of pRB loss. Thus, E2F4 is an important
downstream effector of pRB function and this study has provided insights into the requirement
for the various E2F proteins in the cellular processes regulated by pRB.
pRB and E2F4 in tumorigenesis
We assessed the consequences of E2F4 loss on the tumor phenotype in Rb+' mice.
Homozygous mutation of E2f4 in the Rb+' animals considerably suppressed tumor formation in
the pituitary and thyroid glands and subsequently extended their lifespan. We also found that
loss of E2F4 suppressed inappropriate proliferation in Rb-deficient MEFs. Molecular analyses
detected novel complexes of p107 and p130 with the activating E2Fs in the absence of pRB
and/or E2F4. These findings support a model whereby p107 and p130 compensate for pRB
deficiency by re-establishing the proper regulation of the activating E2Fs. Therefore, E2F4
indirectly promotes tumor progression in the Rb+'- mice by restricting the levels of free p107 and
p130. These data suggest that tumor formation is dependent on the relative levels of activating
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E2F activity, instead of the widely held view that increased tumorgenicity is due to the loss of
repressive pocket protein-E2F complexes.
Despite the fact that our proposed mechanism can account for the differential tumor
suppressive properties of the pocket proteins, the functional relevance of the rearranged pocket
protein-E2F complexes remains to be determined. It has not been technically feasible to assess
the levels of the free activating E2Fs in the wild-type, Rb +' and Rb+'-;E2f4-'- tissues due to the
relatively low cellular levels of these proteins. Another way to substantiate our model would be
to directly alter the levels of the compensatory pocket proteins in the Rb+'-;E2f4' background. If
diminishing the levels of p107 and/or p130 did not affect tumor formation in the Rb+'-;E2f4- -
mice, then this would indicate that an alternative mechanism is at work. We have combined the
Rb, E2f4 and p107 mutations with this aim; however, the results have been inconclusive thus far
(Appendix A). Tumor development was not possible to analyze in the Rb' -; E2f4-'-;p1 07 -'
animals, because mice with homozygous mutations in the E2f4 and p107 genes had a severely
reduced survival potential. In order to circumvent the early lethality, conditional knockout mice
could be generated. Additionally, transgenic mice expressing the truncated SV40 large T
antigen, T 12 1, in a tissue-specific manner could be used (Saenz Robles et al. 1994; Xiao et al.
2002; Simin et al. 2004). Since T121 results in the inactivation of all the pocket proteins, loss of
E2F4 would be predicted to have no effect on tumor formation. Along the same lines, analogous
experiments could be performed in MEFs. For example, acute loss of Rb in quiescent primary
fibroblasts stimulates cell cycle re-entry due to an inability to induce p107 in a timely manner
(Sage et al. 2003). Based on our model, acute loss of Rb in quiescent E2f4-deficient MEFs
should resemble Rb-'- cells and remain arrested, since the absence of E2F4 would liberate
sufficient amounts of p107 and p130 to compensate for the abrupt loss of pRB.
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A complementary approach to validate the complex rearrangement model would be to
modulate the levels of the activating E2Fs. Loss of an activating E2F, E2F1 or E2F3, in Rb' -
mice also leads to suppression of the pituitary tumors (Yamasaki et al. 1998; Appendix C).
Thus, decreasing the amounts of the activating E2Fs should have the same effect as the loss of
E2F4 in Rb-deficient MEFs. Our preliminary analyses of the cell cycle properties of Rb';E2fl - -,
Rb'';E2f3-'- and Rb"°x"'°X;E2f4-- primary fibroblasts have not been consistent (Appendix B),
which may reflect the differing functions or expression levels of the E2Fs. Furthermore, we
cannot rule out the possibility that another mechanism is responsible. Curiously, Rb-'-;E2fl -', Rb-
'-;E2J3'- and Rb'°x/X;E2f4-'/ cells transformed with activated Ras and Myc act in the same
manner and are less tumorigenic than transformed Rb-'- cells. This may suggest that there is a
differential requirement for the E2Fs and pRB in tumorigenesis than in normal cell cycle control.
Further investigation is necessary to make any definitive conclusions, but these initial results
indicate that loss of E2F4 acts in a cell autonomous manner to suppress the oncogenic capacity
of Rb' - cells. Since it has been difficult to process the results from the cell cycle
characterizations, an additional method to test our model would be to knock down expression of
p107 or p130 in the various compound mutant cells using RNAi technology. According to our
model, this should lead to a reversion of the Rb mutant phenotype in the Rb'°ox;E2f4- 4 - MEFs
while there should not be a significant effect in the Rb-'-;E2f3-'- cells.
Although our data are consistent with the complex rearrangement model, this does not
exclude other possibilities. One potential mechanism is that loss of E2F4 may sensitize Rb+'-
cells to undergo apoptosis upon loss of the remaining wild-type allele, an event that normally
promotes tumorigenesis in the Rb+- mice. This model is supported by our observation that there
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was increased apoptosis in cultured Rb °ox/i°X;E2f4-/- erythroblasts (data not shown). This effect,
however, may be cell type-specific since Rbl°-x/llx;E2f4- '- MEFs did not display a decreased
survival potential when expanded in culture or in response to DNA damaging agents (Appendix
B; data not shown). Furthermore, E2F4 is generally not thought to be involved in apoptosis
(DeGregori et al. 1997; Wang et al. 2000), and in the studies that do link E2F4 to this process,
overexpression induces programmed cell death (Dirks et al. 1998; Chang et al. 2000), which is in
opposition to this model. A straightforward way to address the apoptotic potential of the Rb-'-
;E2f4-'- cells in the pituitary and thryroid tissues would be through the analysis of chimeric
animals generated from double mutant ES cells injected into wild-type blastocysts. If the double
knockout cells were present in the tumor-prone tissues at adulthood, the apoptosis model would
not be supported. On the other hand, if the double knockout cells initially contribute to the
tissues during development and then are not detectable by adulthood, this would strongly support
the notion of decreased viability of Rb-' ;E2f4-'- cells. This outcome is also consistent with a cell
non-autonomous effect; however, our preliminary characterization of transformed Rb'°x'°X;E2f4-
' cells supports that the reduced oncogenic capacity is a cell intrinsic function.
It is also formally possible that E2F4 contributes to tumor development in the same
manner that the activating E2Fs function. In support of this, there are a number of studies
showing that E2F4 induces proliferation and activation of E2F-responsive genes when
ectopically expressed (Ginsberg et al. 1994; Lukas et al. 1996; DeGregori et al. 1997; Wang et
al. 2000). These effects are most likely a consequence of overexpression since loss of E2f4 has
no physiological effect on proliferation (Humbert et al. 2000; Rempel et al. 2000). Furthermore,
E2F4 loss has opposing effects to the absence of an activating E2F in the Rb'- background (Tsai
et al. 1998; Ziebold et al. 2001), which is inconsistent with this model. This model could be
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addressed by generating a knock-in mouse which expresses E2F4 with a mutated transactivation
domain, and an intact pocket protein binding domain, and then crossing this strain with the Rb' -
mice. If there is significant tumor suppression in the resulting animals, similar to the Rb'-;E2f4 - '
mice, then the ability of E2F4 to activate transcription is important for tumorigenesis. On the
other hand, if tumor formation is comparable to that observed in the Rb' - mice, then it would
imply that the function of E2F4 in tumor development relies upon pocket protein binding,
supporting our complex rearrangement model. Thus, these experiments are aimed at exploring
the mechanism by which the absence of E2F4 suppresses tumors in the Rb+' mice.
We currently favor the complex rearrangement model, but further work is needed to
confirm this. Determining the precise mechanism through which loss of E2F4 suppresses tumor
formation in the Rb+'- mice will be important for better understanding the role of the E2Fs in the
tumor suppressive properties of pRB. Ultimately, this may provide new strategies for
developing chemotherapeutic treatments.
pRB and E2F4 in development
We also determined the effects of concomitant loss of E2F4 and pRB on murine
development. E2F4 deficiency resulted in earlier lethality of the Rb-' mice due to placental
insufficiency. When compound mutant mice were provided with a normal functioning placenta,
the animals were present at birth, confirming that the absence of E2F4 resulted in aggravation of
the extra-embryonic tissue defect in the Rb mutant animals. With respect to the embryonic
phenotypes, loss of E2F4 did not modulate any defects associated with the absence of pRB,
including inappropriate proliferation, apoptosis and differentiation defects. These results are in
stark contrast to the consequences of ablating an activating E2F in the Rb' - background. Thus,
179
E2F4 does not have overlapping functions with the activating E2Fs in mediating the effects of
pRB loss during normal development.
Although we were not able to determine the precise nature of the defect in the Rb'-;E2f4-'-
placentas, we provide new insight into the placental defect arising from the loss of pRB. It has
previously been reported that pRB loss results in overproliferation of trophoblast stem (TS) cells
in the labyrinth layer (Wu et al. 2003). Our data, however, indicate that the proportion of TS
cells in the Rb- - placentas is similar to that in the wild-type placentas. Instead, we suggest that a
stem cell population distinct from TS cells is overrepresented in the Rb mutant placentas
compared to wild-type tissues. We found that Dppa5 (Esg-1), a pluripotent ES cell marker, was
strikingly elevated in the Rb mutant placentas. Since the expression levels of other ES cell-
specific markers were unchanged and this expression pattern is only observed in trophoectoderm
cells (Tanaka et al. 2002), we propose that loss of pRB results in an increase in cells resembling
the trophoectoderm, which are precursors of TS cells and give rise to many cell lineages in the
extra-embryonic tissues (reviewed in Rossant and Cross 2001).
Further work will be needed to verify that a trophoectoderm-like population persists
beyond the blastocyst stage in the absence of pRB. First, in order to correlate increased Dppa5
expression with the histological defect in the Rb-' placentas, it will be important to determine the
spatial localization of the Dppa5-expressing cells in the Rb' - placentas by in situ hybridization.
Second, if Dppa5 expression is indicative of a persistent cell population analogous to the
trophectoderm, a systematic analysis of the timing of Dppa5 expression from E3.0 (blastocyst
stage) to E13.5 (time of obvious placental dysfunction) will be useful. We detected increased
Dppa5 transcript levels as early as E11.5, a time when the Rb mutant defect is not obvious, and it
will be necessary to look at earlier time points. This experiment would be most informative if
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done by in situ hybridization since it may indicate whether the formation of trophoectoderm-
derived tissues is affected. For example, the trophoectoderm gives rise to the extra-embryonic
ectoderm and the ectoplacental cone by E6.0, and if Dppa5 is confined to one of these regions,
then it may suggest that there is a defect in cell fate determination to that compartment. On the
other hand, if DppaS expression is repressed in Rb-' placentas after E3.5, paralleling that in wild-
type placentas, and then reappears, this could indicate de-differentiation of a subset of cells. This
is a possibility since we did not detect any differences in differentiation markers for the various
placental layers. In this case, investigating the differentiation properties of Rb mutant TS cells in
culture would be helpful. These experiments would also be beneficial for determining whether
there is simply a failure to repress DppaS in TS cells. Third, promoter analysis of the DppaS
gene may yield insight into its upstream regulation by pRB. Our data indicate that E2F4 does
not participate in regulating DppaS (chapter 3) and preliminary analysis of the Dppa5 promoter
did not reveal any E2F binding sites (data not shown). Thus, a more in-depth analysis for other
pRB-binding transcription factor consensus sites, as well as for Id2 interactors, should be
performed. Finally, the physiological function of Dppa5 remains to be determined and
understanding its role in vivo may provide insight into its relationship with pRB.
It is clear that loss of E2F4 leads to a more severe placental defect in the Rb-' mice. As
such, it will be important to pinpoint the defect in the compound mutant placentas. Our
microarray analysis of Rb--;E2f4-' and wild-type placentas identified 44 differentially expressed
genes in the Rb-';E2f4- ' tissues. Four of the genes (i.e., prolactin, growth hormone, matrix
metalloproteinase 9 and X inactive specific transcript) are potential candidates for further
investigation since they have previously been linked to placental development. To begin
analyzing the involvement of these factors in the Rb-';E2f4-' placentas, the differential expression
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of these genes needs to be verified by an alternative method, such as quantitative real-time PCR
or in situ hybridization. Then, performing the same analysis on Rb-'- and E2f4-' placentas will
clarify whether deregulation is a result of pRB and/or E2F4 loss. Promoter analysis followed by
chromatin immunoprecipitation assays could establish if these potential targets are directly
regulated by E2F4 in cooperation with the pocket proteins. Thus, further investigation of these
promising targets may aid in defining the cause of placental dysfunction in the Rb--;E2f4 -' -
placentas.
Since the Rb-related defect has not been fully characterized, it has been difficult to
establish whether E2F4 cooperates with pRB in the extra-embryonic tissues or whether they have
separate functions. There are many similarities between the Rb-';E2f4- '1 mice and the Rb-'; p 107 -'
animals (Lee et al. 1996), suggesting that the loss of repressive E2F-pocket protein complexes is
important for placental development. If E2F4 has a redundant function to p107, then it would be
predicted that Rb -';E2f4 - -;p107' mice would resemble Rb -/'; E2f4-'- embryos, since both
genotypes result in the same repressive complexes. On the other hand, if E2F4 loss alone affects
placental development, then determining the defect in the E2f4 - - placentas may help to define the
defect in the Rb -' -;E2f4-' placentas. The generation of conditional E2f4-' animals provided with a
wild-type placenta could address this. If the resulting E2f4-' animals were no longer growth
retarded, then this would support that E2F4 may have a distinct role in the placenta and further
investigation would be required. Thus, the functional relevance of pRB-E2F4 complexes in
regulating placental development remains incomplete.
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The role of E2F4 in pRB-mediated growth suppresion
It is curious that E2F4 loss significantly extends the lifespan of the Rb+'- mice, but
decreases the viability of the Rb'- embryos. These differing outcomes may indicate differential
mechanisms through which E2F4 functions in these two settings. We currently favor the idea
that inappropriate proliferation in the developing embryo proper and tumorigenesis in the
absence of pRB are critically dependent upon the activating E2Fs, while the repressive E2F-
pocket protein complexes are important for regulating placental development. Therefore, the
overall contribution of the activating and repressive E2Fs to target gene expression may be
dictating cell growth and division. We found that loss of E2F4 suppressed inappropriate cell
division in the Rb-' MEFs, but had no effect on proliferation levels in the Rb-'- embryos. In
contrast, loss of E2F3, an activating E2F, suppresses ectopic proliferation in the Rb-' mice
(Ziebold et al. 2001), yet did not alter levels of inappropriate proliferation in Rb-'- MEFs cultured
in low serum (data not shown). Further investigation will be needed to determine the levels of
the various E2Fs and the pocket proteins in these mutant cells and whether the relative
proportions change in different cell types. It will also be important to determine whether the
activating E2Fs rescue the Rb-- embryos through suppression of the placental defect.
Understanding the role of E2F4 and the activating E2Fs in the extra-embryonic tissues may help
to clarify their functions.
Alternatively, E2F4 may be acting through one mechanism to mediate the effects in the
Rb+' and Rb-'- mice. For example, if cells lacking E2F4 and pRB are inclined to undergo
apoptosis (as discussed above), then this could result in the suppression of tumors as well as the
earlier embryonic lethality. Furthermore, this may be linked to the inappropriate expression of
pituitary-specific hormones, prolactin and growth hormone, detected in the double mutant
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placentas. If they are also deregulated in the pituitary, then it may result in cellular
abnormalities, such as apoptosis. Additional work will be needed to determine whether these
factors are also deregulated in the tumor-prone tissues of the Rb'-;E2f4-' mice, and the
consequences of the inappropriate expression.
This has been the first study to investigate the physiological role of a repressive E2F in
the growth suppressive functions of pRB. Although our analyses have led to a number of
unresolved issues, we have clearly demonstrated that E2F4 loss has significant effects in the Rb-
deficient mice. Therefore, these findings have broadened our understanding of the molecular
signals contributing to tumorigenesis and development in the absence of pRB.
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Appendix A
Partial reduction of p107 levels does not alter the tumor phenotype in
Rb+;E2f4'- mice
Eunice Y. Lee and Jacqueline A. Lees
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In chapter two, we found that E2F4 loss dramatically suppressed tumorigenesis in the
Rb+' mice and promoted the formation of novel E2F-pocket protein complexes in vivo. These
results led to a model whereby E2F4 loss indirectly inhibited tumor progression in the Rb+' mice
by increasing the levels of free p107 and p130 that can compensate for pRB deficiency. In order
to determine whether this is the underlying mechanism for the tumor suppression, we have
introduced the p107 mutation in the Rb+'-;E2f4- /- background. Directly reducing the levels of a
compensatory pocket protein should lead to a reversion of the Rb' - tumor phenotype. If there
were no effect, however, then this would indicate that an alternative mechanism is at work.
Since a fraction of the expected number of Rb+'-; p 07' animals survive to adulthood (Lee
et al., 1996), we thought that additional loss of E2F4 may not alter the recovery rate. In order to
generate Rb/-;E2f4--;p07' animals, three crosses were set up on a mixed C57B1/6 x 129/Sv
background: 1) Rb+'-;E2f4+1-;p07'- x Rb+'-;E2f4+'-;p07 +'-, 2) Rb+'-;E2f4+'-;pl07+'- x Rb+'-;E2f4+' -
;plO7 +'-, 3) Rb+'-;E2f4+'-;pO7+'- x Rb +'+;E2f4+'-;p07 +'-. We did not detect any Rb+/-;E2f4-'-;p107
animals from our crosses at 3 weeks of age (Table 1). In fact, none of the E2f4-/-;p107' animals
were present at this time, suggesting that these animals have severely reduced viability. Further
work is needed'to determine the precise timing and cause of lethality in the E2f4-'-;p107'-
animals.
Given that it was not possible to analyze tumor formation in the Rb+'-;E2f4-';p07'
animals, we assessed the Rb'l-;E2f4-'-;p107 +'- animals. The frequency at which these mice arose
was near the expected value (Table 1). Furthermore, these animals survived to adulthood,
allowing for scoring of tumor development. The majority of the Rb+'-;E2f4-'-;pl07+'- animals
(4/6) lived longer than the Rb' - littermates, which died between 8 and 14 months of age (Table
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Table 1. Offspring viability from Rb;E2f4;p107 intercrosses
at 3 weeks of age
Genotype
Rb +'-;E2f4-'-,p1 0 7+'-
Rb+'-;E2f4-'-;p107'-
Rb+/+;E2f4- -;,p 07'-
E2f4-'- *
plOT7- *
# Expected
8.4
5.8
5.6
33.75
46.75
Total number of mice
# Observed
6
0
0
14
21
135
* Includes all possible genotypes at other two loci.
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Table 2. Histological Analysis of Rb+/' ;E2f4- -;p 010 7+- Mice
Age Pituitary Thyroid Cause of Death
(Months) Tumor* Tumor*
9 +++- Pituitary tumor
13 - - Unknown
14.9 ++++ - Pituitary tumor
14.9 nd nd Unknown
15.3 +++ - Pituitary tumor
20.7 Unknown
nd = not determined
* Tumor size is indicated as follows: "-" indicates no tumor growth and "+ I ! +"
indicates tumors comparable to those of Rb+' mice.
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2). Upon inspection of tumor development, 3/5 Rb+'-;E2f4-'-;p107+' animals had pituitary tumors
and 0/5 had thyroid lesions (Table 2). Therefore, the loss of one wild-type allele of pl07 has no
effect on the lifespan and tumorigenesis in the Rb+'-;E2f4-' - animals (chapter 2).
These data are inconclusive with respect to defining the mechanistic basis of tumor
suppression in the Rb'-;E2f4 - 1- animals. While we can clearly state that partial reduction in p107
is insufficient to overcome the tumor suppression, it is entirely possible that the remaining pool
of free p107 and p130 is more than enough to compensate for diminished pRB function. Thus,
alternative approaches are required to test the complex rearrangement model.
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Appendix B
Cell cycle characterization of Rb;E2f mutant primary fibroblasts
Eunice Y. Lee, Tiziana Parisi, Alison Taylor and Jacqueline A. Lees
The author contributed all of the text and Figures 1A, 1B, 1D, 1E and Figure 2A. The author and
Tiziana Parisi contributed to Figure 2B. Alison Taylor contributed Figure 1C and F. All work
was done in the laboratory of Jacqueline A. Lees.
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Based on mutant mouse studies in the Rb+' background, loss of E2F4 (chapter 2) or an
activating E2F results in significant tumor suppression in the pituitary gland (Yamasaki et al.
1998; Ziebold et al. 2003). In order to determine if these E2Fs are working through a common
mechanism to regulate cell cycle progression, we characterized various Rb;E2f mutant MEFs.
We hypothesized that the compound mutant cells should have equivalent properties, according to
the complex rearrangement model proposed in chapter 2. For the most part, our results are
preliminary and somewhat inconclusive.
We analyzed Rb - -; E2fl -', Rb'-;E2f 3--, and Rb°/'°ox/;E2f4 -/- cells in proliferation, cell cycle
re-entry, apoptosis and transformation assays. All MEFs were generated from E13.5 embryos.
Since Rb-';E2f4-' - mice were severely underrepresented at this time, we generated Rb;E2f4
mutant cells from the conditional double knockout animals provided with a functional placenta,
as described in chapter 3. It has been reported that asynchronous Rb- ' primary fibroblasts display
a normal proliferation rate (Herrera et al. 1996). In our assays, most MEF lines generated from
Rb mutant embryos had growth rates similar to the control MEFs (Figure 1A and B), though
some proliferated slightly faster (Figure 1C). We also noticed that some lines reached a higher
saturation density than controls (Figure 1A), which is most likely indicative of the defective
confluence arrest response in the absence of pRB. For the most part, we found that simultaneous
loss of pRB and E2F4 (Figure 1A) or E2F1 (Figure 1C) had equivalent proliferation rates as the
control fibroblasts. Consistent with previous findings (Humbert et al. 2000), the E2F3-deficient
cells had a proliferation defect (Figure B). Furthermore, the Rb' -;E2f3-' cells had slightly
reduced proliferation rates intermediate to the E2f3 -'- and wild-type cells, suggesting that in the
absence of pRB the deregulation of the remaining activating E2Fs is responsible for the
increased proliferation over the E2f3-'- cells.
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Figure 1. Cell cycle properties of Rb;E2F mutant MEFs.
A-C) The proliferation rates of asynchronously dividing wild-type, Rb mutant,
RbnoxlIox;E2f4- (A), Rb';E2f3- (B) and Rb';E2fl' (C) fibroblasts were determined by
plating 2xl04cells in a 12-well plate well on day 0 and then counting the cells at the
indicated times. D-F) Serum starved wild-type, Rb mutant, Rbnoxnlox;E2f4/ (D), Rb'
;E2f3' (E) and Rb';E2fl' (F) MEFs were induced to re-enter the cell cycle upon
readdition of serum. Cell cycle progression was monitored by H3-Thymidine
incorporation.
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We also performed cell cycle re-entry assays to determine the cell cycle kinetics. MEFs
were synchronized in GO/G1 by serum starvation and then stimulated enter S phase upon
addition of serum. As previously reported, Rb mutant MEFs progressed through G1 more
rapidly than control cells. In general, the Rb ' -;E2fl -' (Figure IF) and RbH°X/'°X;E2f4-/- (Figure D)
MEFs either resembled the control cells or the Rb-' fibroblasts. We examined the protein levels
of p107 and cyclin E, which are derepressed in Rb mutant cells, and found that their expression
mimicked their cell cycle kinetics (data not shown). For example, in the compound mutant cells
that entered S phase more quickly, p107 and cyclin E were elevated to equivalent levels as
observed for the Rb mutant cells. In contrast, we consistently found that the Rb-'-;E2f3-' cells had
normal cell cycle kinetics, which was in-between the Rb-' cells and the E2f3 -'- cells (Figure 1E).
It may be worthwhile to investigate the differences in the two classes of Rb'-;E2fl'- cells, as well
as of RbO°XO°X;E2f4-'- cells. If the cause for the differences within a given genotype can be
determined, this may aid in understanding the functional relevance of the various E2F-pRB
complexes.
We also determined whether the Rb-'-;E2fl-' and the Rbl°x/J°Ox;E2f4-/- cells were sensitive
to apoptosis in response to DNA damaging agents. Asynchronously dividing MEFs were treated
with cisplatin (8MM or 16MM) or y-irradiation (5G or 10G) and then stained for annexin V and
propidium iodide followed by flow cytometry analysis. In response to y-irradiation, there was no
alteration in apoptosis levels for all of the genotypes examined (data not shown). In contrast, the
Rb ' -;E2fl -'- MEFs were highly susceptible to undergo programmed cell death after cisplatin
treatment (40.6% versus 19.6% in control cells and 14.7% inE2fl' cells). E2F1 has been
demonstrated to have roles in apoptosis and the DNA damage checkpoint (discussed in
Introduction), which may reflect the observed differences.
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Finally, we transformed the various Rb;E2f mutant cells with activated Ras and Myc in
order to analyze the oncogenic capacity of these cells. We confirmed that Ras and Myc were
expressed in all the transformed cells by Western blot analysis (data not shown). In contrast to
the cell cycle results which were variable, transformed Rb- -;E2fl - -', Rb '-;E2f3- -, and
Rbl'°'/x"°X;E2f4' MEFs all had diminished transformation potential to form tumors in
immunocompromised mice relative to transformed Rb-' cells (Figure 2). Most notably, the
tumors induced by transformed Rb°'"°X;E2f4- - cells at 25 days post injection (dpi) were
comparable in volume to those arising from Rb °ox'l°o cells at 16 dpi (Figure 2A). This has only
been done with one MEF line per genotype and needs to be confirmed. Yet, these results thus far
indicate that loss of E2F4 acts in a cell autonomous manner to suppress the oncogenic potential
of Rb-' cells.
Our preliminary analyses of the cell cycle properties of Rb-' ;E2fl -' - and Rb "° xm°x;E2f4'- primary
fibroblasts have not been consistent. In contrast, the Rb-'-;E2f3-' cells exhibit reduced cell
proliferation and cell cycle kinetics in all the assays performed. These differences may reflect
the differing functions of the E2Fs during cell cycle regulation or the differing levels of the
available activating E2Fs. Since it is not possible to determine the relative amounts of the free
activating E2Fs, analyses of target gene expression and promoter occupancy may be useful.
With respect to oncogenic potential, the various Rb;E2f mutant cells functioned in the same
manner, which may suggest a differential requirement for the E2Fs and pRB in tumorigenesis
than in normal cell cycle control. Further investigation is necessary to make any definitive
conclusions.
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Figure 2. Oncogenic capacity of Rb;E2F mutant MEFs.
Wild-type, Rb mutant, RboxOx;E2f4` (A), Rb-;E2f3/ (B) and Rb';E2fl' - (C) MEFs
were transformed with activated Ras and Myc. The abilities of the transformed cells to
form tumors in nude mice were assessed. Briefly, 106 cells were injected per injection
site and tumor growth was monitored at the indicated times post injection.
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Appendix C
E2F3 loss has opposing effects on different pRB-deficient tumors resulting in suppression
of pituitary tumors but metastasis of medullary thyroid carcinomas
Ulrike Ziebold, Eunice Y. Lee, Roderick T. Bronson and Jacqueline A. Lees
Mol Cell Biol (2003) 23: 6542-6552
Ulrike Ziebold contributed all of the text, tables and figures, except Figure 5A which was
contributed by the author. Roderick T. Bronson consulted on murine tumor pathology. All work
was done in the laboratory of Jacqueline A. Lees.
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ABSTRACT
The E2F transcription factors are key downstream targets of the retinoblastoma protein
(pRB) tumor suppressor. We have previously shown that E2F3 plays a critical role in mediating
the mitogen-induced activation of E2F-responsive genes and contributes to both the
inappropriate proliferation and p53-dependent apoptosis that arises in pRB-deficient embryos.
Here we show that E2F3 also has a significant effect on the phenotype of the tumor prone Rb+'
mice. The absence of E2F3 results in a significant expansion in the lifespan of these animals that
correlates with a dramatic alteration in the tumor spectrum. E2F3 loss suppresses the
development of the pituitary tumors that normally account for the death of Rb' - mice. However,
it also promotes the development of the medullary thyroid carcinomas yielding metastases at
high frequency. This increased aggressiveness does not seem to result from any change in p53
levels or activity in these tumors. Instead, we show that E2F3 loss leads to an increase in the
rate of tumor initiation. Finally, analysis of Rb+';E2f3'- mice shows that this tumor suppressive
function of E2F3 is dose dependent.
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INTRODUCTION
The retinoblastoma gene (RB-I) was identified by virtue of its absence in early childhood
retinoblastoma (Friend et al. 1986; Fung et al. 1987; Lee et al. 1987). Subsequent studies
revealed that RB-I is mutated in approximately one third of all human tumors (reviewed by
Weinberg 1992). To elucidate the precise role of the retinoblastoma protein (pRB) in both
tumorigenesis and development, a number of mutant mouse strains have been established
(reviewed by Mulligan and Jacks 1998). Their analyses underscore the importance of pRB as
both a tumor suppressor and as a key regulator of cellular growth in normal development.
Consistent with the familial cancer syndromes, mice carrying a single Rb mutant allele are highly
cancer prone (Hu et al. 1994; Williams et al. 1994). These animals develop pituitary tumors with
almost complete penetrance and a significant number also display medullary thyroid tumors
(MTCs). In addition, pRB is essential for embryogenesis (Clarke et al. 1992; Jacks et al. 1992;
Lee et al. 1992). The mid-gestation lethality of pRB-deficient embryos is accompanied by the
defective development of the fetal liver, erythrocytes, neurons and lens that result from a
combination of ectopic S phase entry and inappropriate programmed cell death. Subsequent
studies showed that the apoptosis can be either p53-dependent or p53-independent depending on
the particular tissue (Morgenbesser et al. 1994; Macleod et al. 1996).
The growth suppressive properties of pRB are thought to be largely dependent upon its
ability to regulate the E2F transcription factors (reviewed by Dyson 1998; Trimarchi and Lees
2002). The E2Fs control the expression of genes essential for cell proliferation, including key
components of both the DNA replication and cell cycle machinery. pRB binds to E2F during the
G l phase of the cell cycle and inhibits the activation of E2F dependent target genes. In response
to mitogenic signals, pRB is phosphorylated by the cell cycle dependent kinases cyclin D/cdk4,6
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and cyclinE/cdk2 and transcriptionally active E2F is released. Notably, almost all pRB-positive
tumors contain activating mutations in cycD1 or cdk4 or inactivating mutations in the cdk
inhibitor p16 (reviewed by Sherr 1996). This suggests that functional inactivation of pRB, and
thereby inappropriate release of E2F activity, is an essential step in tumorigenesis.
To date, six genes that encode for members of the E2F family have been cloned
(reviewed by Dyson 1998; Trimarchi and Lees 2002). Although most of these genes encode a
single protein product, E2Jf3 has two alternative promoters that yield two distinct proteins, called
E2F3a and E2F3b, which differ in their N-terminal sequences. E2F3b has only recently been
identified and its biological properties are not well understood. The remaining E2F proteins
have been divided into three distinct subgroups based on significant differences in their structure
and function.
E2F1, 2 and 3a represent one subgroup and they are believed to be the key downstream
targets of pRB. These three E2Fs are specifically regulated by pRB, and not the pRB-related
proteins p107 or p130 (Lees et al. 1993). When over-expressed, E2F1, 2 and 3a are potent
transcriptional activators and are each sufficient to induce quiescent cells to enter S phase (Lukas
et al. 1996; DeGregori et al. 1997). The endogenous E2F1, 2 and 3a proteins are released from
pRB during late G1 and then associate with E2F-responsive promoters just prior to the activation
of E2F-responsive genes (Takahashi et al. 2000; Rayman et al. 2002). Taken together, these data
suggest that E2F1, 2 and 3a play a key role in the induction of cellular proliferation. Consistent
with this hypothesis, mouse embryonic fibroblasts (MEFs) that lack E2F3a and E2F3b (for
simplicity, herein referred to as E2F3) have a defect in the mitogen-induced activation of almost
all known E2F-responsive genes that impairs the proliferation of both primary and transformed
cells (Humbert et al. 2000b). Moreover, the combined loss of E2F1, E2F2 and E2F3 completely
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blocks cellular proliferation suggesting that these proteins have overlapping roles in vivo (Wu et
al. 2001). Finally, these "activator E2Fs" can trigger cells to undergo apoptosis through both
p53-dependent (Qin et al. 1994; Shan and Lee 1994; Wu and Levine 1994) and p53-independent
mechanisms (Hsieh et al. 1997; Phillips et al. 1997).
The analysis of E2f mutant mouse strains suggests that the activating E2Fs play both
overlapping and unique roles in normal development. E2F1 and E2F2 are not required for
embryonic development, but adult E2fl- ' and E2f2'- mice each develop a unique spectrum of
tissue-specific abnormalities including defined, but distinct, defects in T lymphocyte
development (Yamasaki et al. 1996; Zhu et al. 1999; Garcia et al. 2000; Murga et al. 2001; Zhu
et al. 2001). E2fl mutant mice are also susceptible to hematopoietic malignancies and the tumor
incidence appears to be increased by E2f2 mutation (Yamasaki et al. 1996; Zhu et al. 2001).
Tumorigenesis is not dependent upon loss of the remaining wild-type E2fl and/or E2f2 allele and
there is still considerable debate about the underlying basis for these tumor suppressive
properties (reviewed by Trimarchi and Lees 2002). Initially, this was thought to be due to
E2Fl's role in the active repression of E2F-responsive genes via recruitment of pRB and
associated histone deacetylases. However, others have suggested that E2F1 acts as a tumor
suppressor through its ability to induce apoptosis and/or its participation in a DNA damage
response (Meng et al. 1999; Lin et al. 2001; Maser et al. 2001).
In contrast to the other activating E2Fs, the loss of E2F3 causes a high frequency of
neonatal lethality (Humbert et al. 2000b; Cloud et al. 2002). In certain mixed strain
backgrounds, a small proportion of the E2f3-'- mice survive to adulthood, but most die
prematurely of congestive heart failure (Cloud et al. 2002). The analysis of E2fl ;E2f3
compound mutant mice indicates that the developmental defects arising in the individual E2fl or
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E2f3 mutant mice are exacerbated by their combined mutation (Cloud et al. 2002). This strongly
suggests that these genes have critical, overlapping functions in development. However, E2f3
mutation has no detectable effect on the tumor incidence of E2fl mutant mice raising the
possibility that tumor suppression is a specific property of E2fl and E2f2, but not E2f3 (Cloud et
al. 2002).
Compound Rb;E2f mutant mouse models have been used to determine how pRB's
growth suppressive properties relate to its role in the inhibition of the activating E2Fs. These
studies show that the absence of either E2F1 or E2F3 greatly suppresses the ectopic S-phase
entry, p53-dependent and p53-independent apoptosis arising in pRB-deficient embryos and
thereby significantly extends their lifespan (Tsai et al. 1998; Ziebold et al. 2001). This suggests
that E2F1 and E2F3 both make significant contributions to the phenotypic consequences of pRB-
deficiency. Consistent with this hypothesis, E2F1 loss has been shown to significantly reduce
the development of pRB-deficient tumors (Yamasaki et al. 1998). However, the lack of a
complete rescue raised the possibility that one or more additional E2Fs might also contribute to
the tumor phenotype. This notion is supported by the finding that E2F4 loss greatly suppresses
the formation of tumors in Rb+/- mice by enabling p107 and p130 to bind, and presumably
inhibit, both E2F1 and E2F3 (Lee et al. 2002). In this study, we have generated Rb;E2f3
compound mutant mice to assess how E2F3 contributes to the Rb mutant phenotype. Our
analysis reveals an unexpected role for E2F3 in suppressing metastasis of pRB-deficient
medullary thyroid tumors.
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RESULTS
Rb mutation increases the viability of the E2J3'- neonates
We have previously shown E2F3 is critical for cellular proliferation and contributes to
the inappropriate proliferation and apoptosis that arise in pRB-deficient embryos (Humbert et al.
2000b; Ziebold et al. 2001). Given these observations, we hypothesized that E2F3 might
contribute to the development of pRB-deficient tumors. Since the viability of the E2f3 -'- mice
and the severity of the tumor phenotype of the Rb+'- mice are both influenced by strain specific
modifiers (Cloud et al. 2002), we conducted crosses between Rb (Jacks et al. 1992) and E2f3
(Humbert et al. 2000b) mutant mouse strains in both the 129/Sv and mixed (129/Sv x C57BL/6)
backgrounds.
Initially, we examined the ability of the compound Rb;E2f3 mutant genotypes to survive
until weaning. In the pure 129/Sv background (data not shown), we observed complete
embryonic lethality of the E2f3 -'- mice as previously described (Cloud et al. 2002).
Unfortunately, the presence of a single Rb mutant allele did not suppress the lethality of the E2f3-
/' animals. However, Rb +'- and Rb'-;E2f3 +' mice were both generated at the expected Mendelian
ratio and were aged for analysis of adult phenotypes. In the mixed, 129/Sv x C57BL/6, strain
background, a small fraction of the E2f3- - mice survived to weaning (Cloud et al. 2002).
Significantly, matings of mixed background Rb+';E2f3'- females with either Rb+'-;E2f3+' or Rb'
;E2f3-' males yielded surviving E2f3- ' animals at a significantly higher frequency in the presence
(25.75 + 4.05% of expected) versus the absence (11.4 + 0.3% of expected frequency) of one Rb
mutant allele (Table I). This strongly suggests that a reduction in pRB levels is sufficient to
overcome the requirement for E2F3 in one or more developmental processes that are essential for
neonatal viability.
205
Table I. Rb mutation increases the viability of the E2f3-'- neonates
Number of % expected
Genotype animals frequency
Rb'+-;E2f3 + '- WT 60 100%
x Rb+-;E2f3+'- E2f3+' 110 104.5%
Rb+'- 85 91.7%
Rb+'- ; E2f3+'- 191 70.8%
E2f3- '- 7 11.7%
Rb+/-; E2f3-'- 26 21.7%
(Z=479 animals)
E2f3 +/' 99 100%
Rb+'-;E2f3+ '- Rb+'- ; E2f3+ '- 206 104%
x Rb+-;E2f3- E2f3-- 11 11.1%
Rb+'-; E2f3- '- 59 29.8%
(Z=375 animals)
Genotypic analysis of the progeny was performed at weaning or
21 days of age.
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E2f3 mutation increases the lifespan of the tumor-prone Rb' mice
To determine whether E2F3 loss alters the viability of Rb' - adults, we aged a large cohort
of surviving neonatal E2f3;Rb mutant littermates and compared their lifespan (Figure 1, Table
II). In the inbred 129/Sv mice,. we observed a significant increase (log rank test, p=0.0008) in
the mean survival of the Rb+'-;E2f3+' (9.8 1.3 months) versus the Rb +'- (8.6 1.2 months)
littermates. Similarly, in the mixed (129/Sv x C57BL/6) strain, the lifespan of the Rb'- mice
(10.2 1.6 months) was progressively increased by the presence of either one (10.8 1.8
months) or two (13 2.6 months) E2f3 mutant alleles. Both of these changes are statistically
significant (log rank test, p=0.0128 and <0.00001, respectively). Thus, E2f3 mutation increases
the viability of the Rb+' mice in a dose dependent manner. Importantly, the Rb+'-;E2f3'- mice
could also be clearly distinguished from their E2f3-' littermate controls; they died earlier and had
no evidence of the congestive heart failure that causes the death of most E2f3-'- adults (Cloud et
al. 2002). Thus, the Rb mutation is influencing the viability of these Rb+'-;E2f3' adults.
E2f3 mutation suppresses development of pituitary tumors in Rb+'- mice
Since E2f3 mutation extends the lifespan of the Rb+'- animals, we first examined whether
it had any effect on either the incidence or size of the intermediate lobe pituitary tumors that is
the documented cause of death of Rb heterozygotes (Hu et al. 1994; Riley et al. 1994; Williams
et al. 1994; Harrison et al. 1995; Nikitin and Lee 1996). For these studies, we focused primarily
on the mixed 129/Sv x C57BL/6 background because all genotypes of interest were
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Figure 1. Effect of E2f3 status on the lifespan of Rb heterozygous mice.
Progeny arising from Rb+'-;E2f3+' - intercrosses were aged together. Log-rank survival curves
depict the survival (%) over the age of the animals (days). A) In the pure 129/Sv
background, the lifespan of Rb+'-;E2f3"+ - animals (n=25) was significantly increased as
compared to Rb+ /- animals (n=28). Additionally, E2f3+' - animals (n=19) were aged as a
control. B) In the mixed 129/Sv x C57BL/6 background, the lifespan of the Rb+'-;E2f3+'-
(n=125) and Rb+/-;E2f3- /- animals (n=40) increased progressively relative to that of the Rb+'-
(n=50) animals, but was decreased as compared to E2f3 -'- animals (n=18).
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Table II. E2f3 loss increases lifespan of Rb+'l mice in a mixed
(129/Sv x C57BL/6) and in a pure (129/Sv) genetic background
Genetic Genotype Number Mean survival Survival
background of animals (months) (days) range
Rb +' - 50 10.2 +/ 1.6 194 to 431
Mixed Rb+'- ;E2f3 '- 125 10.8 +/_1.8 166 to 437
(129/Sv x Rb+/-; E2f3-/- 50 13.0 +/2.6 252 to 582
C57BL/6) E2f3-'- 18 17.1 +/5.5 213 to 770
Rb +/ - 28 8.6 +/1.2 157 to 316
Pure Rb+/-; E2f3 +/- 25 9.8 +/ 1.3 262 to 388
129/Sv E2f3+/- 19 19.5 +/ 5.3 157 to 810
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available for analysis. The phenotypes of the Rb*' littermate controls were entirely consistent
with previous reports. We observed melanotroph carcinomas that had arisen from the
intermediate lobe of the pituitary (Figure 2A and data not shown). In almost every case, the
tumors had expanded to compress adjacent brain structures, causing the death of these animals.
In contrast, microscopic histological examination showed that the pituitaries of E2f3 mutant
littermates were completely normal (Figure 2A and data not shown).
At the time of death, the pituitary tumors of the Rb'-;E2f3' - mice were indistinguishable
from those of the Rb'- controls as judged by incidence, size and pathological criteria (Figure 2A,
C and data not shown). Since there is a short increase in lifespan of the Rb'-;E2f3'- animals
relative to the Rb+'- controls, it seems likely that these tumors develop slightly slower. Consistent
with this hypothesis, the complete absence of E2F3 had a major effect on pituitary tumor
development. Although all of the Rb+';E2f3- ' mice displayed pituitary carcinomas, these were
significantly smaller than those detected in the Rb+' controls (Figure 2B and C). Indeed, in
several cases, the tumor was still primarily contained within the intermediate layer of the
pituitary causing little disruption of the other layers (Figure 2B). The suppression of tumor
formation is particularly striking given that the Rb+'-;E2f3- '- animals live longer than their Rb'-
controls. Importantly, in about 30% of the Rb'-;E2f3-' animals the pituitary tumor was ruled out
as the cause of death. We therefore conclude that E2F3 acts to promote the development of
pituitary tumors in Rb mutant mice.
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Figure 2. Loss of E3f3 suppresses tumor formation in the pituitary.
A) Hematoxylin and Eosin stained sections of pituitaries from a healthy E2f3' - animal who
died at 14 months due to congestive heart failure, and Rb+' and Rb'l;E2f3'- mice that died at
10.5 months of age due to the pituitary tumors (20X). B) Hematoxylin and Eosin stained
sections of pituitaries from a healthy wildtype animal sacrificed at 12 months of age and two
Rb+';E2J3'- mice that died at 10.5 and 12 months (40X). C) Comparison of the pituitary
tumor size (as judged by area of median section) at the time of death of Rb'l - (n= 12), Rb'l -
;E2Jf3' (n= 11) and Rb+';E2Jf3 (n=15) mice.
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E2f3 mutation promotes the development of pRB-deficient medullary thyroid tumors
Since the pituitary tumors could not account for the death of all Rb+';E2f3-' animals, we
next examined whether E2f3 status altered the known MTC tumor phenotype of the Rb
heterozygotes. Rb+'- mice are predisposed to develop c-cell hyperplasia that subsequently
progress into medullary thyroid carcinomas (Hu et al. 1994; Williams et al. 1994; Harrison et al.
1995; Park et al. 1999). Depending on the specific recombinant mouse mutant used and genetic
background, the incidence of these tumors varies from 50-90%. In our study, 56% of Rb *'-
cohort displayed either c-cell hyperplasia or MTCs
(Figure 3A). Consistent with previous reports, the ensuing MTCs were mostly small,
predominantly unilateral, non-aggressive and showed sings of necrosis. In contrast, ten E2f3- '
and 15 E2f3+'- littermates that were aged together with our Rb+' cohort showed no signs of c-cell
abnormalities (data not shown).
Significantly, the mutation of E2f3 dramatically increased the development of these
tumors. In the Rb+'-;E2f3+' animals, MTCs were detected with almost complete penetrance
(98%). Moreover, almost all of these compound mutants had bilateral, rather than unilateral,
tumors and these were much larger than those observed in the Rb+'- controls (Figure 3A). In
many cases, these tumors had invaded adjacent structures and were palpable in the living mice
(Figure 3A). In a subset of the Rb*'-;E2f3' - animals, this tumor had begun to compress the
trachea and impede breathing. In these mice, the pituitary and c-cell tumors were both
sufficiently severe to be considered as the cause of death. The relatively small difference in the
time of death of Rb+'- (10.2 ± 1.6 mo) and Rb+'-;E2f3+'- (10.8 ± 1.8 mo) mice, strongly
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Figure 3. E3f3 mutation promotes thyroid tumor development.
A) Hematoxylin and Eosin stained sections of thyroids from a healthy control wild-type
animal sacrificed at 10.5 months of age versus MTCs derived from Rb'-, Rb+';E2f3' - and
Rb+';E2f3' mice that died at 10.5, 11 and 12 months of age, respectively. Arrowheads
indicate the location of thyroid (Thy), trachea (Tra) and esophagus (Esop) in the wild-
type controls. The open arrowhead highlights the infiltration of the tumor into the intra-
tracheal space in an Rb+'-;E2f3' animal. B) Cross-section of metastatic tumor growth in
the bone marrow, lung, lymph nodes and liver of four different Rb+';E2f3' animals.
Selected sites of secondary tumor growth (ST) are indicated. C) PCR based LOH
analysis of DNA extracted from freshly isolated biopsies from either MTCs (T),
mestastases (Met) or matching normal tissues (N) derived from either Rb`' (T ) or Rb÷'-
;E2f3 ' (T2-8, Met8-1 and Met8-2) mice alongside a water only control reaction (H20).
All of the tumors showed LOH of Rb, but not E2f3. An E2f4-specific PCR was used to
confirm equal input of DNA.
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suggests that the increase in MTC development is induced by the change in E2f3 dosage rather
than the change in lifespan.
The aggressiveness of this particular tumor located in the thyroid was further increased in
the Rb' -; E2f 3 '- mice. MTCs were detected at high frequency (92%) and the vast majority were
bilateral and showed extensive infiltration into adjacent structures (Figure 3A). In several
animals (3/38), the tumors were found to have traversed the muscle and cartilage layers and
invaded into tracheal space (open arrowhead in Figure 3A). Histologically, the MTCs of the
Rb +'-;E2f 3-'- mice also appeared much more aggressive than those of the Rb +' and Rb +'-;E2f 3 +'
littermates as judged by a significant increase in the nuclear/cytoplasmatic ratio (data not
shown). Importantly, these highly aggressive MTCs and/or the resulting metastases (see below)
could account for the death of the subset of Rb+'-;E2f3-' mice that had insignificant pituitary
tumors. Thus, in the same animal, E2f3 mutation is suppressing tumor development in the
pituitary while promoting the development of c-cell tumors.
E2f3 mutation promotes metastasis of pRB-deficient medullary thyroid tumors in a dose
dependent manner
In a significant fraction of the Rb+'-;E2f3-- mice (37.5%), we observed metastasis of the
MTC (Figure 3B, Table II). These secondary tumors were easily observed in the liver and lung
upon macroscopic inspection. Further histo-pathological analyses revealed the presence of
metastases in numerous other organs including the kidneys, intestines, lymph nodes and adrenals
and more importantly into the marrow of various bones. Importantly, metastases were detected
in Rb+'-;E2f3-' mice that died at the earliest (e.g., 252 days) as well as the latest time points (e.g.,
582 days) indicating that onset of metastasis is not merely as a result of the extension of lifespan.
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In comparison, only a small fraction of the Rb' controls (9%) developed metastases and these
were primarily located in the lung (Table III). Interestingly, there was also an increase in the
frequency of metastasis in the Rb'-;E2f3'- mice (23%) although these were also mostly present
in the lung and liver and merely a few animals developed secondary tumors in numerous organs
comparable to the Rb'-;E2f3 -' mice (Table III). Additionally, onset of metastasis was detected
despite similar age of these animals as compared to Rb' - mice (Table II). Taken together, these
data show that E2F3 acts to suppress the development of the pRB-deficient thyroid tumor and to
inhibit its metastasis.
We wished to establish whether the increased aggressiveness of MTCs and ensuing
metastasis in the Rb+';E2f3 +' mice required inactivation of the wild-type E2f3 allele. To address
this issue, we micro-dissected late-stage MTCs from the various Rb;E2f3 genotypes and
performed semi-quantitative PCR to screen for loss of heterozygosity (LOH) of both the Rb and
E2f3 genes. Consistent with previous analysis (Nikitin and Lee 1996), we observed LOH of Rb
in all of the tumors derived from the Rb+', Rb+';E2f3 +'- and Rb+/-;E2f3-'- animals (Figure 3C; data
not shown) confirming that our tumor samples are of sufficient purity to detect LOH. In
contrast, we consistently detected the wild-type E2f3 allele in tumors derived from the eight Rb+'
and 15 Rb'-;E2Jf3' mice (Figure 3C; data not shown). Importantly, there was no evidence of
LOH of E2f3 in either the primary thyroid tumors or any of the ten metastatic lesions that we
examined. We therefore conclude that E2F3 is acting in a dose dependent manner to suppress
the development and the metastatic growth of MTCs in mice.
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Rb;E2f3 mutant animals display several novel tumorigenic lesions
In addition to the change in the MTC phenotype, our necropsy studies showed that the
Rb;E2f3 compound mutant mice also developed novel tumorigenic lesions at low frequency
(Figure 4). We detected tumors that had clearly initiated in the anterior lobe of the pituitary in
both an Rb+'-;E2f3-' and an Rb'-; E2f3' - animal. In the latter case, the anterior lobe tumor had
developed alongside, but clearly independently from, the typical intermediate lobe pituitary
tumor. The remaining, novel tumors were all specifically detected in the Rb+';E2f3-' and not the
Rb+';E2f3+' mice. First, two animals developed islet cell tumors that were large, highly
vascularized and non-necrotic. Although this incidence is low, histological examination revealed
a significant incidence of islet cell hyperplasia in the majority of Rb+';E2f 3-' animals that is
clearly distinct from the background level of occasional hyperplastic islet cells that arise in many
ageing animals of this specific genetic background. Finally, we also observed one parathyroid
tumor and one pineoblastoma in two independent Rb'-;E2f3-' animals. Interestingly, islet cell
tumors, parathyroid tumors and pineoblastomas are not observed in the Rb+'- controls (this study;
(Hu et al. 1994; Riley et al. 1994; Williams et al. 1994; Harrison et al. 1995; Nikitin and Lee
1996) but were previously detected in Rb+'-;p53+'- and Rb +'-p53 -' mutant mice (Williams et al.
1994; Vooijs et al. 2002). The presence of these novel tumor types in the Rb +';E2f 3 -' - mice
reinforces our conclusion that E2F3 can act to suppress tumor formation in the mouse.
E2J3 mutation does not alter p53 levels or activity in the pRB-deficient tumors
Inhibition of apoptosis is often a critical event in tumor development and p53, or its
upstream regulators, are frequent targets for mutation (reviewed by Hanahan and Weinberg
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Figure 4. Additional, novel tumor types arise in the Rb+';E2f3' mice.
A) Comparison of normal islets (N) in a wild-type mouse versus the islet-cell tumors (T)
from two Rb+';E2f3' mice (all 20x magnification). B) Histological appearance of a typical
Rb mutant intermediate lobe (IL) pituitary tumor versus pituitary tumors from two different
Rb+';E2f3' mice that had initiated in both the intermediate (IL) and anterior lobe (AL) or
solely the anterior lobe (AL) of a pituitary (all 40x magnification). C) A pheocytochroma,
parathyroid tumor and an uterine endometrial adenoma detected in different Rb'l;E2f3'-
mice. D) Incidence of various lesions in Rb' -, Rbl';E2J3+', Rb'7;E2f3' and E2J3+' mice (all
40x magnification).
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2000). We have previously shown that E2f3 contributes to the induction of p53-dependent
apoptosis arising in pRB-deficient embryos (Ziebold et al. 2001) and now find that the Rb +' -
;E23 - '- mice develop a similar spectrum (although not the same incidence) of novel tumors as the
Rb+';-p53+'- and Rb+'-,p53'- animals. These observations suggested that E2f3 mutation might
promote the development of pRB-deficient tumors by reducing the activation of p53 and
therefore reducing the need to functionally inactivate this protein. To test this hypothesis, we
first compared p53 protein levels in size matched, late-stage MTCs derived from eight Rb+'',
twelve Rb+'-;E2f3+'- and nine Rb+';E2f3-'- animals (Figure 5A and data not shown). Regardless of
genotype, p53 was expressed at very low levels in most of the tumor samples. Although a small
fraction of the tumor samples (2/8 Rb+'-, 3/12 Rb+'-;E2f3+'- and 1/9 Rb+'-;E2f3- -) expressed slightly
higher levels of p53, we did not observe any significant differences between the various
genotypes (Figure 5A and data not shown).
To determine whether the p53 protein was functionally active, we used electrophoretic
mobility shift assays (EMSAs) to screen for p53 DNA binding activity. For the majority of
tumor samples, including those with the highest levels of p53, there was a direct correlation
between p53 protein levels and DNA binding activity (Figure 5A and data not shown). This was
also true of the metastases that were assayed (data not shown). Although we cannot rule out the
possibility that a low level of mutant p53 is present in a subset of these tumors, our data suggest
that the majority of the MTCs and their metastases still maintain a low level of functional wild-
type p53. These data suggest that the functional inactivation of p53 is not a pre-requisite for the
development or metastasis of the MTCs in the Rb+' mice. Thus, there is little reason to believe
that E2F3 loss promotes the development of these tumors through the regulation of p53.
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Figure 5. Further characterization of tumors derived from Rb;E2f3 mice.
A) The levels p53 protein in MTCs derived from Rb`' versus Rb+';E2f3/ mice was assayed
by western blotting (WB) whole cellular extracts derived from various tumors (upper panel).
Whole cell lysates from wild-type MEFs that had been subjected to 1 Grey of y-irradiation (y-
irr. WT) or a lymphoma derived from a p53 -/ mouse (p53-/) were used as positive and
negative controls, respectively. 3-tubulin (13-Tub) was used as a loading control. The same
cell extracts were also screened for the presence of p53 activity using EMSAs (lower panel).
The samples were incubated with mutant competitor (1), wild-type competitor (2) and/or
mutant competitor that included p53-specific antibody (3). The p53/DNA complex is
indicated with an arrow. B) Number of Rb' -, Rb+ ;E2Jf3+ and Rb+';E2f3' animals that had
c-cell lesions or developed MTCs at the indicated time after histological analysis of serial
sections of thyroids. C) There was a considerable difference in the size of the tumors in the
various Rb;E2f3 genotypes. For example, the tumor in a 210 day old Rb +' animal was
smaller than that present in an age-matched Rb"';E2f3+' mouse and closely resembled that of
a 150 day old Rb+'-;E2f3/ animal. D) Analysis of p53, pRB and pCalc (Calcitonin gene-
product) expression in early c-cell adenomas of Rb+';E2f3' mice using
immunohistochemistry. Closed arrowheads highlight presence of low level p53 and high
level pCalc, but absence of pRB expression in early adenomas. Open arrowheads depict
expression of p53, pRB and pCalc in c-cells of the thyroid. All lesions in C) and D) were
photographed with the same magnification (40x).
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E2f3 mutation promotes the initiation of the MTC
We next tested whether E2f3 status affected the development of pRB-deficient MTC by
influencing the time of onset. To address this question, Rb+', Rb+'-;E2f3+' - and Rb'-;E2J3- /-
littermates were sacrificed at 90, 150, 210, 240 and 270 days of age and their thyroids were screened
for the presence of hyperplastic c-cell lesions or early tumors by serial sectioning (Figure 5C and
data not shown). Up to 90 days of age, there was no evidence of lesions in any of the animals
examined. However, by 150 days we observed a significant difference in both the frequency and size
of tumors in the three genotypes. While tumors were not detected in the Rb+' - controls (0/4), they
were present in half of the Rb+'-;E2f3+'- (3/6) and all of the Rb'-;E2f3-' - (3/3) animals that we
examined. However, two of the lesions in the Rb+'-;E2f3-' mice were larger than those arising in the
Rb+'-;E2f3+' - littermates (data not shown). C-cell tumors were first detected in the Rb+' - mice at 210
days of age. Importantly, these were much smaller than those arising in age matched, Rb'l-;E2f3+'-
mice and were of a similar size to the tumors of Rb+'-;E2f3'- mice at just 150 days of age.
Immunohistochemistry confirmed that early tumorigenic lesions of the Rb'-;E2f3 - '- mice had all of
the hallmarks of pRB-deficient MTCs (Figure 5D). The tumor stained positive for calcitonin, a
specific marker of c-cells (open arrowhead). Moreover, pRB was clearly expressed in the c-cells, but
not the MTC, confirming that its loss is required for tumorigenesis. Finally, in agreement with our
analysis of late-stage tumors, we detected low level p53-staining in the early MTCs derived from
Rb'-;E2f3 -' - and also Rb+'- and Rb+'-;E2f3+'- mice (Figure 5D and data not shown). Taken together,
these data indicate that E2f3 acts in a dose dependent manner to suppress the initiation of MTCs.
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DISCUSSION
We have previously described an E2f3 mutant mouse strain in which expression of E2F3a
and E2F3b is abrogated and shown that E2F3 contributes to the induction of cellular proliferation
in both wild-type and pRB-deficient cells (Humbert et al. 2000b; Ziebold et al. 2001). In this
study, we have used Rb;E2f3 compound mutant mice to determine how E2F3 contributes to the
development of pRB-deficient tumors. This analysis reveals considerable interplay between
E2F3 and pRB in both normal development and tumorigenicity (Figure 6).
E2F3 and pRB act in opposition to one another in normal development
With regard to development, all of our findings support a simple model in which pRB
and E2F3 act in direct opposition to one another (Figure 6). Our data clearly show that mutation
of a single Rb allele is sufficient to increase the fraction of surviving E2f3'- neonates by two- to
threefold. Moreover, it also completely suppresses the congestive heart failure that is
responsible for the death of most E2J3- '- adults (this study (Cloud et al. 2002). This directly
complements the previous finding that E2f3 mutation suppresses the inappropriate proliferation
and apoptosis in pRB-deficient embryos and thereby greatly extends their lifespan (Ziebold et al.
2001; Saavedra et al. 2002). Significantly, many of the properties of E2F3 in normal
development are shared by E2F1. The phenotypes of Rb-';E2f3 -/ and Rb ' -;E2fl -'- embryos are
similar to one another (Tsai et al. 1998; Ziebold et al. 2001). Moreover, the analysis of
E2fl ;E2f3 compound mutant mice shows that the developmental and age-related defects of the
individual E2fl or E2f3 mice are exacerbated by the mutation of the other E2f (Cloud et al.
2002). Together, these data indicate that E2F1 and E2F3 play critical, overlapping roles in the
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Figure 6. Relative roles of pRB and E2F3 in both development and tumorigenesis.
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development and maintenance of a variety of tissues and pRB opposes the action of these factors.
Importantly, this regulation appears to be critically dependent upon the appropriate balance of
pRB and E2F proteins since a reduction in Rb or E2f gene dosage can either disrupt or restore
development.
E2f3 acts as either an oncogene or tumor suppressor in different Rb mutant tumors
In contrast to the developmental regulation, the relative roles of pRB and E2F3 in
tumorigenesis appear highly complex. It is well documented that the retinoblastoma gene
behaves as a classic tumor suppressor. Humans or mice carrying a germline Rb mutation
develop tumors with complete penetrance and tumor development is accompanied by LOH
(reviewed by Mulligan and Jacks 1998). One significant difference is the spectrum of tumors,
retinoblastoma in humans versus pituitary and c-cell carcinomas in mice. In this study, we show
that E2F3 loss in mice has a differential effect on the development of these specific tumor types.
In the pituitary, the absence of E2F3 significantly suppressed tumor formation resulting in an
extension of lifespan. Thus, E2F3 acts as an oncogene in this tissue. In contrast, in the c-cells,
E2F3 loss clearly increases tumorigenicity leading to the formation of highly aggressive
carcinomas that metastasize to form secondary tumors within a wide variety of other tissues.
Indeed, these MTCs and/or their metastases, and not pituitary tumors, are responsible for the
death of a significant fraction of the Rb+';E2f3-'- animals. This represents the first evidence that
E2F3 can collaborate with pRB to act as a tumor suppressor in vivo. This conclusion is
supported by the finding that Rb'-;E2f3 -- mice develop additional tumor types that are not
observed in the Rb' - controls. Thus, in different tissues of a single animal, E2F3 acts as either an
oncogene or a tumor suppressor (Figure 6). This underscores the importance of tissue-specific
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roles for E2F3 and raises questions about the underlying mechanism of these opposing activities.
Clearly, since the E2f3 mutation affects expression of both E2F3a and E2F3b it is entirely
possible that this results from differential activities of the two E2F isoforms.
Before further discussion of potential mechanisms, it is important to consider what we
now know about the tumorigenic properties of the various E2F family members. The concept
that E2fs could function as tumor suppressors was originally deduced from the analysis of E2fl
mutant mice (Yamasaki et al. 1996; Yamasaki et al. 1998). This early study showed that both
E2fl +' and E2fl -' - mice had an increased propensity to develop tumors with late onset and low
penetrance (Yamasaki et al. 1996). It was subsequently shown that E2f2 mutant mice are tumor
prone and that the combined mutation of E2fl and E2f2 increases both the incidence and time of
onset of tumorigenesis (Zhu et al. 2001). Thus, at least in certain tissues, E2F1 and E2F2 have
similar, additive roles in the suppression of tumors. In contrast, we have found that the mutation
of E2f3, either alone or in combination with E2fl, or E2f4 has no detectable effect on
tumorigenesis (Humbert et al. 2000a; Cloud et al. 2002). This initially suggested that tumor
suppression might be a specific property of E2fl and E2f2, but not E2f3 or E2f4.
Significantly, the tumorigenic properties of the individual E2fs appear quite different
when analyzed in the context of the Rb' - mutant background. In this setting, E2fl clearly
displays oncogenic not tumor suppressive properties. E2F1 loss suppresses the development of
pRB-deficient brain tumors in a large T-antigen transgenic mouse model (Pan et al. 1998) and
the formation of both pituitary and thyroid tumors in Rb+'- mice yielding a dramatic extension of
lifespan (Yamasaki et al. 1998). In contrast, E2F3 loss has opposing effects on the pituitary
tumors (suppressing) and the thyroid tumors (promoting) indicating that it is behaving as both
oncogene and tumor suppressor. The phenotype of the Rb'-;E2f4 - ' mice adds to this complexity.
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E2F4 loss suppresses the pituitary and thyroid tumors arising the Rb+' mice more effectively that
the loss of any other E2F tested to date (Lee et al. 2002). However, molecular analyses suggest
that this occurs via an indirect mechanism in which the absence of E2F4 allows it associated
pocket proteins, p107 and p130, to bind, and presumably suppress the activity of, E2F1 and
E2F3 (Lee et al. 2002). Thus, it appears that the complete loss of E2F3 has a different effect on
the tumor spectrum of Rb+'- mice than restoration of the normal pocket protein regulation of the
endogenous E2F1 and E2F3. We cannot rule out the possibility that the consequences of E2F3
loss result from changes in the regulation or activity of the remaining E2F proteins. However,
together these observations show that the activating E2Fs (E2F1, 2 and 3) all have the ability to
either promote or suppress tumorigenicity depending on the setting.
It is widely believe that the activating E2Fs' oncogenic activity results from the known,
shared (cell autonomous) role of these proteins in the transcriptional activation of E2F-
responsive genes and the induction of cellular proliferation (Humbert et al. 2000b; Wu et al.
2001). In contrast, there is still considerable debate about the underlying basis for the E2F's
tumor suppressive activity. Several models have been proposed to account for the E2Fs' tumor
suppressive activity, all of which are cell autonomous. One of the most popular is that this
results in the known ability of the E2Fs to activate p53-dependent apoptosis (Qin et al. 1994;
Shan and Lee 1994; Wu and Levine 1994). Since, apoptosis requires a higher threshold level of
E2F activity than the induction of cellular proliferation, this offers a simple explanation for the
E2Fs ability to act as an oncogene (low level induces proliferation) or a tumor suppressor (high
level induces apoptosis). Our analysis of Rb;E2f3 mutant tumors provides some insight into this
model. Initially, our observation that Rb+'-;E2f3-' animals develop the same novel tumor types as
Rb+'-;p53+' and Rb+/-,p53-'- mutant mice seemed to support it. Perhaps E2F3 loss promoted
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tumor development by reducing the requirement to inactivate p53-dependent apoptosis.
However, our additional analysis did not support this conclusion. Regardless of whether the
MTCs and their metastases were isolated from Rb +'-, Rb+'-;E2f3+'- or Rb+'-;E2f3-'- mice, the
majority retained a low level of functional p53 protein. Thus, p53-inactivation is not a pre-
requisite for the development of MTCs or subsequent metastases and E2f3 status does not appear
to alter its frequency. This suggests that, at least in this specific tumor type, E2f3 does not exert
its tumor suppressor effect by altering the need to inactivate p53. Obviously, this does not rule
out the possibility that the apoptosis mechanism is operating in other tumor types including the
additional, rare tumors arising in the Rb+' ;E2J3- mice that phenocopy those arising in the Rb+'-
;p53 mutant animals.
Importantly, our analysis of staged tumors strongly suggests that E2f3 status affects the
rate of tumor onset. Specifically, tumorigenic lesions arise at a progressively earlier time in the
thyroids of Rb +/-;E23 -/- , Rb+/-;E23 +/ - and Rb+/ - mice. This observed acceleration of tumor
onset is consistent with three other models of E2Fs' tumor suppressor function. First, since the
activating E2Fs bind pRB family members and their associated histone deacetylases it is widely
believed that they can participate in the repression of E2F-responsive genes [see (Rayman et al.
2002) for example]. Second, E2F1 has been also implicated as a component of the ATM/ATR-
Nbsl/Mrel 1 damage response pathway (Meng et al. 1999; Lin et al. 2001; Maser et al. 2001).
Finally, it has recently been reported that E2F3 loss can lead to centrosome amplification, mitotic
spindle defects and aneuploidy (Saavedra et al. 2003). Significantly, these latter two
mechanisms have been primarily linked to E2F1 and E2F3 respectively. This raises the
possibility that the activating E2Fs might suppress tumor formation through distinct mechanisms.
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The tumor suppressive properties of E2fl and E2f3 do have at least one, unusual
characteristic in common. The analysis of tumors derived from E2f "'- mice showed that there is
no evidence of LOH of E2f] (Yamasaki et al. 1996; Zhu et al. 2001; Cloud et al. 2002). This is
entirely consistent with the finding that E2fl' - and E2fl -'- mice have a similar spectrum,
incidence and kinetics of tumor formation and it strongly suggests that a reduction in E2F1 levels
is sufficient to negate its tumor suppressive properties. Here we now show that the development
of the pRB-deficient thyroid tumors is promoted by the heterozygous mutation of E2f3 and the
primary and secondary tumors retain the wild-type E2f3 allele (in a mixed background). This is
further supported by the fact that heterozygous mutation of E2f3 also increases both the
incidence of MTCs in the pure 129/Sv background Rb+'- mutant mice (data not shown). Thus, in
an analogous manner to E2fl, a mere reduction in E2f3 dosage is sufficient to impair tumor
suppression. This is not a unique phenomenon, but it has been ascribed to only a small number of
tumor suppressors (reviewed by Cook and McCaw 2000; Quon and Berns 2001). Thus, the
finding that this is a shared property of E2fl and E2f3 supports the notion that they may suppress
tumor formation via a similar mechanism.
Interestingly, the tumorigenicity of Rb'-;E2f3+' and Rb' ;E2J3'- animals is not
equivalent. Mutation of the second E2f3 allele increases the aggressiveness of the MTC,
broadens the tissue spectrum of the resulting metastases and allows the formation of novel tumor
types. There are two possible explanations for these different tumor phenotypes. E2f3 could
simply act to suppress tumors in a dose dependent manner. Alternatively, the heterozygous and
homozygous mutation of E2f3 could promote tumorigenesis via different mechanisms. Indeed, it
seems possible that E2f3 haploinsufficiency could promote tumor formation through a
mechanism that is shared with E2F1 while complete loss of E2F3 might act through a unique
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mechanism, for example centrosome amplification. Obviously, additional experiments will be
required to address all potential models.
Regardless of the underlying mechanism, it now seems clear that the activating E2Fs
(E2F1, 2 and 3) all display similar abilities to promote or suppress tumorigenicity. However, the
observed behavior appears to be highly context dependent, being greatly influenced by the
absence or presence of pRB and the levels/activity of the remaining E2F species. The simplest
explanation for this finding is that the individual E2Fs have both positive and negative functions
that are integrated to determine the rate of cell proliferation and/or survival. In this manner, the
changes in the individual E2Fs could either promote or suppress tumor formation depending on
the balance of positive and negative activities in individual tissues.
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EXPERIMENTAL PROCEDURES
Animal maintenance and histological analysis
The Rb and E2f3 mutant mouse strains were genotyped using previously described PCR
protocols (Jacks et al. 1992; Humbert et al. 2000b). Animals were sacrificed just prior to death
or as warranted by the size of the tumors. In some cases, animals were examined after they were
found dead. Full necropsy was performed on all animals according to standard procedures. For
histology all tissues were fixed in 10% phosphate buffered formalin or Bouin's solution,
embedded in paraffin blocks and 4-6 m representative sections were stained with hematoxylin
and eosin. For more detailed analysis of the pathology of thyroids and c-cell lesions as well as
ensuing metastasis in lungs sections from four to six different levels of these organs were
produced. Tumor genotypes were determined by conducting semi-quantitative PCR in tissues
that had been isolated using a dissection microscope.
Statistical analysis and establishment of relative tumor areas
Survival and longevity statistical analyses were calculated with Excel (Microsoft) and
Stata 6.0 (Stata-Corporation) programs. To establish relative pituitary tumor areas, low power
microscopic views of Rb mutant pituitary tumors were photographed and a normalized grid was
electronically merged with the entire tumor area. The largest pituitary carcinoma was set to
100% and tumors of all other genotypes were measured accordingly.
Immunohistochemistry, western blotting and gel retardation assays.
Immunohistochemical detection of p53 (CM5; Novocastra), pRB (144011A; BD
Bioscience) and Calcitonin (CMC-101; Cell Marque) was performed on formalin fixed, paraffin
embedded 4 pm sections. Antigen retrieval was performed by boiling the specimen in Trilogy
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(Cell Marque). Detection of primary antibodies was performed using biotinylated secondary
antiserum facilitated by ABC, avidin-peroxidase-biotin complex, as suggested by manufacturer
(Vector Lab.). Specificity of a-pRB primary antibodies was verified using CNS sections of WT
and viable Rb - - E13.5 embryos. All stainings had a control reaction that did not contain any
primary antibody. Western blotting and gel retardation assays were performed on whole cell
extracts of dissected late stage MTCs as previously described (Tsai et al. 2002).
ACKNOWLEDGEMENTS
We wish to thank Alicia Caron for excellent technical support in the generation of
histological sections and stainings. We are also extremely grateful for the gift of key reagents
from Tyler Jacks (Rb mutant mice), David MacPherson (y-irradiated fibroblasts) and Frances
Connor (p53- /- tumor specimen). We wish to thank members of the Lees lab for comments on
the manuscript. This work was supported by stipends to U.Z. from the DFG zi/98 and
MERCK/MIT and a grant to J.A.L from the NIH (PO1-CA42063).
230
REFERENCES
Clarke, A.R., E.R. Maandag, M. van Roon, N.M. van der Lugt, M. van der Valk, M.L. Hooper,
A. Berns, and H. te Riele. 1992. Requirement for a functional Rb-1 gene in murine
development. Nature 359: 328-30.
Cloud, J.E., C. Rogers, T.L. Reza, U. Ziebold, J.R. Stone, M.H. Picard, A.M. Caron, R.T.
Bronson, and J.A. Lees. 2002. Mutant mouse models reveal the relative roles of E2F1
and E2F3 in vivo. Mol Cell Biol 22: 2663-72.
Cook, W.D. and B.J. McCaw. 2000. Accommodating haploinsufficient tumor suppressor genes
in Knudson's model. Oncogene 19: 3434-8.
DeGregori, J., G. Leone, A. Miron, L. Jakoi, and J.R. Nevins. 1997. Distinct roles for E2F
proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 94: 7245-50.
Dyson, N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-62.
Friend, S.H., R. Bernards, S. Rogelj, R.A. Weinberg, J.M. Rapaport, D.M. Albert, and T.P.
Dryja. 1986. A human DNA segment with properties of the gene that predisposes to
retinoblastoma and osteosarcoma. Nature 323: 643-6.
Fung, Y.K., A.L. Murphree, A. T'Ang, J. Qian, S.H. Hinrichs, and W.F. Benedict. 1987.
Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:
1657-61.
Garcia, I., M. Murga, A. Vicario, S.J. Field, and A.M. Zubiaga. 2000. A role for E2F1 in the
induction of apoptosis during thymic negative selection. Cell Growth Differ 11: 91-8.
Hanahan, D. and R.A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70.
Harrison, D.J., M.L. Hooper, J.F. Armstrong, and A.R. Clarke. 1995. Effects of heterozygosity
for the Rb-ltl9neo allele in the mouse. Oncogene 10: 1615-20.
Hsieh, J.K., S. Fredersdorf, T. Kouzarides, K. Martin, and X. Lu. 1997. E2F1-induced apoptosis
requires DNA binding but not transactivation and is inhibited by the retinoblastoma
protein through direct interaction. Genes Dev 11: 1840-52.
Hu, N., A. Gutsmann, D.C. Herbert, A. Bradley, W.H. Lee, and E.Y. Lee. 1994. Heterozygous
Rb-i delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly
complete penetrance. Oncogene 9: 1021-7.
Humbert, P.O., C. Rogers, S. Ganiatsas, R.L. Landsberg, J.M. Trimarchi, S. Dandapani, C.
Brugnara, S. Erdman, M. Schrenzel, R.T. Bronson, and J.A. Lees. 2000a. E2F4 is
essential for normal erythrocyte maturation and neonatal viability. Mol Cell 6: 281-91.
231
Humbert, P.O., R. Verona, J.M. Trimarchi, C. Rogers, S. Dandapani, and J.A. Lees. 2000b. E2f3
is critical for normal cellular proliferation. Genes Dev 14: 690-703.
Jacks, T., A. Fazeli, E.M. Schmitt, R.T. Bronson, M.A. Goodell, and R.A. Weinberg. 1992.
Effects of an Rb mutation in the mouse. Nature 359: 295-300.
Lee, E.Y., H. Cam, U. Ziebold, J.B. Rayman, J.A. Lees, and B.D. Dynlacht. 2002. E2F4 loss
suppresses tumorigenesis in Rb mutant mice. Cancer Cell 2: 463-72.
Lee, E.Y., C.Y. Chang, N. Hu, Y.C. Wang, C.C. Lai, K. Herrup, W.H. Lee, and A. Bradley.
1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and
haematopoiesis. Nature 359: 288-94.
Lee, W.H., R. Bookstein, F. Hong, L.J. Young, J.Y. Shew, and E.Y. Lee. 1987. Human
retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:
1394-9.
Lees, J.A., M. Saito, M. Vidal, M. Valentine, T. Look, E. Harlow, N. Dyson, and K. Helin. 1993.
The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol
13: 7813-25.
Lin, W.C., F.T. Lin, and J.R. Nevins. 2001. Selective induction of E2F1 in response to DNA
damage, mediated by ATM-dependent phosphorylation. Genes Dev 15: 1833-44.
Lukas, J., B.O. Petersen, K. Holm, J. Bartek, and K. Helin. 1996. Deregulated expression of E2F
family members induces S-phase entry and overcomes p16INK4A-mediated growth
suppression. Mol Cell Biol 16: 1047-57.
Macleod, K.F., Y. Hu, and T. Jacks. 1996. Loss of Rb activates both p53-dependent and
independent cell death pathways in the developing mouse nervous system. Embo J 15:
6178-88.
Maser, R.S., O.K. Mirzoeva, J. Wells, H. Olivares, B.R. Williams, R.A. Zinkel, P.J. Farnham,
and J.H. Petrini. 2001. Mrel 1 complex and DNA replication: linkage to E2F and sites of
DNA synthesis. Mol Cell Biol 21: 6006-16.
Meng, R.D., P. Phillips, and W.S. El-Deiry. 1999. p53-independent increase in E2F-1 expression
enhances the cytotoxic effects of etoposide and of adriamycin. Int J Oncol 14: 5-14.
Morgenbesser, S.D., B.O. Williams, T. Jacks, and R.A. DePinho. 1994. p53-dependent apoptosis
produced by Rb-deficiency in the developing mouse lens. Nature 371: 72-4.
Mulligan, G. and T. Jacks. 1998. The retinoblastoma gene family: cousins with overlapping
interests. Trends Genet 14: 223-9.
Murga, M., O. Fernandez-Capetillo, S.J. Field, B. Moreno, R.B. L, Y. Fujiwara, D. Balomenos,
A. Vicario, A.C. Carrera, S.H. Orkin, M.E. Greenberg, and A.M. Zubiaga. 2001.
232
Mutation of E2F2 in Mice Causes Enhanced T Lymphocyte Proliferation, Leading to the
Development of Autoimmunity. Immunity 15: 959-70.
Nikitin, A. and W.H. Lee. 1996. Early loss of the retinoblastoma gene is associated with
impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice.
Genes Dev 10: 1870-9.
Pan, H., C. Yin, N.J. Dyson, E. Harlow, L. Yamasaki, and T. Van Dyke. 1998. Key roles for
E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors.
Mol Cell 2: 283-92.
Park, M.S., J. Rosai, H.T. Nguyen, P. Capodieci, C. Cordon-Cardo, and A. Koff. 1999. p27 and
Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci
U S A 96: 6382-7.
Phillips, A.C., S. Bates, K.M. Ryan, K. Helin, and K.H. Vousden. 1997. Induction of DNA
synthesis and apoptosis are separable functions of E2F- 1. Genes Dev 11: 1853-63.
Qin, X.Q., D.M. Livingston, W.G. Kaelin, Jr., and P.D. Adams. 1994. Deregulated transcription
factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl
Acad Sci U S A 91: 10918-22.
Quon, K.C. and A. Berns. 2001. Haplo-insufficiency? Let me count the ways. Genes Dev 15:
2917-21.
Rayman, J.B., Y. Takahashi, V.B. Indjeian, J.H. Dannenberg, S. Catchpole, R.J. Watson, H. te
Riele, and B.D. Dynlacht. 2002. E2F mediates cell cycle-dependent transcriptional
repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes
Dev 16: 933-47.
Riley, D.J., C.C. Lai, C.Y. Chang, D. Jones, E.Y. Lee, and W.H. Lee. 1994. Susceptibility to
tumors induced in mice by ethylnitrosourea is independent of retinoblastoma gene
dosage. Cancer Res 54: 6097-101.
Saavedra, H.I., B. Maiti, C. Timmers, R. Altura, Y. Tokuyama, K. Fukasawa, and G. Leone.
2003. Inactivation of E2F3 results in centrosome amplification. Cancer Cell 3: 333-46.
Saavedra, H.I., L. Wu, A. de Bruin, C. Timmers, T.J. Rosol, M. Weinstein, M.L. Robinson, and
G. Leone. 2002. Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced
by loss of Rb. Cell Growth Differ 13: 215-25.
Shan, B. and W.H. Lee. 1994. Deregulated expression of E2F-1 induces S-phase entry and leads
to apoptosis. Mol Cell Biol 14: 8166-73.
Sherr, C.J. 1996. Cancer cell cycles. Science 274: 1672-7.
233
Takahashi, Y., J.B. Rayman, and B.D. Dynlacht. 2000. Analysis of promoter binding by the E2F
and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes
Dev 14: 804-16.
Trimarchi, J.M. and J.A. Lees. 2002. Sibling rivalry in the E2F family. Nature Reviews Mol.
Cell. Biol. 3: 11-20.
Tsai, K.Y., Y. Hu, K.F. Macleod, D. Crowley, L. Yamasaki, and T. Jacks. 1998. Mutation of
E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-
deficient mouse embryos. Mol Cell 2: 293-304.
Tsai, K.Y., D. MacPherson, D.A. Rubinson, D. Crowley, and T. Jacks. 2002. ARF is not
required for apoptosis in Rb mutant mouse embryos. Curr Biol 12: 159-63.
Vooijs, M., H. te Riele, M. van der Valk, and A. Berns. 2002. Tumor formation in mice with
somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding
protein-expressing cells. Oncogene 21: 4635-45.
Weinberg, R.A. 1992. The retinoblastoma gene and gene product. Cancer Surv 12: 43-57.
Williams, B.O., L. Remington, D.M. Albert, S. Mukai, R.T. Bronson, and T. Jacks. 1994.
Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7: 480-
4.
Wu, L., C. Timmers, B. Maiti, H.I. Saavedra, L. Sang, G.T. Chong, F. Nuckolls, P. Giangrande,
F.A. Wright, S.J. Field, M.E. Greenberg, S. Orkin, J.R. Nevins, M.L. Robinson, and G.
Leone. 2001. The E2F1-3 transcription factors are essential for cellular proliferation.
Nature 414: 457-62.
Wu, X. and A.J. Levine. 1994. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad
Sci U S A 91: 3602-6.
Yamasaki, L., R. Bronson, B.O. Williams, N.J. Dyson, E. Harlow, and T. Jacks. 1998. Loss of
E2F-1 reduces tumorigenesis and extends the lifespan of Rbl(+/-)mice. Nat Genet 18:
360-4.
Yamasaki, L., T. Jacks, R. Bronson, E. Goillot, E. Harlow, and N.J. Dyson. 1996. Tumor
induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-48.
Zhu, J.W., D. DeRyckere, F.X. Li, Y.Y. Wan, and J. DeGregori. 1999. A role for E2F1 in the
induction of ARF, p53, and apoptosis during thymic negative selection. Cell Growth
Differ 10: 829-38.
Zhu, J.W., S.J. Field, L. Gore, M. Thompson, H. Yang, Y. Fujiwara, R.D. Cardiff, M.
Greenberg, S.H. Orkin, and J. DeGregori. 2001. E2F1 and E2F2 Determine Thresholds
for Antigen-Induced T-Cell Proliferation and Suppress Tumorigenesis. Mol Cell Biol 21:
8547-64.
234
Ziebold, U., T. Reza, A. Caron, and J.A. Lees. 2001. E2F3 contributes both to the inappropriate
proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev 15: 386-91.
235
